Methods for treating demyelination disorders

ABSTRACT

This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in the present invention are particularly useful for drug screening and/or treatment of demyelination disorders.

CROSS REFERENCE

This application claims the benefit of U.S. Provisional Application No.60/690,691 filed Jun. 14, 2005. Provisional Application No. 60/744,826filed Apr. 13, 2006, and U.S. Provisional Application No. 60/792,007filed Apr. 14, 2006, all of which are incorporated herein by referencein their entirety.

TECHNICAL FIELD

This invention is in the field of neurology. Specifically, the inventionrelates to the discovery and characterization of molecular componentsthat play a role in neuronal demyelination or remyelination. Inaddition, the invention relates to the generation of an animal modelthat exhibits hypomyelination. The compositions and methods embodied inthe present invention are particularly useful for drug screening and/ortreatment of demyelination disorders.

BACKGROUND OF THE INVENTION

Neuronal demyelination is a deleterious condition characterized by areduction of myelin protein in the nervous system. Myelin is a vitalcomponent of the central (CNS) and peripheral (PNS) nervous system,which encases the axons of neurons and forms an insulating layer knownas the myelin sheath. The presence of the myelin sheath enhances thespeed and integrity of nerve signal in form of electric potentialpropagating down the neural axon. The loss of myelin sheath producessignificant impairment in sensory, motor and other types of functioningas nerve signals reach their targets either too slowly, asynchronously(for example, when some axons in a nerve conduct faster than others),intermittently (for example, when conduction is impaired only at highfrequencies), or not at all.

The myelin sheath is formed by the plasma membrane, or plasmalemma, ofglial cells-oligodendrocytes in the CNS, and Schwann cells in the PNS.During the active phase of myelination, each oligodendrocyte in the CNSmust produce as much as approximately 5000 μm² of myelin surface areaper day and approximately 10⁵ myelin protein molecules per minute(Pfeiffer, et al. (1993) Trends Cell Biol. 3: 191-197). Myelinatingoligodendrocytes have been identified at demyelinated lesions,indicating that demyelinated axons may be repaired with the newlysynthesized myelin.

Neuronal demyelination is manifested in a large number of hereditary andacquired disorders of the CNS and PNS. These disorders include MultipleSclerosis (MS), Progressive Multifocal Leukoencephalopathy (PML),Encephalomyelitis, Central Pontine Myelolysis (CPM), Anti-MAG Disease,Leukodystrophies: Adrenoleukodystrophy (ALD), Alexander's Disease,Canavan Disease, Krabbe Disease, Metachromatic Leukodystrophy (MLD),Pelizaeus-Merzbacher Disease, Refsum Disease, Cockayne Syndrome, Van derKnapp Syndrome, and Zellweger Syndrome, Guillain-Barre Syndrome (GBS),chronic inflammatory demyelinating polyneuropathy (CIDP), multifocualmotor neuropathy (MMN), Alzheimer's disease and progressive supernuclearpalsy. For many of these disorders, there are no cures and few effectivetherapies.

Multiple sclerosis is the most common demyelinating disease of thecentral nervous system, affecting approximately 1,000,000 peopleworldwide and some 250,000 to 350,000 people in the United States. Thedisease is characterized clinically by relapses and remissions, andleading eventually to chronic disability. The earlier phase of multiplesclerosis is characterized by the autoimmune inflammatory strike againstmyelin sheath leading to paralysis, lack of coordination, sensorydisturbances and visual impairment. The subsequent chronic progressivephase of the disease is typically due to active degeneration of themyelin sheath and inadequate remyelination of the demyelinated lesions(Franklin (2002) Nat. Rev. Neurosci. 3: 705-714; Bruck, et al. (2003) J.Neurol. Sci. 206: 181-185; Compston, et al. (2002) Lancet 359:1221-1231).

The precise etiology and pathogenesis of this disease remain unknown.However, pathologic, genetic, and immunologic features have beenidentified which suggest that the disease involves inflammatory andautoimmune basis. See, for example Waksman, et al. (1984) Proc. Soc.Exp. Biol. Med. 175:282-294; Hafler et al. (1987) Immunol. Rev.100:307-332. It is now known that pleotropic cytokine interferon-γ(IFN-γ) which is secreted by activated T Lymphocytes and natural killercells, plays a deleterious role in immune-mediated demyelinatingdisorders including MS and experimental allergic encephalomyelitis (EAE)(Popko et al. (1997) Mol. Neurobiol. 14:19-35; Popko and Baerwald (1999)Neurochem. Res. 24:331-338; Steinman (2001a) Mult. Scler. 7:275-276).This cytokine is normally absent in the CNS, and becomes detectableduring the symptomatic phase of these disorders (Panitch (1992) Drugs44:946-962). In vitro studies have shown that IFN-γ His capable ofpromoting apoptosis in purified developing oligodendrocytes (Baerwaldand Popko (1998) J. NeuroSci. Res. 52:230-239; Andrews et al. (1998) J.Neurosci. Res. 54:574-583; Feldhaus et al. (2004) J. Soc. Gynecol.Investig. 11:89-96). Despite these extensive studies, the precisemechanism by which the secretion of IFN-γ leads to oligodendroglialabnormalities and alteration to the myelin sheath is not wellunderstood.

There thus remains a considerable need for compositions and methodsapplicable for elucidating the molecular bases of neuronaldemyelination. There also exists a pressing need for developingbiologically active agents effective in treating demyelinationdisorders.

SUMMARY OF THE INVENTION

The present invention provides a method of developing a biologicallyactive agent that reduces neuronal demyelination. The method involvesthe steps of (a) contacting a candidate agent with a myelinating cell;(b) detecting an altered expression of a gene or gene product or analtered activity of said gene product relative to a control cell, saidgene or gene product being correlated with endoplasmic reticulum (ER)stress; and (c) selecting said agent as a candidate if the level ofexpression of said gene or gene product, or the level of activity ofsaid gene product is modulated relative to said control cell.

The present invention also provides a method of developing abiologically active agent that promotes neuronal remyelination. Themethod comprises (a) contacting a candidate biologically active agentwith a myelinating cell from a demyelinated lesion of a subject; and (b)detecting an altered expression of a gene or gene product or an alteredactivity of said gene product relative to a control cell, said gene orgene product being correlated with endoplasmic reticulum (ER) stress;and (c) selecting said agent as a candidate if the level of expressionof said gene or gene product, or the level of activity of said geneproduct is modulated relative to said control cell.

The present invention further provides a method of testing for abiologically active agent that modulates a phenomenon associated with ademyelination disorder. Such method involves (a) administering acandidate agent to a non-human transgenic animal, wherein demyelinationoccurs in said animal upon expression of said INF-γ, and (b) determiningthe effect of said agent upon a phenomenon associated with ademyelination disorder.

Also provided in the present invention is a method of testing for abiologically active agent that modulates a phenomenon associated with ademyelination disorder, by performing the following steps: (a)contacting a candidate agent with a cell derived from a non-humantransgenic animal; (b) detecting an altered expression of a gene or geneproduct or an altered activity of said gene product relative to acontrol cell, said gene or gene product being correlated withendoplasmic reticulum (ER) stress; and (c) selecting the agent aseffective to modulate a phenomenon associated with demyelinationdisorder if the level of expression of said gene or gene product, or thelevel of activity of said gene product is modulated relative to saidcontrol cell.

The present invention provides another method for testing for abiologically active agent that modulates a phenomenon associated with ademyelination disorder. The method involves the steps of: (a)administering a candidate biologically active agent to a test animalgenerated by a method comprising (i) inducing neuronal demyelination insaid test animal, and (ii) allowing said test animal to recover from thedemyelination induction for a sufficient amount of time so thatremyelination of a demyelinated lesion is exhibited; and (b) determiningthe effect of said agent upon a phenomenon associated with ademyelination disorder.

In various embodiments of the present invention, the phenomenonassociated with a demyelination disorder is characterized by a loss ofoligodendrocytes in the central nervous system or Schwann cells in theperipheral nervous system. In other embodiments, the phenomenonassociated with a demyelination disorder is characterized by a decreasein myelinated axons in the central nervous system or peripheral nervoussystem. In yet other embodiments, phenomenon associated with ademyelination disorder is characterized by a reduction in the levelsoligodendrocytes or Schwann cell markers, preferably proteinaceousmarkes. Non-limiting exemplary marker protein of a myelinating cell(including oligodendrocyte and Schwann cell) is selected from the groupconsisting of CC1, myelin basic protein (MBP), ceramidegalactosyltransferase (CGT), myelin associated glycoprotein (MAG),myelin oligodendrocyte glycoprotein (MOG), oligodendrocyte-myelinglycoprotein (OMG), cyclic nucleotide phosphodiesterase (CNP), NOGO,myelin protein zero (MPZ), peripheral myelin protein 22 (PMP22), protein2 (P2), galactocerebroside (GalC), sulfatide and proteolipid protein(PLP). MPZ, PMP22 and P2 are preferred markers for Schwann cells.

In certain embodiments, the demyelination disorder referred therein ismultiple sclerosis. In other embodiments, the demyelination disorder isselected from the group consisting of Progressive MultifocalLeukoencephalopathy (PML), Encephalomyelitis, Central Pontine Myelolysis(CPM), Anti-MAG Disease, Leukodystrophies: Adrenoleukodystrophy (ALD),Alexander's Disease, Canavan Disease, Krabbe Disease, MetachromaticLeukodystrophy (MLD), Pelizaeus-Merzbacher Disease, Refsum Disease,Cockayne Syndrome, Ver der Knapp Syndrome, and Zellweger Syndrome,Guillain-Barre Syndrome (GBS), chronic inflammatory demyelinatingpolyneuropathy (CIDP), multifocual motor neuropathy (MMN), Alzheimer'sdisease and progressive supernuclear palsy.

In one aspect of the present invention, the biologically active agentemployed in the cell-based assays may be selected from the groupconsisting of biological or chemical compound such as a simple orcomplex organic or inorganic molecule, peptide, peptide mimetic, protein(e.g. antibody), liposome, small interfering RNA, or a polynucleotide(e.g. anti-sense).

The present invention also provides a non-human transgenic animalhaving: (a) stably integrated into the genome of said animal atransgenic nucleotide sequence encoding interferon-gamma (INF-γ); and(b) an altered expression of at least one other gene; wherein uponexpression of said INF-γ, said animal exhibits a greater degree ofdemyelination relative to a transgenic animal having a stably integratedtransgenic nucleotide sequence encoding interferon-gamma (INF-γ) as in(a), but lacking said altered expression of said at least one othergene.

In one aspect, the at least one other gene is correlated withendoplasmic reticulum stress. Such genes include but are not limited topancreatic. ER kinase gene (p-PERK), eukaryotic translation initiationfactor 2 alpha (eIF-2α, eukaryotic translation initiation factor beta(eIF-2α, inositol requiring 1 (IRE1), activating transcription factor 6(ARTF6), CAATT enhancer-binding protein homologous protein (CHOP),binding-immunoglobulin protein (BIP), caspase-12, growth and DNA damageprotein 34 (GADD34), CreP (a constitutive repressor of eIF2 alphaphosphorylation), suppressor of cytokine signaling 1 (SOCS1), andX-box-binding protein-1 (XBP-1).

In another aspect, the non-human transgenic animal comprises aheterozygous knock-out of pancreatic ER kinase gene (PERK), and stablyintegrated into the genome of said animal a transgenic nucleotidesequence comprising interferon-gamma (INF-γ).

In yet another aspect, the animal exhibits an increased vulnerability toINF-γ-mediated neuronal demyelination relative to a wildtype animal.

Cells derived from such the subject transgenic animals are alsoprovided.

Also included in the present invention is a method of inhibitingneuronal demyelination in a subject comprising administering to saidsubject an amount of biologically active agent effective to modulatestress level of endoplasmic reticulum (ER) in a myelinating cell, in theperheral or in the central nverous system. The myelinating cell can bean oligodendrocyte or a Schwann cell. In one asepect of this embodiment,the biologically active agent is effective to reduce a sustained stresslevel of endoplasmic reticulum (ER) in a myelinating cell. In someaspects, the biologically active agent is an interferon-gamma (INF-γ)antagonist with the proviso that said interferon-gamma (INF-γ)antagonist is not an anti-INF-γ antibody when applied after the onset ofneuronal demyelination. In other aspects, the biologically active agentis an interferon-gamma (INF-γ) or interferon-gamma (INF-γ) agonistadministered prior to the onset of neuronal demyelination to yield aprophylactic effect. Where desired, the biologically active agent can becharacterized by the ability to reduce a sustained stress level of ER,which in turn can be characterized by a decrease in the levels ofproteins correlated with endoplasmic reticulum (ER) stress. Exemplary ERstress correlated proteins include but are not limited to phosphorylatedpancreatic ER kinase gene (p-PERK), eukaryotic translation initiationfactor 2 alpha (eIF-2α), eukaryotic translation initiation factor beta(eIF-2β), inositol requiring 1 (IRE1), activating transcription factor 6(ARTF6), CAATT enhancer-binding protein homologous protein (CHOP),binding-immunoglobulin protein (BIP), caspase-12, growth and DNA damageprotein 34 (GADD34), CreP (a constitutive repressor of eIF2 alphaphosphorylation), and X-box-binding protein-1 (XBP-1).

Further provided in the invention is a method of promoting remyelinationof a neuron in a subject after an occurrence of neuronal demyelination,comprising administering to said subject an amount of pharmaceuticalagent effective to modulate stress level of endoplasmic reticulum (ER)in neuronal tissues undergoing remyelination. In one aspect, thecontemplated biologically active agent is an INF-γ antagonist, includingbut not limited to anti-INF-γ antibody or an antigen-binding fragmentthereof. In another aspect, the biologically active agent is effectiveto reduce a sustained stress level of endoplasmic reticulum (ER) in amyelinating cell. In another aspect, the biologically active agent iseffective to activate eIF-2α pathway by increasing eIF-2α kinaseactivity or increasing the level of phosphorylated eIF-2α present in acell. In yet another aspect, the biologically active agent is effectiveto activate eIF-2α pathway by increasing PERK kinase activity orincreasing the level of phosphorylated PERK or PERK dimer present in acell. In still yet another aspect, the biologically active agent iseffective to activate eIF-2α pathway by deactivating GADD34 pathway. Insome instances, the deactivation of the GADD34 pathway results inreduced GADD34 signaling. In other instances, the deactivation of GADD34pathway results in a reduction of PPI (protein phosphatase 1)phosphatase activity or a reduction in the level of PPI present in acell.

The present invention further provides a method of amelioratingprogression of a demyelination disorder in a subject in need for suchtreatment. The method comprises reducing in said subject the level ofinterferon-gamma (INF-γ) present in said subject's neuronal tissues thatare undergoing remyelination or INF-γ signaling. In some instances, thereduction of the level of INF-γ is effected by delivering to ademyelinated lesion an amount of a pharmaceutical composition comprisedof interferon-gamma (INF-γ) antagonist (e.g., an anti-INF-γ antibody oran antigen-binding fragment). In another aspect, a reduction in INF-γsignaling is effected by a reduction in the level of a downstreamsignaling molecule of INF-γ or biological activity thereof. Thedownstream signaling molecule of INF-γ comprises SOCS1 and/or Stat1.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the results of ELISA analysis of IFN-γ expression patternin double transgenic mice (GFAP/tTA, TRE/IFN-γ). (A) ELISA analysis ofthe expression of IFN-γ protein in the forebrain of double transgenicmice treated with cuprizone (n=2). (B) Real-time PCR analysis of theexpression of MHC-I in the corpus callosum of double transgenic micetreated with cuprizone, n=3, * p<0.05,** p<0.01.

FIG. 2 depicts the comparative results of immunostaining matureoligodendrocytes with anti-CC1 antibodies in the corpus callosum ofdouble transgenic mice treated with cuprizone. (A) Matureoligodendrocytes, detected by CC1 immunostaining (red fluorescence),became depleted in both DOX+ and DOX-double transgenic mice by 5 weeks.The regeneration of oligodendrocytes during recovery was markedlyreduced in DOX− double transgenic mice at 8 weeks. Blue fluorescenceshows DAPI countstain, n=3, scale bar=25 μM. (B) CC1 positive cellnumbers in the corpus callosum of double transgenic mice treated withcuprizone, n=3, * p<0.01.

FIG. 3 depicts the results of immunohistochemical and electronmicroscopic analysis of the corpus callosum of both DOX+ and DOX-doubletransgenic mice. (A) MBP immunostaining showed that the presence ofIFN-γ did not affect cuprizone-induced demyelination at 5 weeks, andsuppressed remyelination at 8 weeks, n=4, scale bar=50 μm (B)Myelination score for MBP immunostaining, with 0 for completedemyelination and 4 for normal myelination of adult male mice, n=4, *p<0.01.

FIG. 4A. Demyelination and remyelination were assessed by EM analysis(n=4), scale bar=0.5 μM. (B) Percentage of remyelinated axons wascalculated from 4 mice at 8 weeks, * p<0.01

FIG. 5 depicts the results of real-time PCR detecting the relative RNAlevels of MBP, PLP and CGT in DOX+ and DOX-double transgenic mice over acourse of 8 weeks. The expression pattern of myelin genes in the corpuscallosum of mice treated with cuprizone, n=3 was obtained. (A) Real-timePCR analysis of the relative mRNA level of MBP, * p<0.05. (B) Real-timePCR analysis of the relative mRNA level of PLP, * p<0.05. (C) Real-timePCR analysis of the relative mRNA level of CGT, * p<0.05.

FIG. 6 depicts the immunostaining of NG2 positive OPCs in the corpuscallosum of DOX+ and DOX-mice treated with curpizone. (A) NG2immunostaining in the corpus callosum of DOX+ double transgenic mice at6 weeks and (B) 8 weeks. (C) NG2 immunostaining in the corpus callosumof DOX− double transgenic mice at 6 weeks and (D) 8 weeks. Redfluorescence represents NG2 immunoreactivity. Blue fluorescence showscounterstaining with DAPI. Scale bar=24 μm. (E) NG2 positive cells inthe corpus callosum of mice treated with cuprizone (n=3), *p<0.05.

FIG. 7 depicts the clinical score for DOX− and DOX+ mice with EAE duringthe onset and recovery from the disorder. CNS delivery of INF-γ at therecovery stage of EAE delays disease recovery. Mean clinical score, n=25for each genotype.

FIG. 8 shows the effect of INF-γ on the CNS during recovery from EAE atPID50. In particular, CNS delivery of INF-γ at the recovery statge ofEAE inhibits remyclination at PID50. (A) MBP immunostaining in thelumbar spinal cord of DOX+ mice. (B) MBP immunostaining in the lumbarspinal cord of DOX− mice that had been released from doxycycline atPID7. (C) Toluidine blue staining in the lumbar spinal cord of DOX+mice. (D) Toluidine blue staining in the lumbar spinal cord of DOX− micethat had been released from doxycycline at PID7. (E) CC1 immunostainingin the lumbar spinal cord of DOX+ mice. (F) CC1 immunostaining in thelumbar spinal cord of DOX− mice that had been released from doxycyclineat PID7. (G) non-phosphorylated neuropfilament-H immunostaining in thelumbar spinal cord of DOX+ mice. (H) non-phosphorylated neuropfilament-Himmunostaining in the lumbar spinal cord of DOX− mice that had beenreleased from doxycycline at PID7. The scale bar for panels A and Bequals 50 μm; the scale bar for panels C—H equals 25 μm The redfluorescence shown in panels E and F reflects CC1 immunoreactivity; theblue fluorescence shows the DAPI counterstain. Experiments were done intriplicate.

FIG. 9 shows the inflammatory infiltration in demyelinating lesions inthe CNS of mice with EAE. CNS delivery of INF-γ at the recovery stage ofEAE enhances inflammatory infiltration in demyelination lesions. (A) CD3immunostatining in the lumbar spinal cord of DOX+ mice. (B) CD3immunostatining in the lumbar spinal cord of DOX− mice that had beenrelease from doxyxycline at PID7. (C) CD11b immunostatining in thelumbar spinal cord of DOX+ mice. (D) CD11b immunostatining in the lumbarspinal cord of DOX− mice that had been release from doxyxycline at PID7.(E) Real-time PCR analysis of the expression of inflammatory markers inthe spinal cord of DOX+ and DOX− mice at PID50. Experiments were done intriplicate; *p<0.05, **p<0.01.

FIG. 10 depicts the effect of INF-γ on the expression ER stress markersduring remyelination. Real time PCR analysis of BIP mRNA (A) and CHOPmRNA (B) in the corpus callosum of DOX+ and DOX-mice in whichdemyelination had been induced with cuprizone (n=3; *p<0.05). (C)Western blot analysis of the expression of CHOP, p-eIF-1α, eIF-2αrelative to actin in the corpus callosum of the DOX+ and DOX− mice in(A). Double immunostaining of CC1 and p-eIF-2α in the corpus callosum ofDOX+ (D) and DOX− (E) mice at week 8. Panels D and E: n=3, scale bar=10μm; red fluorescence reflects CC1 immunoreactivity, green fluorescencereflects p-eIF-2α immunoreactivity. The detrimental effect of INF-γ onremyelination is associated with ER stress.

FIG. 11 shows comparisons of the state of remyelination in the corpuscallosum of DOX+ and DOX− mice that are wild type or are heterozygousfor a mutation in the PERK enzyme (PERK+/−). (A) Electron micrographs ofthe corpus callosum at week 9; n=5, scale bar=0.5 μm. (B) Graph showingthe percent remyelinated axons in 5 mice at week 9, *p<0.01.

FIG. 12 shows a comparison of the number of oligodendrocytes in thecorpus callosum of DOX+ and DOX− mice that are wild type or areheterozygous for a mutation in the PERK enzyme (PERK+/−). (A)Immunostaining of CC1 oligodendrocytes in mice at week 9; the redfluorescence reflects the CC1 cells, and the blue stain is the DAPIcounterstain; n=5, scale bar=25 μm. (B) Graph showing the number of CC1positive oligodendrocytes in mice at week 9, n+5, *p<0.01. (C) Graphshowing the number of CC1 and caspase-3 positive oligodendrocytes inmice at week 9, n=5, p<0.05.

FIG. 13 shows that IFN-γ-induced apoptosis in cultured ratoligodendrocytes is associated with ER stress. (A) Untreatedoligodendrocytes that underwent differentiation for 7 days. (B)Oligodendrocytes that underwent differentiation for 5 days and treatmentwith 70 U/ml IFN-γ for 48 h, revealing cell shrinkage and aggregation ofcell bodies (arrow). (C) TUNEL and CNP double labeling for untreatedoligodendrocytes that underwent differentiation for 7 days. (D) TUNELand CNP double labeling for oligodendrocytes that underwentdifferentiation for 5 days and treatment with 70 U/ml IFN-γ for 48 h.(E) Quantitation of TUNEL and CNPase double positive cells, * p<0.05.(F) Caspase-3 activity assay in the oligodendrocyte lysates, * p<0.01.(G) Real-time PCR analyses of the expression of BIP, CHOP and caspase-12in oligodendrocytes treated with 70 U/ml IFN-γ, * p<0.05. (H) Westernblot analyses of total eIF-2α, p-eIF-2α and caspase-12 inoligodendrocytes treated with 70 U/ml IFN-γ. All experiments wererepeated at least 3 times. Scale bars=30 μM in panels A and B, Scalebars=20 μM in panels C and D.

FIG. 14 shows that hypomyelination induced by ectopically expressedIFN-γ is associated with ER stress. (A) Real-time PCR analyses fordetection of mRNA in the brain of 14-day-old mice ectopically expressingIFN-γ (n=3), * p<0.05, ** p<0.01. (B) Western blot analyses forcaspase-12 in the CNS of 14-day-old double transgenic mice released fromdoxyclycline at E 14. (C) BIP and CC1 double immunostaining in thespinal cord of 14-day-old double transgenic mice that receiveddoxycycline. (D) BIP and CC1 double immunostaining in the spinal cord of14-day-old double transgenic mice released from doxycycline at E 14. (E)p-eIF-2α and CC1 double immunostaining in the spinal cord of 14-day-olddouble transgenic mice that received doxycycline. (F) p-eIF-2α and CC1double immunostaining in the spinal cord of 14-day-old double transgenicmice released from doxycycline at E 14. (G) Caspase-12 and CC1 doubleimmunostaining in the spinal cord of 14-day-old double transgenic micethat received doxycycline. (H) Caspase-12 and CC1 double immunostainingin the spinal cord of 14-day-old double transgenic mice released fromdoxycycline at E 14. Panels C, D, E, F, G and H: n=3, scale bar=30 μM.

FIG. 15 shows hypersensitivity of PERK+/− mice to conditionalmis-expression of IFN-γ. (A) Mouse survival curve (n=40 for each group).(B and C) p-eIF-2α and CC1 double labeling in the spinal cord of14-d-old GFAP/tTA; TRE/IFN-γ, PERK+/− mice that received doxycycline (B)or were released from doxycycline at E 14 (C). (B and C) n=3; bar, 30μM. (D) Real-time PCR analyses of mRNA levels in the brain of 14-d-oldmice (n=3). Error bars represent standard deviation.

FIG. 16 shows that double transgenic mice with a PERK+/− backgrounddevelop severe hypomyelination. (A) MBP immunostaining in the spinalcord of 14-day-old double transgenic mice that received doxycycline. (B)MBP immunostaining in the spinal cord of 14-day-old GFAP/tTA; TRE/IFN-γ;PERK+/− mice that received doxycycline. (C) MBP immunostaining in thespinal cord of 14-day-old double transgenic mice released fromdoxycycline at E 14. (D) MBP immunostaining in the spinal cord of14-day-old GFAP/tTA; TRE/IFN-γ; PERK+/− mice released from doxycyclineat E 14. Panels A, B, C and D: n=3, scale bar=150 μM.

FIG. 17 shows that double transgenic mice with a PERK+/− backgrounddevelop severe hypomyelination. (A) Ultrastructural examination showingnormal myelination in the spinal cord of 14-day-old double transgenicmice that received doxycycline. (B) Ultrastructural examination showingnormal myelination in spinal cord of 14-day-old GFAP/tTA; TRE/IFN-γ;PERK+/− mice that received doxycycline. (C) Ultrastructural examinationshowing minor hypomyelination in the spinal cord of 14-day-old doubletransgenic mice released from doxycycline at E 14. (D) Ultrastructuralexamination showing severe hypomyelination in the spinal cord of14-day-old GFAP/tTA; TRE/IFN-γ; PERK+/− mice released from doxycyclineat E 14. Panels A, B, C, and D: n=3, scale bar=1 μM. (E) The percentageof unmyelinated axons in the white matter of cervical spinal cord wascalculated from three mice per time point, * p<0.01.

FIG. 18 shows that the levels of MBP, PLP and CGT mRNA weresignificantly decreased in the CNS of double transgenic mice with aPERK+/− background. Real-time PCR analyses for myelin gene expression inthe brain of 14-day-old mice (n=3), * p<0.05.

FIG. 19 shows that double transgenic mice with a PERK+/− background losethe majority of the oligodendrocytes in the CNS. (A) Quantitation of CC1positive cells in the CNS of 14-day-old mice (n=3), * p<0.05. (B) TUNELand CC1 double labeling in spinal cord of 14-day-old double transgenicmice that received doxycycline. (C) TUNEL and CC1 double labeling in thespinal cord of 14-day-old GFAP/tTA; TRE/IFN-γ; PERK+/− mice thatreceived doxycycline. (D) TUNEL and CC1 double labeling in the spinalcord of 14-day-old double transgenic mice released from doxycycline at E14. (E) TUNEL and CC1 double labeling in the spinal cord of 14-day-oldGFAP/tTA; TRE/IFN-γ; PERK+/− mice released from doxycycline at E 14.Panels B, C, D and E: n=3; scale bar=60 μM; red fluorescence showing CC1immunoreactivity, green fluorescence showing TUNEL stain and bluefluorescence showing DAPI counter stain. (F) Quantitation of TUNEL ofCC1 double positive cells in the spinal cord of 14-day-old mice (n=3), *p<0.01. (G) Ultrastructural examination showing apoptoticoligodendrocytes contained highly condensed chromatin mass, intactmembrane, shrunken cytoplasm and apoptosis body, scale bar=2 μM.

FIG. 20 shows that oligodendrocytes in adult mice are less sensitive toIFN-γ than actively myelinating oligodendrocytes from younger mice. (A)Real-time PCR analyses of mRNA levels in the brain of 10-week-old mice(n=3), * p<0.05. (B) BIP and CC1 double immunostaining in the cerebellumof 10-week-old double transgenic mice that received doxycycline. (C) BIPand CC1 double immunostaining in the cerebellum of 10-week-old GFAP/tTA;TRE/IFN-γ; PERK+/− mice that received doxycycline. (D) BIP and CC1double immunostaining in the cerebellum of 10-week-old double transgenicmice released from doxycycline at 4 weeks of age. (E) BIP and CC1 doubleimmunostaining in the cerebellum of 10-week-old GFAP/tTA; TRE/IFN-γ;PERK+/− mice released from doxycycline at 4 weeks of age. Panels B, C, Dand E: n=3, scale bar=60 μM; red fluorescence showing CC1immunoreactivity, green fluorescence showing BIP stain and bluefluorescence showing DAPI countstain. (F) Ultrastructural examinationshowing normal myelination in the cerebellum of 10-week-old doubletransgenic mice that received doxycycline. (G) Ultrastructuralexamination showing normal myelination in the cerebellum of 10-week-oldGFAP/tTA; TRE/IFN-γ; PERK+/− mice that received doxycycline. (H)Ultrastructural examination showing normal myelination in the cerebellumof 10-week-old double transgenic mice released from doxycycline at 4weeks of age. (I) Ultrastructural examination showing normal myelinationin the spinal cord of 10-week-old GFAP/tTA; TRE/IFN-γ PERK+/− micereleased from doxycycline at 4 weeks of age. Panels F, G, H and I: n=3,scale bar=2 μM.

FIG. 21 shows a comparison of the onset and progression of EAE in DOX+and DOX− mice that are wild type (DOX triple; PERK+/+) or areheterozygous for a mutation (DOX triple; PERK+/−) in the PERK enzyme.(A) Changes in the mean clinical score for mice with and without EAE. (Band C) Real time PCR analysis for the expression of INF-γ and T-INF inmice at post-immunization days (PID) 14, 17 and 22. Aseteriskp<0.01-0.05, student t test; n=2. Error bars represent standarddeviation.

FIG. 22 shows the results of real time PCR analysis for the expressionof iNOs, TNF-α IL-2, IL-12, IL-10, IL-23 and IL-5 at PID 14 in thespinal cord of DOX+ and DOX− mice with EAE. *p<0.05, student t test;n=4.

FIG. 23 shows that CNS delivery of IFN-γ at EAE onset protects againstEAE-induced demyelination which is dependent on the PERK pathway. (A)MBP immunostaining of lumbar spinal cord tissue showed that CNS deliveryof IFN-γ protected against EAE-induced demyelination in mice with aPERK+/+ background at day 17 postimmunization (PID 17). In contrast,more-severe demyelination was detected in the lumbar spinal cord of DOX−triple mice at PID 17, compared with control mice. N=3, scale bar=50 μm.(B) Toluidine blue staining revealed that the myelin and axons in thespinal cord of DOX− double mice remained almost intact at PID 17. Incontrast, CNS delivery of IFN-γ did not prevent demyelination and axondamage in the lumbar spinal cord of mice with a PERK+/− background byPID 17. N=3, scale bar=10 μm. (C)CC1 immunostaining showed thatoligodendrocytes in the lumbar spinal cord of DOX− double mice remainedalmost intact at PID 17. In contrast, similar to control mice, DOX−triple mice lost the majority of oligodendrocytes in the lumbar spinalcord at PID 17. N=3, scale bar=25 μm. (D) Real-time PCR analysis of therelative MBP mRNA level in the spinal cord at PID 17. A value of 100%represents the MBP mRNA level in the spinal cord of age-matched naivemice; n=3. Error bars indicate standard deviations.

FIG. 24 shows that IFN-γ protected against EAE-induced demyelinationthrough its cytoprotecive effects on oligodendrocyte. A. CD3immunostaining showed CNS delivery of IFN-γ reduced T cell infiltrationin the lumbar spinal cord of mice on a PERK+/+ background at PID 17, butdid not significantly affect T cell infiltration in mice on a PERK+/−background. N=3 scale bar=50 μm. B. CD11b immunostaining revealed thatCNS delivery of IFN-γ did not significantly change the infiltrationpattern of CD11b positive monocytes in the lumbar spinal cord of mice ona PERK+/+ and PERK+/− background at PID 17.N=3, scale bar=50 μm. C. andD. CD 3 immunostaining showed that CNS delivery of IFN-γ did not affectT cell infiltration in lumbar spinal cord at PID 14.

FIG. 25 depicts real-time PCR analysis for the expression pattern ofcytokines in the spinal cord at the peak of disease. (A) CNS delivery ofIFN-γ did not significantly affect the expression of iNOs. (B) CNSdelivery of IFN-γ did not significantly affect the expression of TNF-γ.(C)CNS delivery of IFN-γ decreased the expression of IL-2 in spinal cordof mice on a PERK+/+ background, but did not change IL-12 expression inmice on a PERK+/− background. (D) CNS delivery of IFN-γ decreased theexpression of IL-12 in spinal cord of mice on a PERK+/+ background, butdid not change IL-12 expression in mice on a PERK+/− background. (E) CNSdelivery of IFN-γ decreased the expression of IL-23 in spinal cord ofmice on a PERK+/+ background, but did not change IL-12 expression inmice on a PERK+/− background. (F) CNS delivery of IFN-γ did notsignificantly affect the expression of IL-5. CNS delivery of IFN-γ didnot significantly affect the expression of IL-10. All panels: n=3, errorbars represent standard derivation; asterisk p<0.05. CNS delivery ofIFN-γ did not significantly affect the expression of IL-10. All panels:n=3, error bars represent standard derivation; asterisk p <0.05.

FIG. 26 shows that the clinical disease onset in the GADD34-null mice isdelayed when compared with the onset in littermate control mice. Meanclinical disease severity score, n=6.

FIG. 27 shows dual label immunohistochemical analysis of the effect ofthe loss of function of GADD34. (a) GADD34 was undetectable inoligodendrocytes from the spinal cord of 8-week old naive mice. (b) Thearrow points to GADD34 that was upregulated in oligodendrocytes ofcontrol mice with EAE at PID 17 (scale bar=15 μm, n=3 mice per studygroup). (c) The arrow points to double labeling of CC1 and p-eIF2α,which showed modest activation of eIF2α in a few oligodendrocytes of thelumbar spinal cord of control mice with EAE at PID 17. (d) CC1 andp-eIF2α double labeling showed the level of p-eIF2α was increased inoligodendrocytes (arrow) in GADD34 null mice at PID17. N=3, Scale bar=10μm

FIG. 28 shows immunostaining of MBP in sections of the lumbar spinalcord from GADD34-null mice and control mice. (a) and (b) show MBPimmunostaining of the lumbar spinal cord tissue from GADD34 wild-typeand GADD34-null mice, respectively. The arrow points to a demyelinatinglesion seen in control mice with EAE at PID17 (a), while no obviousdemyelinating lesion was observed in GADD34 null mice with EAE at PID17(b) (n=3, scale bar=50 μm.). (c) and (d) show that toluidine bluestaining of sections of the lumbar spinal cord of GADD34 wild-type andGADD34-null mice, respectively. Severe demyelination in the lesions inthe lumbar spinal cord of control mice at PID17 (c), whereas GADD34deletion protected against EAE-induced demyelination in the lumbarspinal cord of GADD34 null mice at PID17 (d) (n=3, scale bar=10 μm). (e)and (f) CC1 immunostaining of the lumbar spinal cord tissue from GADD34wild-type and GADD34-null mice, respectively. (e) shows that themajority of oligodendrocytes in the demyelinating lesions in the lumbarspinal cord of control mice were lost at PID17, whereas theoligodendrocytes (arrow) in the lumbar spinal cord of GADD34 null miceremained almost intact. (f) (n=3, scale bar=25 μm). (g) and (h) showimmunostaining of non-phosphorylated neurofilament-H immunostaining oflumbar spinal cord tissue from control and GADD34-null mice,respectively. Severe axonal damage is shown by the arrow in thedemyelinating lesions in control mice at PID17 (g), whereas mice withthe GADD34 deletion had markedly reduced axonal damage (arrow) in thelumbar spinal cord of GADD34 null mice (h) (n=3, scale bar=25 μm).

FIG. 29 shows the attenuating effect of Sal on the reduction of MBPlevels mediated by INFγ by Western blot analysis (A), and densitometricanalysis of the MBP protein bands normlized to actin (B).

FIG. 30 shows the expression of Flag-SOCS1. A. PLP/SOCS1 constructcontains 2.4 Kb of the PLP 5′ flanking DNA, exon 1 (no ATG), intron 1(diagonally striped boxes), Flag-SOCS1 and SV40 polyA signal sequence.Expression of the PLP/SOCS1 transgene was characterized at postnatal day21 using several methods. B. Northern blot analysis demonstratedFlag-SOCS1 expression in PLP/SOCS1 brain, lane 2 (T, transgenic brain),compared to wild-type brain, lane 1 (WT, wild-type brain). C. Q-PCRanalysis with transgene-specific primers revealed the highestconcentrations of transgene-derived SOCS1 mRNA were in the brain, spinalcord, and sciatic nerve, with significantly lower levels in otherorgans. D. Western blot. E: Immunoprecipitation. Both demonstrated asingle 19 KD Flag positive band, the expected molecular weight of SOCS1,only in the lanes loaded with brain samples from PLP/SOCS1 mice (brainfSOCS1+). Flag protein was used as a positive control for the antibodyreaction; 15% SDS-PAGE, anti-Flag (M2) antibody. Immunostaining withanti-SOCS1/FITC (F, H, green), and anti-Flag/FITC antibodies (G, 1,green) demonstrated positive signal only in PLP/SOCS1 (H, 1, green), andnot in the wild-type mouse samples (F, G). Cell nuclei werecontrastained with ethidium bromide (F-1, red). Coronal section sectionsof thalamic fiber; Bar=20 μm.

FIG. 31 shows the colocalization of Flag-SOCS1 and PLP in vivo. Dualimmunostaining of wild-type (A-C, top row) and PLP/SOCS1 (D-F, bottomrow) cerebellar tissue, harvested at postnatal day 21, was performedusing anti-PLP/Cy3 (A, D, red) and anti-Flag/FITC (B, E, green)antibodies, and DAPI nuclear stain (C, F, blue). PLP positive structuresof the wild-type samples (A, red) demonstrated no immunopositivity foranti-Flag (B) and no signal colocalization was established (C). Incontrast, PLP positive structures of PLP/SOCS1 samples (D) expressedFlag-SOCS1 (E), and strong co-localization between the anti-PLP andanti-Flag immunopositivity was detected (F, yellow color signifiesco-localization). Sagittal sections of cerebellum; Bar=20 μm.

FIG. 32 shows the Colocalization of flag-SOCS1 and PLP in vitro. Dualimmunostaining of wild-type (A-C, top row) and PLP/SOCS1 (D-F, bottomrow) mixed primary oligodendrocyte cultures was performed usinganti-PLP/FITC (A, D, green) and anti-Flag/Cy3 (B, E, red) antibodies.PLP positive oligodendrocytes in the wild-type culture (A) demonstratedno immunopositivity for anti-Flag (B), and no signal colocalization wasestablished (C). In contrast, PLP positive oligodendrocytes (D) in thePLP/SOCS1 cultures expressed Flag-SOCS1 (E), and strong colocalizationbetween anti-PLP and anti-Flag signals was detected (F). Flag-SOCS1appeared to be localized in the cell body (large arrows) and cellprocesses (small arrows) of oligodendrocytes. Bar 20 μm.

FIG. 33 shows the differential inhibition of Stat1 nucleartranslocation. Mixed primary oligodendrocyte cultures from wild-type(A-D; top row) and PLP/SOCS1 (E-H; bottom row) mice were stimulated with100 U IFN-γ for 30 min, and dual immunostainings using anti-PLP/Cy3 (A,E; red), anti-Stat1 (B, F; green), and DAPI nuclear stain (D, H; blue)were performed and the fluorescent signals digitally overlayed (C and G,overlay between PLP/Cy3 and Stat1/FITC signals; D and H, overlay betweenPLP/Cy3, Stat1/FITC and DAPI signals). In the wild-type cultures, Stat1was colocalized with DAPI stained nuclei of all cells, including the PLPpositive oligodendrocytes (small arrows) (B, D, colocalization betweenStat1 and DAPI). In the PLP/SOCS1 cultures, Stat1 was colocalized withDAPI positive nuclei of the PLP negative cells (small arrows), but notof the PLP positive oligodendrocytes (large arrows) (F, H). Stat1 in thePLP positive oligodendrocytes did not colocalize with DAPI stainednuclei, but remained in the cytoplasm (large arrows) (F, H). Bar=10 μm.

FIG. 34 shows the differential expression of MHC class I molecule inMBP/IFN-γ×PLP/SOCS1 mice. Wild-type (A, B), PLP/SOCS1 (C, D), MBP/IFN-γ(E, F) and MBP/IFN-γ×PLP/SOCS1 (G, H, I, J) mouse brains, harvested atpostnatal day 21, were dual immunostained with anti-MHC class I/FITC (A,C, E, G, I; green) and anti-flag/Cy3 (B, D, F, H, J; red) antibodies,and DAPI nuclear stain (J, blue). Wild-type samples were double negative(A, B). PLP/SOCS1 samples were negative for MHC class I molecule (C) andpositive for Flag (D). MBP/IFN-γ samples were single positive for MHCclass I molecule (E) and negative for Flag (F). Double transgenicMBP/IFN-γ×PLP/SOCS1 samples were double positive for MHC class Imolecule (G) and Flag (H). Higher magnification of MBP/IFN-γ×PLP/SOCS1samples (outlined square in G, H) revealed differential distribution ofthe immunopositivity (1, J); MHC class I positive cells (large arrows)were negative for Flag, whereas Flag positive cells (small arrows) werenegative for MHC class I molecules. Sagittal sections of corpuscallosum; Bar=20 nm (A-H); Bar=10 μm (I, J).

FIG. 35 shows the SOCS1-mediated protection of oligodendrocytes andmyelin. The IFN-γ expression (A), oligodendrocyte density (CC1cells/mm²) (B), G ratio (C), and percent unmyelinated axons (D) wereexamined among littermates of three transgenic systems: 172×PLP/SOCS1,184/110×PLP/SOCS1 and 184/67×PLP/SOCS1 at postnatal day 21 (see Resultsfor complete description). The relative amount of IFN-γ expressiondiffered among the systems but no statistical difference was found inthe levels of expression between littermates from the same transgenicsystem overexpressing either IFN-γ only (IFN-γ) or both IFN-γ and SOCS1(IFN-γ×SOCS1) (A). The IFN-γ overexpressing littermates (IFN-γ)displayed significant dose-dependent oligodendrocyte cell loss (B) andhypomyelination (C, D) as compared to the wild type, single transgeniccontrol (wt/cntrl) and PLP/SOCS1 littermates (* p<0.05, n=3 animals perstudy group). The triple transgenic littermates expressing both IFN-γand SOCS1 (IFN-γ×SOCS1) displayed significant oligodendrocyte (B) andmyelin preservation (C, D) as compared to those overexpressing IFN-γonly (IFN-γ) (** p<0.05, n=3 animals per study group).

FIG. 36 shows SOCS1-mediated oligodendrocyte protection. Representativeimages of the quanitated areas from GFAP/tTA×TRE/IFN-γ×PLP/SOCS1(184/67×PLP/SOCS1) mice at postnatal day 21: A. Wild-type; B. PLP/SOCS1;C. 184/67 and D; 184/67×PLP/SOCS1. Immmunostaining with CC1/Cy3 (red)and DAPI nuclear stain (blue). Sagittal sections of corpus callosum;Bar=20 μm. Note the loss of CC1 positivity in the sample from anIFN-γ-overexpressing mouse (C) compared to the samples from wild-type(A) and PLP/SOCS1 mice (B), and the significant oligodendrocytepreservation in the sample from a mouse overexpressing both IFN-γ andSOCS1 (D).

FIG. 37 shows SOCS1-mediated myelin protection. Representative images ofthe quanitated areas from GFAP/tTA×TRE/IFN-γ×PLP/SOCS1(184/67×PLP/SOCS1) mice at postnatal day 21: A. Wild-type; B. PLP/SOCS1;C. 184/67 and D; 184167×PLP/SOCS1. Electron micrographs of corpuscallosum; Bar 500 nm. Note the hypomyelination in the sample from anIFN-γ-overexpressing mouse (C) compared to the samples from wild type(A) and PLP/SOCS1 mice (B), and the significant myelin preservation inthe sample from a mouse overexpressing both IFN-γ and SOCS1 (D).

DETAILED DESCRIPTION OF THE EMBODIMENTS

Throughout this disclosure, various publications, patents and publishedpatent specifications are referenced by an identifying citation. Thedisclosures of these publications, patents and published patentspecifications are hereby incorporated by reference into the presentdisclosure to more fully describe the state of the art to which thisinvention pertains.

General Techniques:

The practice of the present invention employs, unless otherwiseindicated, conventional techniques of immunology, biochemistry,chemistry, molecular biology, microbiology, cell biology, genomics andrecombinant DNA, which are within the skill of the art. See Sambrook,Fritsch and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2^(nd)edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel,et al. eds., (1987)); the series METHODS IN ENZYMOLOGY (Academic Press,Inc.): PCR 2: A PRACTICAL APPROACH (M. J. MacPherson, B. D. Hames and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, ALABORATORY MANUAL, and ANIMAL CELL CULTURE (R. I. Freshney, ed. (1987)).

Definitions:

As used in the specification and claims, the singular form “a”, “an” and“the” include plural references unless the context clearly dictatesotherwise. For example, the term “a cell” includes a plurality of cells,including mixtures thereof.

The terms “polynucleotide”, “nucleotide”, “nucleotide sequence”,“nucleic acid” and “oligonucleotide” are used interchangeably. Theyrefer to a polymeric form of nucleotides of any length, eitherdeoxyribonucleotides or ribonucleotides, or analogs thereof.Polynucleotides may have any three-dimensional structure, and mayperform any function, known or unknown. The following are non-limitingexamples of polynucleotides: coding or non-coding regions of a gene orgene fragment, loci (locus) defined from linkage analysis, exons,introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes,cDNA, recombinant polynucleotides, branched polynucleotides, plasmids,vectors, isolated DNA of any sequence, isolated RNA of any sequence,nucleic acid probes, and primers. A polynucleotide may comprise modifiednucleotides, such as methylated nucleotides and nucleotide analogs. Ifpresent, modifications to the nucleotide structure may be impartedbefore or after assembly of the polymer. The sequence of nucleotides maybe interrupted by non-nucleotide components. A polynucleotide may befurther modified after polymerization, such as by conjugation with alabeling component.

A “nucleotide probe” or “probe” refers to a polynucleotide used fordetecting or identifying its corresponding target polynucleotide in ahybridization reaction.

“Hybridization” refers to a reaction in which one or morepolynucleotides react to form a complex that is stabilized via hydrogenbonding between the bases of the nucleotide residues. The hydrogenbonding may occur by Watson-Crick base pairing, Hoogstein binding, or inany other sequence-specific manner. The complex may comprise two strandsforming a duplex structure, three or more strands forming amulti-stranded complex, a single self-hybridizing strand, or anycombination of these. A hybridization reaction may constitute a step ina more extensive process, such as the initiation of a PCR, or theenzymatic cleavage of a polynucleotide by a ribozyme.

The term “hybridized” as applied to a polynucleotide refers to theability of the polynucleotide to form a complex that is stabilized viahydrogen bonding between the bases of the nucleotide residues. Thehydrogen bonding may occur by Watson-Crick base pairing, Hoogsteinbinding, or in any other sequence-specific manner. The complex maycomprise two strands forming a duplex structure, three or more strandsforming a multi-stranded complex, a single self-hybridizing strand, orany combination of these. The hybridization reaction may constitute astep in a more extensive process, such as the initiation of a PCRreaction, or the enzymatic cleavage of a polynucleotide by a ribozyme.

As used herein, “expression” refers to the process by which apolynucleotide is transcribed into mRNA and/or the process by which thetranscribed mRNA (also referred to as “transcript”) is subsequentlybeing translated into peptides, polypeptides, or proteins. Thetranscripts and the encoded polypeptides are collectedly referred to as“gene product.” If the polynucleotide is derived from genomic DNA,expression may include slicing of the mRNA in a eukaryotic cell.

“Differentially expressed,” as applied to nucleotide sequence orpolypeptide sequence in a subject, refers over-expression orunder-expression of that sequence when compared to that detected in acontrol. Underexpression also encompasses absence of expression of aparticular sequence as evidenced by the absence of detectable expressionin a test subject when compared to a control.

“Signal transduction” is a process during which stimulatory orinhibitory signals are transmitted into and within a cell to elicit anintracellular response. A molecule can mediate its signaling effect viadirect or indirect interact with downstream molecules of the samepathway or related pathway(s). For instance, INFγ signaling can involvea host of downstream molecules including but not limted to one or moreof the following proteins: PERK, eIF-2α, SOCS1, and Stat1.

The terms “polypeptide”, “peptide” and “protein” are usedinterchangeably herein to refer to polymers of amino acids of anylength. The polymer may be linear or branched, it may comprise modifiedamino acids, and it may be interrupted by non-amino acids. The termsalso encompass an amino acid polymer that has been modified; forexample, disulfide bond formation, glycosylation, lipidation,acetylation, phosphorylation, or any other manipulation, such asconjugation with a labeling component. As used herein the term “aminoacid” refers to either natural and/or unnatural or synthetic aminoacids, including glycine and both the D or L optical isomers, and aminoacid analogs and peptidomimetics.

As used herein, “myelinating cell” refers to those cells capable ofproducing myelin which insulates axons in the nervous system. Exemplarymyelinating cells are oligodendrocytes responsible for producing myelinin the central nervous system, and Schwann cells responsible forproducing myelin in the peripheral nervous system.

A “subject,” “individual” or “patient” is used interchangeably herein,which refers to a vertebrate, preferably a mammal, more preferably ahuman. Mammals include, but are not limited to, murines, simians,humans, farm animals, sport animals, and pets. Tissues, cells and theirprogeny of a biological entity obtained in vivo or cultured in vitro arealso encompassed.

A “control” is an alternative subject or sample used in an experimentfor comparison purpose.

A central aspect of the present invention is the discovery of theassociation of neuronal demyelination with endoplasmic reticulum (ER)stress level in cells that play a role in neuronal myelination.

Cell-Based Assays:

Accordingly, in one embodiment, the present invention provides method ofdeveloping a biologically active agent that reduces neuronaldemyelination. The method involves the steps of (a) contacting acandidate agent with a myelinating cell; (b) detecting an alteredexpression of a gene or gene product or an altered activity of said geneproduct relative to a control cell, said gene or gene product beingcorrelated with endoplasmic reticulum (ER) stress; and (c) selectingsaid agent as a candidate if the level of expression of said gene orgene product, or the level of activity of said gene product is modulatedrelative to said control cell.

In another embodiment, the present invention provides a method ofdeveloping a biologically active agent that promotes neuronalremyelination. The method comprises the steps of (a) contacting acandidate biologically active agent with a myelinating cell from ademyelinated lesion of a subject; and (b) detecting an alteredexpression of a gene or gene product or an altered activity of said geneproduct relative to a control cell, said gene or gene product beingcorrelated with endoplasmic reticulum (ER) stress; and (c) selectingsaid agent as a candidate if the level of expression of said gene orgene product, or the level of activity of said gene product is modulatedrelative to said control cell.

The practice of the invention involves a comparison of the expression ofa gene or gene product or the activity of said gene product in a testmyelinating cell (whether oligodendrocyte or Schwann cell) relative to acontrol cell. The test myelinating cell used for this invention can beisolated from central or peripheral nervous systems, and includes cellculture derived therefrom and the progeny thereof, and section or smearprepared from the source, or any other samples of the brain that containoligodendrocytes or Schwann cells or their progenitors. Where desired,one may choose to use enriched these cell cultures that aresubstantially free of other neuronal cell types such as neurons,microglial cells, and astrocytes. Various methods of isolating,generating or maintaining matured oligodendrocytes and Schwann cells areknown in the art (Baerwald, et al. (1998) J. Neurosci. Res. 52: 230-239;Levi, et al. (1996) J Neurosci Methods. 68(1): 21-6) and are exemplifiedherein.

In certain embodiments, it may be preferable to employ myelinating cellsfrom young subjects whose nervous systems are actively undergoingmyelination. In other embodiments, it may be preferable to useremyelinating cells derived from adult oligodendrocyte precursors indemyelinated lesions, including but not limited to lesions inflicted bypathogens or physical injuries, and lesions caused by toxic agents suchas cuprizone. In yet other embodiments, it may be preferable to usemyelinating cells that are directly exposed to IFN-γ or that are derivedfrom subjects whose nervous systems have been exposed to IFN-γ. Forinstance, one may choose to employ oligodendrocytes derived fromtransgenic animals that are ectopically expressed IFN-γ in the centralnervous systems. In still other embodiments, one may select testmyelinating cells that differentially express any ER-stress relatedgenes. Such myelinating cells may overexpress or underexpress ER-stresscausing genes, or ER-stress suppressing genes (e.g., BIP, and pancreaticER kinase gene (PERK)). These myelinating cells may be derived fromtransgenic animals that have one or more ER-stress related genesknocked-in (overexpress) or knocked-out (underexpress).

Alternatively, such myelinating cells can be generated by introducinginto the cell a genetic vehicle to effect such overexpression orunderexpression. A vast number of genetic vehicles suitable for thepresent invention are available in the art. They include both viral andnon-viral expression vectors. Non-limiting exemplary viral expressionvectors are vectors derived from RNA viruses such as retroviruses, andDNA viruses such as adenoviruses and adeno-associated viruses. Non-viralexpression vectors include but are not limited to plasmids, cosmids, andDNA/liposome complexes. Where desired, the genetic vehicles can beengineered to carry regulatory sequences that direct tissue specific,cell specific, or even organelle specific expression of the exogenousgenes carried therein.

A number of tissue or cell specific regulatory sequences have beendemonstrated applicable for expressing transgenes in the central nervoussystems and peripheral nervous system. An exemplary sequence is thetranscriptional regulatory sequence of the glial fibrillary acidic gene(GFAP). The regulatory sequence allows ectopical expression oftransgenes in the central nervous system and peripheral nervous system(e.g., in the Schwann cells).

A wide variety of subcellular localization sequences have beencharacterized and are applicable for directing organelle specificexpression of transgenes. For instance, subcellular localizationsequence can be any one of the following: (a) a signal sequence thatdirects secretion of the gene product outside of the cell; (b) amembrane anchorage domain that allows attachment of the protein to theplasma membrane or other membraneous compartment of the cell; (c) anuclear localization sequence that mediates the translocation of theencoded protein to the nucleus; (d) an endoplasmic reticulum retentionsequence (e.g. KDEL sequence) that confines the encoded proteinprimarily to the ER; or (e) any other sequences that play a role indifferential subcellular distribution of a encoded protein product.

The genetic vehicles can be inserted into a host cell (e.g., myelinatingcells such as oligodendrocytes or Schwann cells) by any methods known inthe art. Suitable methods may include transfection using calciumphosphate precipitation, DEAE-dextran, electroporation, ormicroinjection.

The selection of an appropriate control cell or tissue is dependent onthe test cell or tissue initially selected and its phenotypic orgenotypic characteristic which is under investigation. Whereas the testmyelinating cell is derived from demyelinated lesions, one or morecounterparts from non-demyelinated tissues can be used as control cells.Whereas the test myelinating cell is treated with IFN-γ, the controlcell may be a non-treated counterpart. It is generally preferable toanalyze the test cell and the control in parallel.

For the purposes of this invention, a biologically active agenteffective to modulate neuronal demyelination is intended to include, butnot be limited to a biological or chemical compound such as a simple orcomplex organic or inorganic molecule, peptide, peptide mimetic, protein(e.g. antibody), liposome, small interfering RNA, or a polynucleotide(e.g. anti-sense). A class of preferred agents include those that blockthe downstream signaling effect of a target molecule. This class ofagents may include soluble ligand receptors or derivatives thereof thatcompete for the binding of the ligands with the native receptors,typically anchored on the cell, thereby preventing the ligands frommediating their downstream effect. The methodology is known in the art.See, e.g., Economides et al. (2003) Nat Med 9(1):47-52.

A vast array of compounds can be synthesized, for example polymers, suchas polypeptides and polynucleotides, and synthetic organic compoundsbased on various core structures, and these are also contemplatedherein. In addition, various natural sources can provide compounds forscreening, such as plant or animal extracts, and the like. It should beunderstood, although not always explicitly stated that the active agentcan be used alone or in combination with another modulator, having thesame or different biological activity as the agents identified by thesubject screening method. A preferred class of agent is IFN-γantagonist. As is understood by one skilled in the art, an antagonistinhibits the biological activity mediated by a target that it interacts.An antagonist can assert its inhibitory effect by directly binding to ordirectly interacting with the target. An antagonist can also assert itsinhibitory effect indirectly by first interacting with a molecule in thesame signaling pathway. The IFN-γ antagonist of the present inventionencompasses simple or complex organic or inorganic molecule, peptide,peptide mimetic, protein (e.g. antibody), liposome, small interferingRNA, or a polynucleotide (e.g. anti-sense) that can reduce thedeleterious effect of IFN-γ on neuronal demyclination.

In some instances where prophylactic effect is desired, IFN-γ or IFN-γagonist (e.g., salubrinol (Sal)) can be applied prior to the onset ofneuronal demyelination. As is understood by one skilled in the art, anagonist activates the biological activity mediated by a target that itinteracts. An agonist can assert its inhibitory effect by directlybinding to or directly interacting with the target. An agonist can alsoassert its stimulatory effect indirectly by first interacting with amolecule in the same signaling pathway. The IFN-γ agonist of the presentinvention encompasses simple or complex organic or inorganic molecule,peptide, peptide mimetic, protein (e.g. antibody), liposome, smallinterfering RNA, or a polynucleotide (e.g. anti-sense) that can reducethe deleterious effect of IFN-γ on neuronal demyelination.

When the agent is a composition other than naked RNA, the agent may bedirectly added to the cell culture or added to culture medium foraddition. As is apparent to those skilled in the art, an “effective”amount must be added which can be empirically determined. When the agentis a polynucleotide, it may be introduced directly into a cell bytransfection or electroporation. Alternatively, it may be inserted intothe cell using a gene delivery vehicle or other methods as describedabove.

As used herein, ER-stress related genes encompass all nucleic acidsencoding proteins that correlate with stress in the ER. Generally, theseproteins play a role in ER homeostasis. There are many ways in whichstress, whether endogenous or exogenous, that can be manifested in acell; these include but are not limited to pathogenic infection,chemical insult, genetic mutation, nutrient deprivation, and even normalcellular differentiation.

In general, disruption of the homeostasis and hence ER stress isevidenced by the accumulation of unfolded or misfolded proteins in theER lumen (Rutkowski, et al. (2004) Trends Cell Biol. 14: 20-28; Ma, etal. (2001) Cell 107: 827-830). This stress elicits the unfolded proteinresponse, a functional mechanism by which cells attempt to protectthemselves against ER stress. The unfolded protein response mayinvolve 1) transcriptional induction of ER chaperone proteins whosefunction is both to increase folding capacity of the ER and preventprotein aggregation; 2) translational attenuation to reduce proteinoverload and subsequent accumulation of unfolded proteins; and 3)removal of misfolded proteins from the ER through retrograde transportcoupled to their degradation by the 26S proteasome. These protectiveresponses act transiently to maintain homeostasis within the ER, butsustained ER stress can ultimately lead to the death of the cell(Rutkowski, et al. (2004) Trends Cell Biol. 14: 20-28; Ma, et al. (2001)Cell 107: 827-830; Rao, et al. (2004) Cell Death Differ. 11: 372-380).As such, genes involved in one or more aspects of the aforementionedunfolded protein response are suitable for practicing the presentinvention. Non-limiting examples of ER-stress related genes includepancreatic ER kinase gene (PERK), eukaryotic translation initiationfactor 2 alpha (eIF-2α, eukaryotic translation initiation factor beta(eIF-2α, inositol requiring 1 (IRE1), activating transcription factor 6(ARTF6), CAATT enhancer-binding protein homologous protein (CHOP),binding-immunoglobulin protein (BIP), caspase-12, growth and DNA damageprotein 34 (GADD34), CreP (a constitutive repressor of eIF2 alphaphosphorylation), and X-box-binding protein-1 (XBP-1).

An altered expression of an ER-stress related gene or gene product canbe determined by assaying for a difference in the mRNA levels of thecorresponding genes between the test myelinating cell and a controlcell, when they are contacted with a candidate agent. Alternatively, thedifferential expression of the ER-stress related gene is determined bydetecting a difference in the level of the encoded polypeptide or geneproduct.

To assay for an agent-induced alteration in the level of mRNAtranscripts or corresponding polynucleotides, nucleic acid contained ina biological sample comprising myelinating cells is first extractedaccording to standard methods in the art. For instance, mRNA can beisolated using various lytic enzymes or chemical solutions according tothe procedures set forth in Sambrook et al. (1989), supra or extractedby nucleic-acid-binding resins following the accompanying instructionsprovided by the manufacturers. The mRNA contained in the extractednucleic acid sample is then detected by amplification procedures orconventional hybridization assays (e.g. Northern blot analysis)according to methods widely known in the art or based on the methodsexemplified herein.

For purpose of this invention, amplification means any method employinga primer and a polymerase capable of replicating a target sequence withreasonable fidelity. Amplification may be carried out by natural orrecombinant DNA polymerases such as TaqGold™, T7 DNA polymerase, Klenowfragment of E. coli DNA polymerase, and reverse transcriptase. Apreferred amplification method is PCR. In particular, the isolated RNAcan be subjected to a reverse transcription assay that is coupled with aquantitative polymerase chain reaction (RT-PCR) in order to quantify theexpression level of an ER-stress related gene.

Detection of the gene expression level can be conducted in real time inan amplification assay. In one aspect, the amplified products can bedirectly visualized with fluorescent DNA-binding agents including butnot limited to DNA intercalators and DNA groove binders. Because theamount of the intercalators incorporated into the double-stranded DNAmolecules is typically proportional to the amount of the amplified DNAproducts, one can conveniently determine the amount of the amplifiedproducts by quantifying the fluorescence of the intercalated dye usingconventional optical systems in the art. DNA-binding dye suitable forthis application include SYBR green, SYBR blue, DAPI, propidium iodine,Hoeste, SYBR gold, ethidium bromide, acridines, proflavine, acridineorange, acriflavine, fluorcoumanin, ellipticine, daunomycin,chloroquine, distamycin D, chromomycin, homidium, mithramycin, rutheniumpolypyridyls, anthramycin, and the like.

In another aspect, other fluorescent labels such as sequence specificprobes can be employed in the amplification reaction to facilitate thedetection and quantification of the amplified products. Probe-basedquantitative amplification relies on the sequence-specific detection ofa desired amplified product. It utilizes fluorescent, target-specificprobes (e.g., TaqMan™ probes) resulting in increased specificity andsensitivity. Methods for performing probe-based quantitativeamplification are well established in the art and are taught in U.S.Pat. No. 5,210,015.

In yet another aspect, conventional hybridization assays usinghybridization probes that share sequence homology with ER-stress relatedgenes can be performed. Typically, probes are allowed to form stablecomplexes with the target polynucleotides (e.g., ER-stress relatedgenes) contained within the biological sample derived from the testsubject in a hybridization reaction. It will be appreciated by one ofskill in the art that where antisense is used as the probe nucleic acid,the target polynucleotides provided in the sample are chosen to becomplementary to sequences of the antisense nucleic acids. Conversely,where the nucleotide probe is a sense nucleic acid, the targetpolynucleotide is selected to be complementary to sequences of the sensenucleic acid.

As is known to one skilled in the art, hybridization can be performedunder conditions of various stringency. Suitable hybridizationconditions for the practice of the present invention are such that therecognition interaction between the probe and target ER-stress relatedgene is both sufficiently specific and sufficiently stable. Conditionsthat increase the stringency of a hybridization reaction are widelyknown and published in the art. See, for example, (Sambrook, et al.,(1989), supra; Nonradioactive In Situ Hybridization Application Manual,Boehringer Mannheim, second edition). The hybridization assay can beformed using probes immobilized on any solid support, including but arenot limited to nitrocellulose, glass, silicon, and a variety of genearrays. A preferred hybridization assay is conducted on high-densitygene chips as described in U.S. Pat. No. 5,445,934.

For a convenient detection of the probe-target complexes formed duringthe hybridization assay, the nucleotide probes are conjugated to adetectable label. Detectable labels suitable for use in the presentinvention include any composition detectable by photochemical,biochemical, spectroscopic, immunochemical, electrical, optical orchemical means. A wide variety of appropriate detectable labels areknown in the art, which include fluorescent or chemiluminescent labels,radioactive isotope labels, enzymatic or other ligands. In preferredembodiments, one will likely desire to employ a fluorescent label or anenzyme tag, such as digoxigenin, β-galactosidase, urease, alkalinephosphatase or peroxidase, avidin/biotin complex.

The detection methods used to detect or quantify the hybridizationintensity will typically depend upon the label selected above. Forexample, radiolabels may be detected using photographic film or aphosphoimager. Fluorescent markers may be detected and quantified usinga photodetector to detect emitted light. Enzymatic labels are typicallydetected by providing the enzyme with a substrate and measuring thereaction product produced by the action of the enzyme on the substrate;and finally colorimetric labels are detected by simply visualizing thecolored label.

An agent-induced change in expression of ER-stress related genes canalso be determined by examining the corresponding gene products.Determining the protein level typically involves a) contacting theprotein contained in a biological sample comprising myelinating cellswith an agent that specifically bind to the ER-stress related protein;and (b) identifying any agent:protein complex so formed. In one aspectof this embodiment, the agent that specifically binds an ER-stressrelated protein is an antibody, preferably a monoclonal antibody.

The reaction is performed by contacting the agent with a sample of theER-stress related proteins derived from the test samples underconditions that will allow a complex to form between the agent and theER-stress related proteins. The formation of the complex can be detecteddirectly or indirectly according to standard procedures in the art. Inthe direct detection method, the agents are supplied with a detectablelabel and unreacted agents may be removed from the complex; the amountof remaining label thereby indicating the amount of complex formed. Forsuch method, it is preferable to select labels that remain attached tothe agents even during stringent washing conditions. It is preferablethat the label does not interfere with the binding reaction. In thealternative, an indirect detection procedure requires the agent tocontain a label introduced either chemically or enzymatically. Adesirable label generally does not interfere with binding or thestability of the resulting agent:polypeptide complex. However, the labelis typically designed to be accessible to an antibody for an effectivebinding and hence generating a detectable signal.

A wide variety of labels suitable for detecting protein levels are knownin the art. Non-limiting examples include radioisotopes, enzymes,colloidal metals, fluorescent compounds, bioluminescent compounds, andchemiluminescent compounds.

The amount of agent:polypeptide complexes formed during the bindingreaction can be quantified by standard quantitative assays. Asillustrated above, the formation of agent:polypeptide complex can bemeasured directly by the amount of label remained at the site ofbinding. In an alternative, the ER-stress related protein is tested forits ability to compete with a labeled analog for binding sites on thespecific agent. In this competitive assay, the amount of label capturedis inversely proportional to the amount of ER-stress related proteinpresent in a test sample.

A number of techniques for protein analysis based on the generalprinciples outlined above are available in the art. They include but arenot limited to radioimmunoassays, ELISA (enzyme linked immunoradiometricassays), “sandwich” immunoassays, immunoradiometric assays, in situimmunoassays (using e.g., colloidal gold, enzyme or radioisotopelabels), western blot analysis, immunoprecipitation assays,immunofluorescent assays, and SDS-PAGE.

Antibodies that specifically recognize or bind to ER-stress relatedproteins are preferable for conducting the aforementioned proteinanalyses. Where desired, antibodies that recognize a specific type ofpost-translational modifications (e.g., ER-stress induciblemodifications) can be used. Post-translational modifications include butare not limited to glycosylation, lipidation, acetylation, andphosphorylation. These antibodies may be purchased from commercialvendors. For example, anti-phosphotyrosine antibodies that specificallyrecognize tyrosine-phosphorylated proteins are available from a numberof vendors including Invitrogen and Perkin Elmer. Anti-phosphotyrosineantibodies are particularly useful in detecting proteins that aredifferentially phosphorylated on their tyrosine residues in response toan ER stress. Such proteins include but are not limited to eukaryotictranslation initiation factor 2 alpha (eIF-2α). Alternatively, theseantibodies can be generated using conventional polyclonal or monoclonalantibody technologies by immunizing a host animal or anantibody-producing cell with a target protein that exhibits the desiredpost-translational modification.

In practicing the subject method, it may be desirable to discern theexpression pattern of an ER-stress related protein in different bodilytissue, in different cell types, and/or in different subcellularstructures. These studies can be performed with the use oftissue-specific, cell-specific or subcellular structure specificantibodies capable of binding to protein markers that are preferentiallyexpressed in certain tissues, cell types, or subcellular structures.

For example, to localize a target ER-stress related protein to aspecific cell type such as oligodendrocyte, co-staining with one or moreantibodies specific for oligodendrocyte markers can be used. Exemplarymarkers for oligodendrocyte include but are not limited to CC1, myelinbasic protein (MBP), ceramide galactosyltransferase (CGT), myelinassociated glycoprotein (MAG), myelin oligodendrocyte glycoprotein(MOG), oligodendrocyte-myelin glycoprotein (OMG), cyclic nucleotidephosphodiesterase (CNP), NOGO, myelin protein zero (MPZ), peripheralmyelin protein 22 (PMP22), protein 2 (P2), galactocerebroside (GalC),sulfatide and proteolipid protein (PLP). To detect or quantify anER-stress related protein localized in a specific subcellular structure,co-staining with one or more antibodies directed to antigensdifferentially present in such structure is preferably performed. A widevariety of organelle specific antibodies is available in the art.Non-limiting examples include endoplasmic reticulum (ER) specificantibodies directed to the ER resident protein BIP, plasma membranespecific antibodies reactive with cell surface receptors such asepidermal growth factor receptor (EGF receptor), Golgi specific antibodyy-adaptin, and cytokeratin specific antibodies which differentiatecytokeratins from different cell types (e.g., between epithelial andstromal cells). To detect and quantify the immunospecific binding,digital image systems including but not limited to confocal microscopecan be employed.

An altered expression of an ER-stress related gene can also bedetermined by examining a change in activity of the gene productrelative to a control cell. The assay for an agent-induced change in theactivity of an ER-stress related protein will dependent on thebiological activity and/or the signal transduction pathway that is underinvestigation. For example, where the ER-stress related protein is akinase, a change in its ability to phosphorylate the downstreamsubstrate(s) can be determined by a variety of assays known in the art.Representative assays include but are not limited to immunoblotting andimmunoprecipitation with antibodies such as anti-phosphotyrosineantibodies that recognize phosphorylated proteins. In addition, kinaseactivity can be detected by high throughput chemiluminescent assays suchas AlphaScreen™ (available from Perkin Elmer) and eTag™ assay (Chan-Hui,et al. (2003) Clinical Immunology 111: 162-174).

Where the ER-stress related protein is part of a signaling cascadeleading to a fluctuation of intracellular pH condition, pH sensitivemolecules such as fluorescent pH dyes can be used as the reportermolecules. In another example where the ER-stress related protein is anion channel, fluctuations in membrane potential and/or intracellular ionconcentration can be monitored. A number of commercial kits andhigh-throughput devices are particularly suited for a rapid and robustscreening for modulators of ion channels.

Representative instruments include FLIPR™ (Molecular Devices, Inc.) andVIPR (Aurora Biosciences). These instruments are capable of detectingreactions in over 1000 sample wells of a microplate simultaneously, andproviding real-time measurement and functional data within a second oreven a minisecond.

In yet another example where the ER-stress related protein is aprotease, its activity in cleaving substrate proteins can be detected byanalyzing the cleaved polypeptides. Several methods for analyzingpolypeptides are available in the art. Non-limiting exemplary methodsare 2-D electrophoresis, mass spectrum analysis, and peptide sequencing.

The candidate agents identified by the subject method can be furthercharacterized, in whole or in part, by their abilities to modulateneuronal demyelination that occurs in a wide variety of conditions. Forinstance, neuronal demyelination may occur in disorders inflicted bypathogens or physical injuries, disorders attributable to geneticpredispositions, inflammation and/or autoimmune responses. Specifically,neuronal demyelination may occur upon bacterial or viral infection asin, e.g., HIV-vacuolar myelinopathy and HTLV. It may also result fromdirect contact with toxic substances or accumulation of toxicmetabolites in the body as in, e.g., central pontine myelinolysis andvitamin deficiencies. Neuronal demyelination may also manifest in spinalcord injury, genetic disorders including but not limited toleukodystrophies, adrenoleukodystrophy, degenerative multi-systematrophy, Binswanger encephalopathy, tumors in the central nervoussystem, and multiple sclerosis.

Morphologically, neuronal demyelination can be characterized by a lossof oligodendrocytes in the central nervous system or Schwann cells inthe peripheral nervous system. It can also be determined by a decreasein myelinated axons in the nervous system, or by a reduction in thelevels of oligodendrocyte or Schwann cell markers. Exemplary markerproteins of oligodendrocytes or Schwann cells include but are notlimited to CC1, myelin basic protein (MBP), ceramidegalactosyltransferase (CGT), myelin associated glycoprotein (MAG),myelin oligodendrocyte glycoprotein (MOG), oligodendrocyte-myelinglycoprotein (OMG), cyclic nucleotide phosphodiesterase (CNP), NOGO,myelin protein zero (MPZ), peripheral myelin protein 22 (PMP22), protein2 (P2), galactocerebroside (GalC), sulfatide and proteolipid protein(PLP). As such, the candidate agents identified by the subject methodencompass substances that can inhibit the deleterious morphologicalcharacteristics of neuronal demyelination.

Candidate agents identified by the subject method can be broadlycategorized into the following two classes. The first class encompassesagents that when administered into a cell or a subject, reduce the levelof expression or activity of an ER-stress causing gene or protein. Thesecond class includes agents that augment the level of expression oractivity of an ER-stress suppressing gene or protein (e.g., BIP andPERK). In one aspect, the agent reduces the levels of proteins (e.g.,major histocompatibility complex I) that are characteristic of anendoplasmic reticulum stress in remyelinating oligodendrocytes in thecentral nervous system or Schwann cells in the peripheral nervoussystem.

Animal Studies:

The development of a biologically active agent beneficial for a neuronaldemyelination condition may also involve the use of animal models.Accordingly, the present invention provides a method of using animalmodels for testing a biologically active agent that modulates aphenomenon associated with a demyelination disorder. The methodcomprises the steps of: (a) administering a candidate biologicallyactive agent to a test animal generated by a method comprising (i)inducing neuronal demyelination in said test animal, and (ii) allowingsaid test animal to recover from the demyelination induction for asufficient amount of time so that remyelination of a demyelinated lesionis exhibited; and (b) determining the effect of said agent upon aphenomenon associated with a demyelination disorder.

The animal models of the present invention encompass any non-humanvertebrates that are amenable to procedures yielding a neuronaldemyelination condition in the animal's nervous systems including thecentral and peripheral nervous system. Preferred model organisms includebut are not limited to mammals, primates, and rodents. Non-limitingexamples of the preferred models are rats, mice, guinea pigs, cats,dogs, rabbits, pigs, chimpanzees, and monkeys. The test animals can bewildtype or transgenic.

In one aspect, the subject method employs a transgenic animal havingstably integrated into the genome a transgenic nucleotide sequenceencoding interferon-gamma (INF-γ). In another aspect, the subject methodinvolves a transgenic animal having an altered expression of at leastone other gene, wherein upon expression of INF-γ, the animal exhibits agreater degree of demyelination relative to a transgenic animal having astably integrated transgenic nucleotide sequence encodinginterferon-gamma (INF-γ) alone. In a preferred aspect, the at least oneother gene encodes an ER-stress related protein. In another preferredaspect, the test animal is a heterozygous knock-out of pancreatic ERkinase gene (PERK), having a stably integrated into the genome atransgenic nucleotide sequence encoding interferon-gamma (INF-γ).Preferably, expression of the transgene(s) carried in the transgenicanimal are inducible to effect expression that is ectopical, tissuespecific, cell type specific, or even organelle specific.

As described above, tissue specific and cell specific regulatorysequences are available for expressing transgenes in the central nervoussystems. An exemplary sequence is the transcriptional regulatorysequence of the glial fibrillary acidic gene (GFAP). The regulatorysequence allows ectopical expression of transgenes in the centralnervous system and specifically in the astrocytes. Where expression ofthe transgene in particular subcellular location is desired, thetransgene can be operably linked to the corresponding subcellularlocalization sequences by recombinant DNA techniques widely practiced inthe art. Exemplary subcellular localization sequences include but arenot limited to (a) a signal sequence that directs secretion of the geneproduct outside of the cell; (b) a membrane anchorage domain that allowsattachment of the protein to the plasma membrane or other membraneouscompartment of the cell; (c) a nuclear localization sequence thatmediates the translocation of the encoded protein to the nucleus; (d) anendoplasmic reticulum retention sequence (e.g. KDEL sequence) thatconfines the encoded protein primarily to the ER; or (e) any othersequences that play a role in differential subcellular distribution of aencoded protein product.

A demyelination condition in the test animal generally refers to adecrease in myelinated axons in the nervous systems (e.g., the centralor peripheral nervous system), or by a reduction in the levels ofmarkers of myelinating cells, such as oligodendrocytes and Schwanncells. Exemplary markers for identifying myelinating cells include butare not limited to CC1, myelin basic protein (MBP), ceramidegalactosyltransferase (CGT), myelin associated glycoprotein (MAG),myelin oligodendrocyte glycoprotein (MOG), oligodendrocyte-myelinglycoprotein (OMG), cyclic nucleotide phosphodiesterase (CNP), NOGO,myelin protein zero (MPZ), peripheral myelin protein 22 (PMP22), protein2 (P2), galactocerebroside (GalC), sulfatide and proteolipid protein(PLP).

These phenomena can be observed by immunohistochemical means or proteinanalysis described herein. In one aspect, sections of the test animal'sbrain can be stained with antibodies that specifically recognize anoligodendrocyte marker. In another aspect, the expression levels ofoligodendrocyte markers can be quantified by immunoblotting,hybridization means, and amplification procedures, and any other methodsthat are well-established in the art and/or provided herein.

A number of methods for inducing demyelination in a test animal havebeen established. For instance, neuronal demyelination may be inflictedby pathogens or physical injuries, agents that induce inflammationand/or autoimmune responses in the test animal. A preferred methodemploys demyelination-induced agents including but not limited to IFN-γand cuprizone (bis-cyclohexanone oxaldihydrazone). The cuprizone-induceddemyelination model is described in Matsushima, et al. (2001) BrainPathol. 11: 107-116. In this method, the test animals are typically fedwith a diet containing cuprizone for a few weeks ranging from about 1 toabout 10 weeks.

After induction of a demyelination condition by an appropriate method,the animal is allowed to recover for a sufficient amount of time toallow remyelination at or near the previously demyelinated lesions.While the amount of time required for developing remyelinated axonsvaries among different animals, it generally requires at least about 1week, more often requires at least about 2 to 10 weeks, and even moreoften requires about 4 to about 10 weeks. Remeylination can beascertained by observing an increase in myelinated axons in the nervoussystems (e.g., in the central or peripheral nervous system), or bydetecting an increase in the levels of marker proteins of a myelinatingcell. The same methods of detecting demyelination can be employed todetermine whether remyelination has occurred.

Determining the effect of the test agent upon a phenomenon associatedwith a demyelination may involve any suitable methods known in the art,including but not limited to those mentioned in the above cell-basedassay section. In general, immunohistochemical and electron microscopicanalysis can be performed to visualize the effect of the test agent. Inaddition, procedures applicable for detecting differential expression ofER-stress related genes or gene products can be employed. Techniques formeasuring activities of ER-stress related proteins are also applicable.As described above, non-limiting examples of ER-stress related genesinclude pancreatic ER kinase gene (PERK), eukaryotic translationinitiation factor 2 alpha (eIF-2α, eukaryotic translation initiationfactor beta (eIF-2β, inositol requiring 1 (IRE1), activatingtranscription factor 6 (ARTF6), CAATT enhancer-binding proteinhomologous protein (CHOP), binding-immunoglobulin protein (BIP),caspase-12, growth and DNA damage protein 34 (GADD34), CreP (aconstitutive repressor of eIF2 alpha phosphorylation), and X-box-bindingprotein-1 (XBP-1).

In a separate embodiment, the present invention provides a non-humantransgenic animal suitable for elucidating the pathogenesis of neuronaldemyelination conditions. The transgenic animal is also useful fordeveloping biologically active agent effective to inhibit neuronaldemyelination or promote remyelination of demyelinated lesions. In oneaspect, the subject transgenic animal has (a) stably integrated into thegenome of the animal a transgenic nucleotide sequence encodinginterferon-gamma (INF-γ); and (b) an altered expression of at least oneother gene, wherein upon expression of said INF-γ, the animal exhibits agreater degree of demyelination relative to a transgenic animal having astably integrated transgenic nucleotide sequence encodinginterferon-gamma (INF-γ) as in (a), but lacking said altered expressionof said at least one other gene.

The present invention contemplates transgenic animals that carry one ormore desired transgenes in all their cells, as well as animals whichcarry the transgenes in some, but not all their cells, i.e., mosaicanimals. Animals of any species, including, but not limited to, mice,rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-humanprimates, e.g., baboons, monkeys, and chimpanzees may be used togenerate the subject transgenic animals.

A desired transgene may be integrated as a single copy or inconcatamers, e.g., head-to-head tendems or head-to-tail tandems. Thedesired transgene may also be selectively introduced into and activatedin a particular tissue or cell type, preferably cells within the centralnervous system. The regulatory sequences required for such a cell-typespecific activation will depend upon the particular cell type ofinterest, and will be apparent to those of skill in the art. Preferably,the targeted cell types are located in the nervous systems, includingthe central and peripheral nervous systems.

When it is desired that the transgene be integrated into the chromosomalsite of the endogenous counterpart, gene targeting is preferred.Briefly, when such a technique is to be utilized, vectors containingsome nucleotide sequences homologous to the endogenous counterpart aredesigned for the purpose of integrating, via homologous recombinationwith chromosomal sequences, into and disrupting the function of thenucleotide sequence of the endogenous gene.

Advances in technologies for embryo micromanipulation now permitintroduction of heterologous DNA into fertilized mammalian ova as well.For instance, totipotent or pluripotent stem cells can be transformed bymicroinjection, calcium phosphate mediated precipitation, liposomefusion, retroviral infection or other means. The transformed cells arethen introduced into the embryo, and the embryo will then develop into atransgenic animal. In a preferred embodiment, developing embryos areinfected with a viral vector containing a desired transgene so that thetransgenic animals expressing the transgene can be produced from theinfected embryo. In another preferred embodiment, a desired transgene iscoinjected into the pronucleus or cytoplasm of the embryo, preferably atthe single cell stage, and the embryo is allowed to develop into amature transgenic animal. These and other variant methods for generatingtransgenic animals are well established in the art and hence are notdetailed herein. See, for example, U.S. Pat. Nos. 5,175,385 and5,175,384.

The transgenic animals of the present invention can be broadlycategorized into two types: “knockouts” and “knockins”. A “knockout” hasan alteration in the target gene via the introduction of transgenicsequences that results in a decrease of function of the target gene,preferably such that target gene expression is insignificant orundetectable. A “knockin” is a transgenic animal having an alteration ina host cell genome that results in an augmented expression of a targetgene, e.g., by introduction of an additional copy of the target gene, orby operatively inserting a regulatory sequence that provides forenhanced expression of an endogenous copy of the target gene. Theknock-in or knock-out transgenic animals can be heterozygous orhomozygous with respect to the target genes. Both knockouts and knockinscan be “bigenic”. Bigenic animals have at least two host cell genesbeing altered. A preferred bigenic animal carries a transgene encodingIFN-γ and another transgenic sequence that disrupts the function of atleast one other gene.

In certain aspect of this embodiment, the at least one other gene is anER-stress related gene. In another aspect, the other gene can be anexogenous gene, i.e., a gene that is not present in the host cell, or anendogenous gene, i.e., the introduced gene finds an endogenouscounterpart native to the recipient animal. Such ER-stress related genemay be selected from the group consisting of pancreatic ER kinase gene(PERK), eukaryotic translation initiation factor 2 alpha (eIF-2α,eukaryotic translation initiation factor beta (eIF-2β, inositolrequiring 1 (IRE1), activating transcription factor 6 (ARTF6), CAATTenhancer-binding protein homologous protein (CHOP),binding-immunoglobulin protein (BIP), caspase-12, growth and DNA damageprotein 34 (GADD34), CreP (a constitutive repressor of eIF2 alphaphosphorylation), and X-box-binding protein-1 (XBP-1).

A preferred non-human transgenic animal comprises a heterozygousknockout of pancreatic ER kinase gene (PERK), and has stably integratedinto the genome a transgenic nucleotide sequence comprisinginterferon-gamma (INF-γ). In one aspect, a preferred transgenic animalexhibits an increased vulnerability to INF-γ-mediated neuronaldemyelination relative to a wildtype animal.

Also provided in the present invention are cells of the subjectnon-human transgenic animal. In one aspect, the cells comprise stablyintegrated in the genome a transgene encoding INF-γ and an alteration inat least one other gene encoding a protein correlated with ER stress. Inanother aspect, the subject cells are from the central nervous system.In yet another aspect, the subject cells are oligodendrocytes. In yetanother aspect, the subject cells are from the peripheral nervous systemincluding but not limited to Schwann cells.

As discussed in the sections above, these cells are particularly usefulfor conducting cell-based assays for elucidating the molecular bases ofneuronal demyelination conditions, and for developing agents effectivefor inhibiting neuronal demyelination or promoting remyelination.

Pharmaceutical Compositions of the Present Invention:

The selected biologically active agents effective to modulate ER-stressrelated genes or proteins may be used for the preparation of medicamentsfor treating neuronal demyelination disorders. A preferred class ofagents is effective to alleviate IFN-γ elicited ER stress inoligodendrocytes.

In one aspect, the selected agent of this invention can be administeredto treat neuronal demyelination inflicted by pathogens such as bacteriaand viruses. In another aspect, the selected agent can be used to treatneuronal demyelination caused by toxic substances or accumulation oftoxic metabolites in the body as in, e.g., central pontine myelinolysisand vitamin deficiencies. In yet another aspect, the agent can be usedto treat demyelination caused by physical injury, such as spinal cordinjury. In still yet another aspect, the agent can be administered totreat demyelination manifested in disorders having genetic attributes,genetic disorders including but not limited to leukodystrophies,adrenoleukodystrophy, degenerative multi-system atrophy, Binswangerencephalopathy, tumors in the central nervous system, and multiplesclerosis.

Various delivery systems are known and can be used to administer abiologically active agent of the invention, e.g., encapsulation inliposomes, microparticles, microcapsules, expression by recombinantcells, receptor-mediated endocytosis (see, e.g., Wu and Wu, (1987), J.Biol. Chem. 262:4429-4432), construction of a therapeutic nucleic acidas part of a retroviral or other vector, etc. Methods of deliveryinclude but are not limited to intra-material, intra-muscular,intravenous, intranasal, and oral routes. In a specific embodiment, itmay be describable to administer the pharmaceutical compositions of theinvention locally to the area in need of treatment; this may be achievedby, for example, and not by way of limitation, local infusion duringsurgery, by injection, or by means of a catheter. In certain embodiment,the agents are delivered to a subject's nerve systems, preferably thecentral nervous system In another embodiment, the agents areadministered to neuronal tissues undergoing remyelination.

Administration of the selected agent can be effected in one dose,continuously or intermittently thoughout the course of treatment.Methods of determining the most effective means and dosage ofadministration are well known to those of skill in the art and will varywith the composition used for therapy, the purpose of the therapy, thetarget cell being treated, and the subject being treated. Single ormultiple administrations can be carried out with the dose level andpattern being selected by the treating physician.

The preparation of pharmaceutical compositions of this invention isconducted in accordance with generally accepted procedures for thepreparation of pharmaceutical preparations. See, for example,Remington's Pharmaceutical Sciences 18th Edition (1990), E. W. Martined., Mack Publishing Co., PA. Depending on the intended use and mode ofadministration, it may be desirable to process the active ingredientfurther in the preparation of pharmaceutical compositions. Appropriateprocessing may include mixing with appropriate non-non-toxic andnon-interfering components, sterilizing, dividing into dose units, andenclosing in a delivery device.

Pharmaceutical compositions for oral, intranasal, or topicaladministration can be supplied in solid, semi-solid or liquid forms,including tablets, capsules, powders, liquids, and suspensions.Compositions for injection can be supplied as liquid solutions orsuspensions, as emulsions, or as solid forms suitable for dissolution orsuspension in liquid prior to injection. For administration via therespiratory tract, a preferred composition is one that provides a solid,powder, or aerosol when used with an appropriate aerosolizer device.

Liquid pharmaceutically acceptable compositions can, for example, beprepared by dissolving or dispersing a polypeptide embodied herein in aliquid excipient, such as water, saline, aqueous dextrose, glycerol, orethanol. The composition can also contain other medicinal agents,pharmaceutical agents, adjuvants, carriers, and auxiliary substancessuch as wetting or emulsifying agents, and pH buffering agents.

Where desired, the pharmaceutical compositions can be formulated in slowrelease or sustained release forms, whereby a relatively consistentlevel of the active compound are provided over an extended period.

Other Applications of the Identified ER-Stress Related Genes:

Another embodiment of the present invention is a method of promotingremyelination using stem cells in a subject. In this approach, culturedstem cells are typically transfected with a gene capable of amelioratingER stress in myelinating oligodendrocytes. The genetically modified stemcells are then introduced into the CNS of a subject suffering from aneuronal demyelination condition. Any means effective to deliver thegenetically modified stem cells are applicable. Typically, the stemcells are directly injected into the nervous system of a subject. Thismethodology is described in detail in e.g., Morris, et al. (1997) J BiolChem. 272(7): 4327-34, which is incorporated herein by reference.Candidate genes to be introduced into stem cells include but are notlimited to BIP, PERK, and suppressor of cytokine signaling 1 (SOCS1).

It is documented that BIP is required to protect cells from ER stress;overexpression of BIP permits continued translation of cellular mRNAs,and hence reduces ER stress. SOCS1 is known to block INF-γsignaltransduction. As such, stem cells overexpressing SOCS1 and hencemyelinating cells derived from such stem cells, are expected to be lesssensitive to the demyelinating effect mediate by INF-γ.

Populations of neuronal cells can be produced from differentiatingcultures of embryonic stem cells (Li et al., (1998) Curr. Biol. 8:971-974), and have been used in experimental models to correct variousdeficits in animal model systems (review, Svendsen and Smith, Trends inNeurosci. 22: 357-364).

In humans, neuronal cells can be derived from human embryonal carcinomacells, and can be induced to differentiate using retinoic acid. Theseembryonic stem cells have been shown to correct deficits in experimentalmodels of CNS disease. In some embodiments, modulators of ER stress canbe expressed in pluripotent stem cells. Preferably, the engineered stemcells can be introduced into patients in need thereof to induceregeneration and/or protect neuronal cells from demyelination associatedwith anyone of the disorders cited herein. Pluripotent stem cells may beembryonic stem cells (ES) or embryonic germ cells (EG). Generation ofneural progenitors from stem cells in vitro may serve as an unlimitedsource of cells for tissue reconstruction and for the delivery andexpression of genes in the nervous system.

Methods for culturing ES and EG cells are known in the art. Forinstance, ES and EG lines may be cultured on feeder layers, and may begrown and maintained in an undifferentiated state in the presence ofrecombinant hormones such as Fibroblast Growth Factor and LeukemiaInhibitory Factor. Differentiation can be initiated either by changingthe hormonal milieu, forming embryoid bodies or a combination of both.Embryoid body formation is the most widely used process. Alternatively,tissue-specific reversible transformation can be used foe establishingdifferentiated neuronal cell lines using stem cells as a startingmaterial according to the method described in US Patent Application20060068496, which is incorporated herein by reference. US PatentApplication 20060068496 discloses methods that employ tissue specificexpression of a transforming gene, which can be used to identify andculture the particular cell type. This transforming event can, in someforms of the method, then be reversed, using one of a number of possibleprocesses, leaving a clonal or semi-purified population ofnon-transformed, differentiated cells, including populations ofdifferent or semi-purified cells, or a clonal population of cells, asdiscussed herein. The glial fibrillary acetic protein (GFAP) promoterhas been used to selectively express genes in cells of glial origin.Neuronal progenitor cells can be differentiated to give rise to neuronsand glial cells. Markers that can be used to identify a neuronal cellinclude but are not limited to GFAP and MPB.

The preferred cell for use in cell therapy is human embryonic stem cell.In one aspect, the present invention provides an enriched preparation ofundifferentiated human embryonic stem cells capable of expressing amodulator of one or more ER stress proteins and that can proliferate invitro and differentiate into neural progenitor cells, neuron cellsand/or glial cells. In another embodiment of the present invention,neural progenitor cells are first derived from human ES cells, which areengineered to express one or more modulators of the ER stress pathway,and subsequently are differentiated into mature neuronal cells, andglial cells inlcuding oligodendrocyte and astrocyte cells.Alternatively, the neuronal progenitor cells are first differentiatedinto mature neuronal cells that include oligodendrocytes and astrocytes,which are subsequently engineered to express one or more modulators ofthe ER stress response.

The modulators that can be induced to be expressed in the neuralprogenitor cells include modulators of protein folding and maturation,protein transport, protein synthesis and modification, Ca²⁺ homeostasis,transcription factors, UPR target genes, and proteins that mediateapoptosis. Modulators of protein folding and maturation include but arenot limited to modulators of BIP/GRP78, proteindisulfide-isomerase-related protein P5, collagen binding protein 2,fourth mammalian ER DNAJ protein (ERdj4), oxygen regulated protein 150kD (ORP150), FK506-binding protein (FKBP13), GRP94, proteindisulfide-isomerase ERp70-like, protein disulfide-isomerase ERp60-like,proline 4-hydroxylase β-subunit (P4HB), hsc70(71-kD heat shock cognateprotein). Modulators of protein transport include but are not limited tomodulators of putative mitochondrial membrane protein import receptor(hTIM44), translocon-associated protein delta subunit (TRAP δ), andtransmembrane protein rnp24. Modulators of protein synthesis andmodification include but are not limited to modulators of glycyl-tRNAsynthase, alanyl-tRNA synathase, asparagine synthase,glutamine-fructose-6-phosphate amidotransferase (GFAT), and integralmembrane protein 1 (ITM1). Modulators of Ca²⁺ homeostasis include butare not limited to modulators of calreticulin, stanniocalcin 2, plasmamembrane Ca²⁺ pumping ATPase, calnexin, novelDNA-binding/EF-hand/leucine zipper protein (NEFA), and nucleonidin 1.Modulators of transcription factors include but are not limited tomodulators of CHOP, C/EBP-beta, TGF-β-stimulated clone 22 (TSC22)-like,X-box-binding protein 1 (XBP-1), and Egr-1. Modulators of UPR targetgenes nclude but are not limited to modulators of HERP and SERP/RAMP4.Modulators of apoptosis include but are not limited to modulators ofBbc3/PUMA, caspase 3, and caspase 12.

Preferably, the modulators that are expressed in the undifferentiated ordifferentiated neuronal cells are modulators of the PERK pathway. In anembodiment, one or more modulators of the PERK pathway can be expressedin the undifferentiated or differentiated neural cells. For example, theneural progenitor cells can be induced to express a synthetic PERKfusion enzyme that enhances the level of the phosphorylated eIF-2α(p-eIF-2α), while simultaneously expressing an inhibitor of the INF-γcytokine signaling pathway e.g. SOCS1.

In yet another aspect, the present invention provides neural progenitorcells, neuronal cells and glial cells that express modulators of thePERK pathway and can used for cell therapy and gene therapy. The routeof delivery that is selected for the stem cells is crucial in that ithelps to determine whether or not repair of the damaged organ willoccur. A high stem cell concentration near the damaged area increasesthe chances that sufficient stem cell localization and differentiationoccurs in order to repair the organ. In many cases this involves thetargeted and regional administration of stem cells.

Gene therapy is an alternative approach for promoting remyelination bymodulating ER stress of myelinating cells. When expression vectors areused for gene therapy in vivo or ex vivo, a pharmaceutically acceptablevector is preferred, such as a replication-incompetent retroviral oradenoviral vector. Pharmaceutically acceptable vectors containing anER-stress suppressing genes of this invention can be further modifiedfor transient or stable expression of the inserted polynucleotide. Asused herein, the term “pharmaceutically acceptable vector” includes, butis not limited to, a vector or delivery vehicle having the ability toselectively target and introduce an ER-stress suppressing gene intocells located in the nerve systems, and preferably oligodendrocytes inthe nerve systems. An example of a replication-incompetent retroviralvector is LNL6 (Miller, A. D. et al. (1989) Bio Techniques 7:980-990).The methodology of using replication-incompetent retroviruses forretroviral-mediated gene transfer of gene markers is well established(Correll et al. (1989) PNAS USA 86:8912; Bordignon (1989) PNAS USA86:8912-52; Culver, K. (1991) PNAS USA 88:3155; and Rill, D. R. (1991)Blood 79(10):2694-700. Clinical investigations have shown that there arefew or no adverse effects associated with the viral vectors, seeAnderson (1992) Science 256:808-13. Alternatively, introduction ofER-stress suppressing genes can be performed using the methodologydescribed in Chernajovsky, et al. (2004) Nat. Rev. Immunol. 4(10):800-11.

The expression of ER stress causing genes can be inhibited or preventedin myelinating cells, including oligodendrocytes and Scwhann cells, byusing RNA interference (RNAi) technology, a type of post-transcriptionalgene silencing. RNAi may be used to create a pseudo “knockout”, i.e. asystem in which the expression of the product encoded by a gene orcoding region of interest is reduced, resulting in an overall reductionof the activity of the encoded product in a system. As such, RNAi may beperformed to target a nucleic acid of interest or fragment or variantthereof, to in turn reduce its expression and the level of activity ofthe product which it encodes. Such a system may be used for functionalstudies of the product, as well as to treat disorders related to theactivity of such a product. RNAi is described in for example Hammond etal. (2001) Science 10; 293(5532): 1146-50., Caplen et al. (2001) ProcNatl Acad Sci US A. 2001 Aug. 14; 98(17):9742-7, all of which are hereinincorporated by reference. Reagents and kits for performing RNAi areavailable commercially from for example Ambion Inc. (Austin, Tex., USA)and New England Biolabs Inc. (Beverly, Mass., USA).

The initial agent for RNAi in some systems is thought to be dsRNAmolecule corresponding to a target nucleic acid. The dsRNA is thenthought to be cleaved into short interfering RNAs (siRNAs) which are21-23 nucleotides in length (19-21 bp duplexes, each with 2 nucleotide3′ overhangs). The enzyme thought to effect this first cleavage step hasbeen referred to as “Dicer” and is categorized as a member of the RNaseIII family of dsRNA-specific ribonucleases. Alternatively, RNAi may beeffected via directly introducing into the cell, or generating withinthe cell by introducing into the cell a suitable precursor (e.g. vectorencoding precursor(s), etc.) of such an siRNA or siRNA-like molecule. AnsiRNA may then associate with other intracellular components to form anRNA-induced silencing complex (RISC). The RISC thus formed maysubsequently target a transcript of interest via base-pairinginteractions between its siRNA component and the target transcript byvirtue of homology, resulting in the cleavage of the target transcriptapproximately 12 nucleotides from the 3′ end of the siRNA. Thus thetarget mRNA is cleaved and the level of protein product it encodes isreduced.

RNAi may be effected by the introduction of suitable in vitrosynthesized siRNA or siRNA-like molecules into cells. RNAi may forexample be performed using chemically-synthesized RNA. Alternatively,suitable expression vectors may be used to transcribe such RNA either invitro or in vivo. In vitro transcription of sense and antisense strands(encoded by sequences present on the same vector or on separate vectors)may be effected using for example T7 RNA polymerase, in which case thevector may comprise a suitable coding sequence operably-linked to a T7promoter. The in vitro-transcribed RNA may in embodiments be processed(e.g. using E. coli RNase III) in vitro to a size conducive to RNAi. Thesense and antisense transcripts are combined to form an RNA duplex whichis introduced into a target cell of interest. Other vectors may be used,which express small hairpin RNAs (shRNAs) which can be processed intosiRNA-like molecules. Various vector-based methods are described in forexample Brummelkamp et al. (2002) Science April 19; 296(5567):550-3.Epub 2002 Mar. 21; Brummelkamp et al. Cancer Cell (2002) September2(3):243-7. Paddison et al. (2002) Genes Dev. 2002 Apr. 15;16(8):948-58. Various methods for introducing such vectors into cells,either in vitro or in vivo (e.g. gene therapy) are known in the art.

Accordingly, in an embodiment the expression of one or more ER-stresscausing genes may be inhibited by introducing into or generating withina cell an siRNA or siRNA-like molecule corresponding to a nucleic acidencoding the ER stress-causing gene or fragment thereof, or to annucleic acid homologous thereto. “siRNA-like molecule” refers to anucleic acid molecule similar to a siRNA (e.g. in size and structure)and capable of eliciting siRNA activity, i.e. to effect theRNAi-mediated inhibition of expression. In various embodiments such amethod may entail the direct administration of the siRNA or siRNA-likemolecule into a cell, or use of the vector-based methods describedabove. In an embodiment, the siRNA or siRNA-like molecule is less thanabout 30 nucleotides in length. In a further embodiment, the siRNA orsiRNA-like molecule is about 21-23 nucleotides in length. In anembodiment, siRNA or siRNA-like molecule comprises a 19-21 bp duplexportion, each strand having a 2 nucleotide 3′ overhang. In embodiments,the siRNA or siRNA-like molecule is substantially homologous to anucleic acid encoding the ER stress-causing gene or a fragment orvariant (or a fragment of a variant) thereof. Such a variant is capableof encoding a protein having ER stress-causing activity.

Such RNAi methods can be used to inhibit expression of IFN-γ in, forexample, the central nervous system. ER stress-causing genes that may beinhibited by RNAi methods include, but are not limited to IFN-γ, GADD34,protein phosphatase 1 (PP1), and one or more genes that mediateapoptosis e.g. genes that encode caspases.

The invention may be better understood by reference to the followingexamples, which are intended to merely illustrate but not limit the modenow known for practicing the invention.

EXAMPLE 1 IFN-γ Does not Affect the Initial Phase Demyelination,Oligodendrocyte Loss or Reduction of Myelin Gene Expression

The effects of IFN-γ on demyelination were evaluated in a cuprizoneanimal model using transgenic mice that allow for temporally regulateddelivery of IFN-γ using the tetracycline controllable system (Lin, etal. (2004) J. Neurosci. 24: 10074-10083). The transgenic mice weregenerated by mating line 110 GFAP/tTA mice on the C57BL/6 backgroundwith line 184 TRE/IFN-γ on the C57BL/6 background to produce GFAP/tTA;TRE/IFN-γ double transgenic mice (Lin, et al. (2004) J. Neurosci. 24:10074-10083). Transcriptional activation of the TRE/IFN-γ transgene bytTA was repressed in the control (DOX+) mice by adding 0.05 mg/mldoxycycline to the drinking water which was provided ad libitum from theday of conception. The DOX+ double transgenic mice were GFAP/tTA;TRE/IFN-γ double transgenic animals fed cuprizone chow and neverreleased from the doxycycline solution. DOX− double transgenic mice wereGFAP/tTA; TRE/IFN-γ double transgenic animals fed cuprizone chow andreleased from doxycycline to induce expression of IFN-γ.

Demyelination was induced in 6-week-old DOX+ and DOX− male mice byfeeding the mice a diet of milled mouse chow containing 0.2% cuprizone(Sigma-Aldrich, St. Louis, Mich.) for up to 6 weeks. Subsequently, bothgroups of mice were returned to a normal diet for up to 3 weeks to allowremyelination to occur. All animal procedures were conducted in completecompliance with the NIH Guide for the Care and Use of Laboratory Animalsand were approved by the Institutional Animal Care and Use Committee ofThe University of Chicago.

The effects of INF-γ and MBP on demyelination were evaluated as thelevel of INF-γ and MHC-1, the loss of oligodendrocytes, and theexpression of myelin genes.

The expression of IFN-γ in these animals was examined by Enzyme-LinkedImmunosorbent Assay (ELISA) analysis as follows. Spinal cord andforebrains were removed, rinsed in ice cold PBS, and immediatelyhomogenized in five volumes of PBS with complete protease cocktail(Roche, Indianapolis, Ind.) using a motorized homogenizer. Afterincubation on ice for 5 min the extracts were cleared by centrifugationat 14000 rpm for 10 min. The protein content of each extract wasdetermined by the DC protein assay (Bio-Rad, Hercules, Calif.). ELISAassays were performed using Mouse IFN-γ Quantikine ELISA kit (R&Dsystem, Minneapolis, Minn.) and MBP antibodies (1:1000; SternbergerMonoclonals) according to the manufacture's instructions.

Real time PCR was used to determine the effect of IFN-yon the expressionof MHC-1. RNA was isolated from the corpus callosum (Jurevics, et al.,2002) using Trizol reagent (Invitrogen, Carlsbad, Calif.) and treatedwith DNAseI (Invitrogen, Carlsbad, Calif.) to eliminate genomic DNA.Reverse transcription was performed using Superscript First StrandSynthesis System for RT-PCR kit (Invitrogen, Carlsbad, Calif.).Real-time PCR was performed with iQ supermix (Bio-Rad, Hercules Calif.)on a Bio-Rad iQ real-time PCR detection system (Bio-Rad, HerculesCalif.). The primers and probes (Integrated DNA Technologies Inc.,Coralville, Iowa) for real-time PCR were as follows:

The sense and antisense primers that were used in the PCR reaction forMHC-1 were: ATTCCCCAAAGGCCCATGT and GTCTCCACAAGCTCCATGTCC, respectively.The probe was MHC-1 probe: TGCTGGGCCCTGGGCTTCTACC

The effect of INF-γ on the population of oligodendrocytes was evaluatedby immunohistochemical analysis of oligodendrocytes using an anti-CC1antibody (APC7, 1:50; EMD Biosciences, Inc., La Jolla, Calif.)Immunohistochemistry was perfomed on brain sections obtained from micethat were first anesthetized mice and perfused through the left cardiacventricle with 4% paraformaldehyde in 0.1M PBS. The brains were removed,postfixed with paraformaldehyde, cryopreserved in 30% sucrose, embeddedin OCT and frozen on dry ice. Frozen sections were cut in a cryostat ata thickness of 10 μm. Coronal sections at the fornix region of thecorpus callosum corresponding to Sidman sections 241-251 were selectedfor use, and all comparative analyses were restricted to midline corpuscallosum (Sidman, et al. (1971) Atlas of the Mouse Brain and Spinal Cord(Harvard Univ. Press, Cambridge, Mass.). For immunohistochemistry,frozen sections were treated with −20° C. acetone, blocked with PBScontaining 10% NGS and 0.1% Triton X-100 and incubated overnight withthe primary antibody diluted in blocking solution. Appropriatefluorochrome- or enzyme-labeled secondary antibodies (VectorLaboratories, Burlingame, Calif.) were used for detection. An antibodyagainst CC1 (APC7, 1:50; EMD Biosciences, Inc., La Jolla, Calif.) wasused as a marker for mature oligodendrocytes. Antibody against MBP(1:1000; Sternberger Monoclonals, Lutherville, Mass.) was used to verifythe degree of myelination. Antibody against active-caspase-3 (1:50, Cellsignaling Technology, Beverly, Mass.) was used as a marker for apoptoticcells. Fluorescent stained sections were mounted with Vectashieldmounting medium with DAPI (Vector Laboratories) and visualized with aZeiss Axioplan fluorescence microscope. Images were captured using aPhotometrics PXL CCD camera connected to an Apple Macintosh computerusing the Open Lab software suite. Immunopositive cells were quantifiedby counting positive cells within the median of the corpus callosum,confined to an area of 0.04 mm². Only those cells with nuclei observableby DAPI staining were counted. Each MBP immunostaining slide was scoredon a scale of zero to four. A score of zero indicates completedemyelination, and a score of four indicates normal myelination in thecorpus callosum of adult mice.

Real time PCR was used as described above to determine the expression ofthe MBP, PLP and CGT using the following primers adn probes: MBP senseprimer: GCTCCCTGCCCCAGAAGT; MBP antisense primer:TGTCACAATGTTCTFGAAGAAATGG; MBP probe: AGCACGGCCGGACCCAAGATG;

PLP sense primer: CACTTACAACTTCGCCGTCCT; PLP antisense primer:GGGAGTTTCTATGGGAGCTCAGA; PLP probe: AACTCATGGGCCGAGGCACCAA;

CGT sense primer: TTATCGGAAATTCACAAGGATCAA; and CGT antisense primer:TGGCGAAGAATGTAGTCTATCCAATA; CGT probe: CCGGCCACCCTGTCAATCGG. The degreeof demyelination was determined as the level of MBP was also determinedby immunohistochemical analysis as described above and using an antibodyagainst MBP (1:1000; Sternberger Monoclonals, Lutherville, Mass.).Demyelination was also assessed by electron microscopy as follows. Micewere anesthetized and perfused with 0.1 M PBS containing 4%paraformaldehyde and 2.5% glutaraldehyde (PH 7.3). Brains were slicedinto 1-mm sections, and the section corresponding to the region of thefornix was trimmed and processed for analysis and oriented to that across-section of the corpus callosum was achieved. Thin sections werecut, stained with uranyl acetate and lead citrate and analyzed aspreviously described (Coetzee, et al. (1996) Cell 86: 209-219). Thetotal percent of remyelinated axons was based on the analysis of aminimum of 300 fibers per mouse.

The results show that DOX+ mice did not express IFN-γ in the forebrainfor the duration of the study, while the DOX− mice began expressingapproximately 20 pg/mg of IFN-γ in the forebrain after 2 weeks ofcuprizone treatment and removal of doxycycline (FIG. 1A). Real-time PCRanalysis showed that the increased level of INN-γ led to a significantincrease in the expression of major histocompatibility complex (MHC)class I (MHC-I), a downstream target of IFN-γ signaling, in the corpuscallosum during remyelination (FIG. 1B). After 5 weeks of cuprizonetreatment demyelination in the corpus callosum of both DOX+ and DOX−double transgenic mice reached maximum levels (FIG. 2), and axons werealmost completely demyelinated (FIG. 3). Also, at this time, CC1positive mature oligodendrocytes were lost within the lesion site inboth DOX+ and DOX− double transgenic mice (FIG. 4). Furthermore, duringthe period of demyelination at 2 and 4 weeks of treatment with cuprizonethere was a reduction in the expression of the myelin genes MBP,proteolipid protein (PLP) and ceramide galactosyltransferase (CGT) thatwas comparable between DOX+ and DOX− double transgenic mice (FIG. 5).

These data suggest that the presence of IFN-γ does not have asignificant effect on the initial pathological processes induced bycuprizone exposure.

Statistics. Data are expressed as mean±standard deviation. Multiplecomparisons were statistically evaluated by one way AVONA test usingSigmastat 3.1 software. Differences were considered statisticallysignificant if p <0.05.

EXAMPLE 2 IFN-γ Suppresses Remyelination in Demyelinated Lesions

The effect of IFN-γ on the remyelination in the cuprizone treated micedescribed in Example 1 was determined following withdrawal of cuprizoneat week 5. The experimental methods used are the same as described inExample 1.

FIGS. 1A and B show that the increased level of INF-γ persisted in theDOX− mice even after withdrawal of cuprizone, and the increase in INF-γwas accompanied by a sustained increase in MCH-1. By week 8, asignificant number of oligodendrocytes were seen in the corpus callosumof the DOX+ mice, while the regeneration of oligodendrocytes in the DOX−was suppressed (FIGS. 2A and B). Remyelination in the corpus callosum ofDOX+ double transgenic mice began at week 6, and was evident 2 weeksafter cuprizone was removed from the diet (week 8; FIG. 3). In controlmice DOX+, a large number of axons showed substantial recovery at 8weeks (48.4%±4%, FIG. 4), whereas remyelination remained markedlysuppressed in the corpus callosum of the DOX− mice (week 8; FIG. 3),with fewer remyelinated axons (26.9%±7%, FIG. 4). Consistent withprevious findings that have shown that myelin genes are upregulatedduring the process of remyelination, the myelin genes MBP, PLP and CGTwere upregulated at week 6, and reached peak levels at week 8 in thecorpus callosum of the control DOX+ mice (FIG. 5). However, theexpression of the same myelin genes was significantly depressed at bothweek 6 and week 8 in the DOX− mice (FIG. 5).

These data indicate that the presence of IFN-γ in demyelinated lesionssuppresses remyelination.

EXAMPLE 3 IFN-γ Dramatically Reduces Repopulation of CC1 PositiveOligodendrocytes in Demyelinated Lesions

Remyelination occurs by the repopulation of demyelinated lesions byoligodendrocyte precursors (OPCs) the site of the lesion where theydifferentiate into oligodendrocytes (Matsushima, et al. (2001) BrainPathol. 11: 107-116; Mason, et al. (2000) J. Neurosci. Res. 61:251-262). CC1 positive oligodendrocytes are derived from NG2 positiveOPCs (Watanabe et al 1998; Mason et al 2000)). Therefore, repopulationof a lesion may be evaluated by the presence of CC1 and/or NG2 positivecells.

The effect of INF-γ on the repopulation of demyelinated lesions byoligodendrocyte precursors (OPC) was evaluated in the mice of Example 2as the number of CC1 positive mature oligodendrocytes and NG2 positiveOPCs that were counted in sections from the corpus callosum of both DOX+and DOX− mice. The methods used for analyzing the oligodendrocytesduring remyelination is the same as that described in Example 2.Immunostaining of NG2 in OPCs was performed using NG2 antibodies (1:50;Chemicon).

After 6 weeks of cuprizone exposure, the CC1 positive oligodendrocytesbegan to reappear (42.5±2.1/0.04 mm2) within the demyelinated corpuscallosum of control DOX+ mice and reached 228.7±20.2/0.04 mm2 at 8weeks. However, in the DOX− double transgenic animals there was adramatic reduction in the number of CC1 positive oligodendrocytes withinthe corpus callosum at the same point in time (8 weeks) (78±12.7/0.04mm2). At week 4 of cuprizone treatment, INF-γ increased significantlythe number of NG2 positive OPCs in the corpus callosum of the DOX− micewhen compared to the number counted in the DOX+ animals (DOX−:46±4.24versus DOX+: 19±2.12/0.04 mm²; p<0.05). However, at week 6 the DOX− micehad fewer NG2 positive OPCs than the DOX+ mice (DOX-31.5±0.71 versusDOX+80±2.8/0.04 mm²; p<0.05). By weeks 7 and 8, the number of NG2positive OPCs in the DOX− mice became comparable to that of the DOX+mice (FIG. 6).

The data indicate that the reduction in the number of CC1 positiveoligodendrocytes contributes to the poor remyelination of demyelinatedlesions in the presence of IFN-γ, and that IFN-γ delays the recruitmentof OPCs to the site of lesion without significantly affecting the numberof OPCs that are recruited.

EXAMPLE 4 INF-γ Inhibits Remyelination in an Animal Model of MS

Double transgenic mice that allow for temporally regulated delivery ofINF-γ to the CNS (Lin et al., J Neurosci 24:10074-10083 (2004)) wereused to assess the role of INF-γ in the pathogenesis of EAE. GFAP/tTA;TRE/IFN-γ double transgenic mice, as described in Example 1 were used todetermine the effect of INF-γ on the demyelination caused by EAE. Allmice were fed doxycycline from the day of conception to repress theexpression of INF-γ, and were immunized with myelin oligodendrocyteprotein (MOG35-55) to induce EAE. AT day 7 postimmunization (PID7),doxycycline was withdrawn from the experimental group (PID7 DOX−).

The level of INF-γ was determined in the control (DOX+) and the PID7DOX− mice using an ELISA immunoassay as described in Example 1, and theseverity of the disease was assessed as a function of a clinical score.Clinical severity scores were recorded daily according to a 0-5 pointscale, where 0=healthy, 1=flaccid tail, 2=ataxia and/or paresis of hindlimbs, 3=paralysis of hind limbs and/or paresis of forelimbs,4=tetraparalysis, and 5=moribund or dead.

The spinal cord from DOX+ and DOX− animals with EAE was immunostainedfor MBP, and the remyelination of axons was evaluated. The number ofoligodendrocytes was determined in the spine from DOX+ and DOX− mice asthe number of CC1 positive cells. Axonal damage was evaluted byimmunostaining of non-phosphorylated neurofilament-H. Antibodies tonon-phosphorylated neurofilament-H were SM132 diluted to 1:1000 andobtained from Sternberger Monoclonals.

The results from the ELISA assay showed that the level of INF-γ in bothDOX+ and DOX− mice was similar (60 pg/mg) at the peak of the diseasePID17. At PID50 the levels of INF-γ were significantly greater in theDOX− mice (40.24 pg/mg) than in the control DOX+ mice (6.22 pg/mg).

The mean maximum clinical score at PID17 was similar for the DOX+ andDOX− PID17 mice (DOX+: 2.66±0.80 and DOX−: 2.69±0.69, respectively). Atthis time, twenty of 25 control mice and 24 of 30 DOX− mice developedhind limb paralysis. The control mice began recovering from EAE by day21, and by day 50 (PID50), the control DOX+ mice were indistinguishablefrom naive mice. However, at PID50 half of the DOX− mice (12/24) thathad developed hind limb paralysis characteristic of EAE, continued tosuffer from the paralysis at a time when recovery was seen in thecontrol group (PID50). While the clinical score of control DOX+ mice haddecreased to less than 1 at PID 50, the score for the DOX− mice remainedat almost 2 (FIG. 7).

At PID7, the level of MBP was notably reduced in the lumbar spinal cordof DOX− mice when compared to that of the DOX+ mice (FIGS. 8A and 8B).Toluidine blue staining showed that a large number of axons from theDOX− mice were unmyelinated, while the axons from the DOX+ mice had veryfew unmyelinated axons (FIGS. 8C and 8D). The number of CC1 positiveoligodendrocytes was significantly decreased at PID50 in the DOX−animals (FIGS. 8E and 8F). Immunostaining of non-phosphorylatedneurofilament-H was imilar in DOX+ and DOX− mice, thus indicating thataxonal damage was not affected by INF-γ (FIGS. 8G and 8H).

These data show that INF-γ delays the recovery from EAE, and that thefailure to remyelinate caused by INF-γ contributed to the poor recoveryof the DOX− mice.

EXAMPLE 5 INF-γ Enhances the Inflammatory Response in Eae DemyelinatingLesions

INF-γ is known to induce MHC antigens and activate macrophages and Tlymphocytes. The inflammatory effect of INF-γ was studied in the CNSduring remyelination by determining the infiltration of T cells andmacrophages, and measuring the expression of MHC-1, TNF-a, IL-2, IL-12and IL-17. Immunohistochemistry was performed in tissues from the DOX+and DOX− mice with EAE as described in Example 4. Experimentalprocedures were followed as described in the examples above.

Immunostaining of CD3 (CD3 antibody 1:50; Santa Cruz, Santa Cruz,Calif.) and CD11b (CD11b antibodies 1:50, Chemicon, Tenecula, Calif.)showed that INF-γ did not increase significantly the number ofinfiltrating T cells and macrophages in the lumbar spinal cord of DOX+adn DOX− mice (FIGS. 9 A and B). Real time PCR analysis, revealed thatINF-γ increased the expression of MHC-1, TNF-a, IL2 and IL-12, anddecrease the expression of IL-17, in DOX− mice when compared to the DOX+animals. INF-γ did not alter the expression of iNOs and IL-23 (FIG. 9E).The probes and primers that were used are: MHC-I sense primer: MHC-Iantisense primer: GTCTCCACAAGCTCCATGTCC MHC-I probe:TGCTGGGCCCTGGGCTTCTACC; TNF-α sense primer GGCAGGTTCTGTCCCTTTCA, TNF-αantisense primer ACCGCCTGGAGTTCTGGA, TNF-α probe CCCAAGGCGCCACATCTCCCT;IL-2 sense primer CTACAGCGGAAGCACAGCAG, IL-2 antisense primerATTTGAAGGTGAGCATCCTGGG, IL-2 probe AGCAGCAGCAGCAGCAGCAGCA; IL-12 senseprimer CTCTATGGTCAGCGTTCCAACA, IL-12 antiense primerGGAGGTAGCGTGATTGACACAT, IL-12 probe CCTCACCCTCGGCATCCAGCAGC; IL-17 senseprimer ATGCTGTTGCTGCTGCTGAG, IL-17 antisense primerTTTGGACACGCTGAGCTTTGAG, IL-17 probe CGCTGCTGCCTTCACTGTAGCCGC; IL-23sense primer CTTCTCCGTTCCAAGATCCTTCG, IL-23 antisense primerGGCACTAAGGGCTCAGTCAGA, IL-23 probe TGCTGCTCCGTGGGCAAAGACCC; induciblenitric oxide synthase (iNOs) sense primer GCTGGGCTGTACAAACCTTCC, iNOssense primer TTGAGGTCTAAAGGCTCCGG, iNOS probeTGTCCGAAGCAAACATCACATTCAGATCC.

These data indicate that INF-γ modestly enhances the immune response indemyelinated lesions at the recovery stage of EAE, and might therebycontribute to the remyelination failure elicited by this cytokine.

EXAMPLE 6

Repression of remyelination by IFN-γ is associated with ER stress.Oligodendrocytes have been shown to be highly sensitive to disruption ofprotein synthesis and perturbation of the secretory pathway (Pfeiffer,et al. (1993) Trends Cell Biol. 3: 191-197; Southwood, et al. (2002)Neuron 36: 585-596; Leegwater, et al. (2001) Nat. Genet 29: 383-388). Todetermine whether IFN-γ interferes with endoplasmic reticulum (ER)function in remyelinating oligodendrocytes, the expression of ER stressmarkers was monitored in the corpus callosum of mice expressing IFN-γ.The study was performed using the transgenic mice described in Example1.

The level of mRNA encoding ER stress associated genes bindingimmunoglobulin protein/78 KDa glucose regulated protein (BIP/GRP78) andthe CAATT enhancer-binding protein homologous protein/growth and DNAdamage protein 153 (CHOP/GADD153), was determined using real time PCR,as described in Example 1 in the corpus callosum of the cuprizonetreated mice of Example 1. The probes, sense and antisense primers thatwere used were: BIP sense primer: ACTCCGGCGTGAGGTAGAAA; BIP antisenseprimer: AGAGCGGAACAGGTCCATGT; BIP probe TTCTCAGAGACCCTTACTCGGGCCAAATT;CHOP sense primer: CCACCACACCTGAAAGCAGAA CHOP antisense primer:AGGTGCCCCCAATTTCATCT; CHOP probe TGAGTCCCTGCCTTTCACCTTGGAGA.

The level of phosphorylated eIF-2α, which inhibits nucleotide exchangeon the eIF-2 complex and attenuates most protein synthesis, was analyzedby Western blot, and the expression was colocalized by immunostainingCC1 antibodies as described above. Western blot analysis was performedas follows. The corpus callosum from 3 mice was rinsed in ice coldphosphate-buffered saline (PBS) and pooled, and immediately homogenizedin 5 volumes of Triton X-100 buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1%Triton X-100, 10% glycerol, 1 mM EDTA, 10 mM tetrasodium pyrophosphate,100 mM NaF, 17.5 mM β-glycerophosphate, 10 mM phenylmethylsulfonylfluoride, 15 μg/ml aprotonin, and 6 μg/ml pepstatin A) using a motorizedhomogenizer. After incubation on ice for 15 min, the extracts werecleared by centrifugation at 14,000 rpm twice for 30 min each. Theprotein content of each extract was datelined by protein assay(Bio-Rad). The extracts (40 μg) were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis and transferred tonitrocellulose. The blots were incubated with primary antibody (seebelow), and the signal was revealed by chemiluminescence after reactingwith horseradish peroxidase-conjugated second antibody. The followingprimary antibodies were used: anti-eIF-2α (1:500; Santa Cruz, SantaCruz, Calif.), anti-p-eIF-2α (1:1000, Cell signaling Technology),anti-CHOP (1:500; Santa Cruz) and anti-actin (1:1000; Sigma, St Louis,Mo.).

The level of mRNA for BIP and CHOP, which are associated with the ERstress response, were increased approximately 2 fold in the corpuscallosum of DOX− double transgenic mice compared to control DOX+ animals(FIGS. 10A and 10B). Elevated levels of the CHOP protein, approximately1.7 fold, were also observed in the corpus callosum of DOX− doubletransgenic mice by Western blot analysis (FIG. 10C). Western blotanalysis also revealed that IFN-γ elevated the level of phosphorylatedeIF-2α (p-eIF-2α) by approximately 1.8 fold in the corpus callosum (FIG.10C) of the same DOX− animals. Furthermore, colocalization analysisusing the CC1 antibody revealed that remyelinating oligodendrocytesdisplayed increased levels of p-eIF-2α (FIGS. 10D and 10E).

These results indicate that the detrimental effect of IFN-γ onremyelination is associated with the activation of the ER stresspathway.

EXAMPLE 7 PERK Modulates the Severity of the Reduction in RemyelinationInduced by IFN-γ

The involvement of the ER stress response in the reduction caused byIFN-γ to remyelinate lesions was examined in transgenic mice that weregenerated to be heterozygous for a loss of function mutation inpancreatic ER kinase (PERK) (Harding, et al., (2001) Mol Cell7:1153-1163), and to be temporally regulated for expressing INF-γ in theCNS. TRE/IFN-γ mice were first crossed with PERK+/− mice (Harding, etal. (2001) Mol. Cell 7: 1153-1163) on the C57BL/6 background to generatemice the carry the PERK mutation, and the resulting progeny were crossedto GFAP/tTA mice to obtain transgenic mice that were heterozygous forthe PERK mutation. The effect of PERK on remyelination in the presenceor absence of INF-γ was evaluated as evaluated as a function of thelevel of meylination of oligodendrocytes in remyelinating lesions andthe number of oligodendrocytes present in the remyelinating lesion.

The extent of remyelination was assessed as described in the previousexamples in the corpus callosum of PERK+/+ and PERK+/− mice that weremade to express INF-γ (DOX−PERK+/+ and DOX−PERK+/−), and in mice inwhich the expression of INF-γ was repressed (DOX+PERK+/+ andDOX+PERK+/−). Remyelination was determined by electron microscopy, andwas related to the number of CC1 positive oligodendrocytes and the levelof caspase-3 expression in the corpus callosum of all animals. The levelof caspase-3 was determined by immunohistochemical methods using anticapsase antibody (active-casoase-3 antibody, 1:50; Cel SignalingTechnology) and according to the method described in Example 1.Demyelination was induced in six-week-old GFAP/tTA; TRE/IFN-γ doubletransgenic mice on a PERK+/− background that had been maintained ondoxycycline, by simultaneously treating the mice with 0.2% cuprizone andreleasing them from doxycycline (DOX−PERK+/−). Remyelination was allowedto occur by withdrawing cuprizone at week 6.

Immunohistochemistry and EM analysis of CC1 positive oligodndrocytesrevealed that a loss of function in PERK did not affect thedemyelination process during cuprizone treatment (data not shown). Incontrast, GFAP/tTA; TRE/IFN-γ, PERK+/− mice that were released fromdoxycycline at the time of cuprizone exposure (DOX−PERK+/−) hadsignificantly fewer remyelinated axons at 9 weeks (15.6%±7.6%, FIG. 11),3 weeks after cuprizone was removed from the diet, than the doubletransgenic mice on a PERK+/+ background (DOX−PERK+/+) (54.0%±4.3% vs31.1%±7.6%; p<0.01). Mice that had been continuously maintained ondoxycycline (DOX+PERK+/− and DOX+PERK+/+) had significantly more (54%)remyelinated axons than the DOX− mice (FIG. 11).

The number of CC1 positive oligodendrocytes that was significantly lower(123.2±27.5/0.04 mm²) in the DOX−PERK+/+ mice than in the DOX+PERK+/+animals (283.2±27.7/0.04 mm²; p<0.01; FIGS. 12A and B), and only a fewoligodendrocytes were detected in the corpus callosum of the DOX−PERK+/−mice (FIGS. 12A and B). In addition, the number of oligodendrocytes thatstained positive for caspase-3 was 2.3 times greater in the DOX−PERK+/−than in the DOX−PERK+/+ mice (FIG. 12C).

These data indicate that ER stress response is associated with thefailure to remyelinate and the reduction of oligodendrocyte numberselicited by IFN-γ, and that PERK is essential for remyelination duringER stress.

EXAMPLE 8 Apoptosis of Oligodendrocytes that is Induced by INF-γ isAssociated with Er Stress In Vitro

To test whether apoptosis of oligodendrocytes that is induced by INF-γaffects ER stress, the effect on the morphology, the degree of apoptosisand the expression of ER markers was studied in a culture ofoligodendrocyte precursor cells (OPC). Oligodendrocyte progenitors werecultured from neonatal rat brains (Baerwald, et al. (1998) J. NeurosciRes. 52: 230-239). A mixed glial culture was grown in flasks in mediumcontaining 10% fetal bovine serum (FBS), and when the astrocyte layerbecame confluent (10-14 days), oligodendrocyte progenitors wereseparated from astrocytes and microglia using an orbital shaker. Cells,greater than 95% of which were A2B5 positive, GFAP negative and CD11bnegative, were cultured in 0.5% FBS containing medium, which alsocontained PDGF (10 ng/ml) and FGF (5 ng/ml) (both from R&D Systems,Minneapolis, Minn.). Then cells were switched to 0.5% FBS medium withoutPDGF and FGF for differentiation. After 5 days in the differentiatingmedium, approximately 40% of cells were positive for myelin protein2′3′-cyclic nucleotide 3′-phosphodiestaerase (CNP). 70 U/ml recombinantrat IFN-γ (Calbiochem, La Jolla, Calif.) was added to the cells that hadbeen allowed to differentiation for 5 days. After 5 d in thedifferentiatiating medium, about 40% of the cells were CNP positive. 70U/ml of recombinant rat INF-γ (Calbiochem) was added to the cells thathad been allowed to differentiate for 5d. To examine theoligodendroglial response to general ER stress-inducing agents,progenitor cells that had been cultured in differentaition medium for 5or 7 days were treated with 2 μg/ml of tunicamycin (Sigma Aldrich) for 6hours.

The level of apoptosis of the OPC cells was determined by doublestaining CNP (1:200; Sternberger Monoclonals, Lutherville, Md.) andTUNEL using the ApopTag Kit (Serologicals Corp., Norcross, Calif.) andfollowing the manufacturer's instructions. Apoptosis was also evaluatedby measuring the activity of caspase-3 in oligodendrocyte lysates usingthe Fluorimetric Caspase 3 Assay Kit (Sigma, St. Louis, Mo.), accordingto the manufacturer's instructions.

To determine whether INF-γ affects ER function, the RNA expression of ERmarkers binding immunoglobulin protein (BIP), CAAT enhancer bindingprotein homologous protein (CHOP), and caspase 12 was determined usingreal time PCR. RNA was isolated from cultured cells and mice brain usingTrizol reagent (Invitrogen, Carlsbad, Calif.) and treated with DNAaseI(Invitrogen) to eliminate genomic DNA. Reverse transcription wasperformed using Superscript First Strand Synthesis System for RT-PCR kit(Invitrogen). Real-time PCR was performed with iQ Supermix (Bio-Rad,Hercules, Calif.) on a Bio-Rad iQ real-time PCR detection system(Bio-Rad). The following primers and probes (Integrated DNA TechnologiesInc., Coralville, Iowa) for real-time PCR were used: mouse CHOP senseprimer CCACCACACCTGAAAGCAGAA; mouse CHOP antisense primerAGGTGCCCCCAATTTCATCT; CHOP probe TGAGTCCCTGCCTTTCACCTTGGAGA; mouse BIPsense primer ACTCCGGCGTGAGGTAGAAA; mouse BIP antisense primerAGAGCGGAACAGGTCCATGT; BIP probe TTCTCAGAGACCCTTACTCGGGCCAAATT;

mouse caspase 12 sense primer ATGCTGACAGCTCCTCATGGA; and mouse caspaseantisense primer TGAGAGCCAGACGTGTTCGT.

To determine the effect of INF-γ on the level of phosphorylated eIF-2αand caspase 12 proteins, western blot analysis was performed using thefollowing antibodies anti-eIF-2α (1:500; Santa Cruz), anti-p-eIF-2α(1:1000, Cell signaling Technology), anti-caspase-12 (1:500; Santa Cruz)and anti-actin (1:1000; Sigma, St Louis, Mo.), and according to thefollowing protocol. Tissues or cultured cells were rinsed in ice coldphosphate-buffered saline (PBS) and then immediately homogenized in 5volumes of Triton X-100 buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1%Triton X-100, 10% glycerol, 1 mM EDTA, 10 mM tetrasodium pyrophosphate,100 mM NaF, 17.5 mM β-glycerophosphate, 10 mM phenylmethylsulfonylfluoride, 15 μg/ml aprotonin, and 6 μg/ml pepstatin A) using a motorizedhomogenizer. After incubation on ice for 15 min, the extracts werecleared by centrifugation at 14,000 rpm twice for 30 min each. Theprotein content of each extract was determined by protein assay(Bio-Rad). The extracts (40 μg) were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis and transferred tonitrocellulose. The blots were incubated with primary antibody (seebelow), and the signal was revealed by chemiluminescence after reactingwith horseradish peroxidase-conjugated second antibody.

Purified oligodendrocyte progenitor cells (OPCs) were allowed todifferentiate for five days in defined media, at which pointapproximately 40% of the cells expressed the myelin protein 2′3′-cyclicnucleotide 3′-phosphodiesterase (CNP) and extended branched processes(FIGS. 13A and 13C). These cells did not extend the flat membrane sheetsthat are characteristic of more mature oligodendrocyte cultures. Whentreated with 70 U/ml IFN-γ for 48 h these cells showed abnormalmorphological changes; including cell shrinkage and aggregation of cellbodies, followed by detachment from the culture plate (FIGS. 13A and13B). Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling(TUNEL) and CNP double labeling revealed that IFN-γ induced apoptosis ina significant number of oligodendrocytes (FIGS. 13C, 13D and 13E).Furthermore, the caspase-3 activity in the cell lysates of IFN-γ-treatedoligodendrocytes was markedly increased (FIG. 13F). Thus, 70 U/ml ofIFN-γ is able to induce apoptosis in oligodendrocytes that are activelysynthesizing myelin components.

To determine whether IFN-γ interferes with ER function, the expressionof markers of ER stress were monitored in cytokine treatedoligodendrocyte cultures. The levels of mRNA encoding the bindingimmunoglobulin protein/78 KDa glucose regulated protein (BIP/GRP78) andthe CAATT enhancer-binding protein homologous protein/growth and DNAdamage protein 153 (CHOP/GADD153), both of which are associated with theER stress response, were increased approximately 2 to 3 times inoligodendrocytes after exposure to IFN-γ (FIG. 13G). The phosphorylationof eIF-2α, which inhibits nucleotides exchange on the eIF-2 complex andattenuates most protein synthesis, occurs within minutes following thedevelopment of ER stress (Ron, 2002). Western blot analysis revealedthat IFN-γ significantly elevated the level of phosphorylated eIF-2α(p-eIF-2α) in oligodendroglial cultures (FIG. 13H). Caspase-12, anER-localized caspase, is activated by ER stress and can lead to cleavageof caspase-3 (Nakagawa, et al. (2000) Nature 403: 98-103; Lamkanfi, etal. (2004) Cell Death Differ. 11: 365-368). The induction of caspase-12was observed after treatment of oligodendrocytes with IFN-γ (FIG. 13G).Moreover, the level of the active fragment of caspase-12 was stronglyelevated after 48 h of IFN-γ treatment (FIG. 13H). These resultsindicate that IFN-γ induced apoptosis in cultured oligodendrocytes isassociated with the activation of the ER stress pathway.

Forty percent of the purified oligodendrocyte progenitor cells (OPCs)that had been allowed to differentiate for five days in defined mediaexpressed the myelin protein 2′3′-cyclic nucleotide 3′-phosphodiesterase(CNP) and extended branched processes (FIGS. 13A and 13C). These cellsdid not extend the flat membrane sheets that are characteristic of moremature oligodendrocyte cultures. When treated with 70 U/ml IFN-γ for 48h these cells showed abnormal morphological changes; including cellshrinkage and aggregation of cell bodies, followed by detachment fromthe culture plate (FIGS. 13A and 13B). Terminal deoxynucleotidyltransferase (TdT) dUTP nick-end labeling (TUNEL) and CNP double labelingrevealed that IFN-γ induced apoptosis in a significant number ofoligodendrocytes (FIGS. 13C, 13D and 13E). Furthermore, the caspase-3activity in the cell lysates of IFN-γ-treated oligodendrocytes wasmarkedly increased (FIG. 13F).

These data indicate that IFN-γ is able to induce apoptosis inoligodendrocytes that are actively synthesizing myelin components.

To determine whether IFN-γ interferes with ER function, the expressionof markers of ER stress were monitored in cytokine treatedoligodendrocyte cultures. The levels of mRNA encoding the bindingimmunoglobulin protein/78 KDa glucose regulated protein (BIP/GRP78) andthe CAATT enhancer-binding protein homologous protein/growth and DNAdamage protein 153 (CHOP/GADD153), both of which are associated with theER stress response, were increased approximately 2 to 3 times inoligodendrocytes after exposure to IFN-γ (FIG. 13G). The phosphorylationof eIF-2α, which inhibits nucleotides exchange on the eIF-2 complex andattenuates most protein synthesis, occurs within minutes following thedevelopment of ER stress (Ron, 2002). Western blot analysis revealedthat IFN-γ significantly elevated the level of phosphorylated eIF-2α(p-eIF-2α) in oligodendroglial cultures (FIG. 13H). Caspase-12, anER-localized caspase, is activated by ER stress and can lead to cleavageof caspase-3 (Nakagawa, et al. (2000) Nature 403: 98-103; Lamkanfi, etal. (2004) Cell Death Differ. 11: 365-368). The induction ofcaspase-12was observed after treatment of oligodendrocytes with IFN-γ (FIG. 13G).Moreover, the level of the active fragment of caspase-12 was stronglyelevated after 48 h of IFN-γ treatment (FIG. 13H).

These results indicate that IFN-γ induced apoptosis in culturedoligodendrocytes is associated with the activation of the ER stresspathway.

EXAMPLE 9 Hypomyelination Induced by Ectopic Expression of Ifn-γ isAssociated with Er Stress

To study the effect of INF-γ on the myelination of oligodendrocytesduring mouse development, transgenic mice that allow for temporallyregulated delivery of IFN-γ to the CNS using the tetracycline (tet)controllable system (Lin, et al. (2004) J. Neurosci. 24: 10074-10083)were generated. To drive tTA expression in astrocytes, thetranscriptional regulatory region of the glial fibrillary acidic protein(GFAP) gene was chosen (Brenner, et al. (1994) J. Neurosci. 14:1030-1037). GFAP/tTA mice were mated with TRE/IFN-γ mice to produceanimals hemizygous for both transgenes. When these mice are maintainedon doxycycline (DOX+), expression of the IFN-γ transgene is repressed(FIG. 10A); when the double transgenic mice are released fromdoxycycline (DOX−) INF-γ is expressed. For the purpose of theseexperiments, mice received doxycycline up to day 14 of development(E14), at which time the experimental animals (DOX−) stopped receivingdoxycycline, while the control animals (DOX+) were continuosly fed thedug. The mRNA for IFN-γ could be detected in the DOX− mice as early as10 days after birth (data not shown).

Real time PCR analysis was performed to determine the levels ofexpression of INF-γ, MHC-1, BIP, CHOP, and caspase 12. The primers forthe PCR reactions for BIP, CHP and caspase 12 are given in example 1.The sense and antisense primers for INF-γ were GATATCTCGAGGAACTGGCAAAAand CTTCAAAGAGTCTGAGGTAGAAAGAGATAAT, respectively; and the sense andantisense primers for MHC-1 were MHC-I sense primer:ATTCCCCAAAGGCCCATGT; and MHC-I antisense primer: GTCTCCACAAGCTCCATGTCC.

Western blot analysis was performed on the CNS of 14 day old mice todetermine the expression of caspase-12 as described in Example 6.

Brain and spinal cord tissue were analyzed using immunohistochemicalmethods as follows. Anesthetized mice were perfused through the leftcardiac ventricle with 4% paraformaldehyde in 0.1M PBS. Thehalf-saggital brains and transcervical spinal cord were removed,postfixed with paraformaldehyde, cryopreserved in 30% sucrose, embeddedin OCT and frozen on dry ice. Frozen sections were cut in a cryostat ata thickness of 10 μm. Coronal sections at the fornix region of thecorpus callosum corresponding to Sidman sections 241-251 were selectedfor use, and all comparative analyses were restricted to midline corpuscallosum (Sidman, et al. (1971) Atlas of the Mouse Brain and Spinal Cord(Harvard Univ. Press, Cambridge, Mass.). For immunohistochemistry,frozen sections were treated with −20° C. acetone, blocked with PBScontaining 10% NGS and 0.1% Triton X-100 and incubated overnight withthe primary antibody diluted in blocking solution. Appropriatefluorochrome- or enzyme-labeled secondary antibodies (VectorLaboratories, Burlingame, Calif.) were used for detection. An antibodyagainst CC1 (APC7, 1:50; EMD Biosciences, Inc., La Jolla, Calif.) wasused as a marker for mature oligodendrocytes. Antibody against MBP(1:1000; Sternberger Monoclonals, Lutherville, Mass.) was used to verifythe degree of myelination. Antibody against active-caspase-3 (1:50, Cellsignaling Technology, Beverly, Mass.) was used as a marker for apoptoticcells. Fluorescent stained sections were mounted with Vectashieldmounting medium with DAPI (Vector Laboratories) and visualized with aZeiss Axioplan fluorescence microscope. Images were captured using aPhotometrics PXL CCD camera connected to an Apple Macintosh computerusing the Open Lab software suite. Immunopositive cells were quantifiedby counting positive cells within the median of the corpus callosum,confined to an area of 0.04 mm². Only those cells with nuclei observableby DAPI staining were counted. Each MBP immunostaining slide was scoredon a scale of zero to four. A score of zero indicates completedemyelination, and a score of four indicates normal myelination in thecorpus callosum of adult mice.

Real-time PCR analysis showed that the DOX− mice expressed robust levelsof IFN-γ and major histocompatibility complex (MHC) class I, adownstream target of IFN-γ activity, in the CNS at postnatal day (PND)14 (FIG. 14A). The double transgenic mice that ectopically expressedIFN-γ (DOX−) in the CNS during development were mildly hypomyelinated(see FIGS. 16 and 17), which is consistent with observations made ontransgenic mice that were previously generated to express IFN-γconstitutively in oligodendrocytes (Corbin, et al. (1996) Mol. Cell.Neurosci. 7: 354-370). The diminished myelination observed in these miceis correlated with IFN-γ-induced oligodendrocyte apoptosis (see FIGS.19A and 19F). IFN-γ upregulated BIP and CHOP expression approximately1.6 and 2 times the control levels and strongly enhanced caspase-12expression in the CNS of these animals (FIG. 14A). More notably, thelevel of the active fragment of caspase-12 was also increased in the CNSof these animals (FIG. 14B). Furthermore, colocalization analysis withthe CC1 antibody revealed that oligodendrocytes increased expression ofBIP (FIGS. 14C and 14D), p-eIF-2α (FIGS. 14E and 14F) and caspase-12(FIGS. 14G and 14H).

These data support the link between ER stress and IFN-γ inducedoligodendrocyte apoptosis and hypomyelination during development.

EXAMPLE 10 Hypersensitivity of PERK+/− Mice to ConditionalMis-Expression of IFN-γ

To examine the involvement of the ER stress response induced by INF-γ,the involvement of the PERK enzyme was evaluated using transgenic micethat are heterozygous for a loss of function of mutation in pancreaticER kinase (PERK) (Harding, et al. (2001) Mol. Cell 7: 1153-1163). Thephenotype of the transgenic animals was analyzed as a function of thelevel of p-eIF-2α was evaluated in the PERK+/− mice.

GFAP/tTA and TRE/IFN-γ double transgenic mice described in Example 1were crossed with PERK+/− mice, and the resulting progeny wereintercrossed to obtain double transgenic mice that were homozygous orheterozygous for the PERK mutation The majority of the double transgenicmice with a PERK−/− background died within 12 days after birth,regardless of whether they received doxycycline during the entire periodor if doxycycline was interchanged with water at embryonic day 14 (E14).Double transgenic GFAP/tTA; TRE/IFN-γ mice on a PERK+/+ background,released from doxycycline at E14 (E14 DOX−PERK+/+) showed the expectedminor tremor and ataxia but good survival. In contrast, the doubletransgenic mice on a PERK+/− background (E14 DOX−PERK+/−) had a muchmore severe phenotype. These animals were considerably smaller thanIFN-γ expressing PERK+/+ littermates or PERK+/− animals that did notinherit the combination of GFAP/tTA and TRE/IFN-γ alleles, and showedsevere tremor and ataxia, and approximately two-thirds of these miceexperienced tonic seizures. Strikingly, more than 90% of the doubletransgenic mice that were released from doxycycline at E14 on a PERK+/−background died by post natal day (PND) 27; whereas, double transgenicmice on a wild-type background displayed normal survival (FIG. 15).

The level of phosphorylted eIF-2α (p-eIF-2α) was determined severity ofthe phenotype of the mice was evaluated. The level of p-eIF-2α wassignificantly greater in the oligodendrocytes from PERK+/+ mice whencompared to that measured in the PERK+/− mice (FIGS. 14E and F), whereasa modest increase in p-eIF-2α was seen in the CNS of the PERK+/− mice(FIG. 15 B and C). The loss of function mutation in pERK did notsignificantly affect the RNA level of BIP, CHOP and Caspase-12 (FIG.15D).

These results suggest that the reduced capacity to elevate p-eIF-2αlevels in response to IFN-γ contributes to the severe phenotype in micemisexpressing IFN-γ on a PERK+/− background.

EXAMPLE 11 IFN-γ Mis-Expression Leads to Severe Hypomyelination in aPERK+/− Background

The tremoring phenotype with tonic seizures displayed by the PERK+/−mice that express IFN-γ in the CNS (as described in Example 3) issuggestive of myelin perturbations. To evaluate the level of myelinationin the PERK+/− mice, the state of myelination was evaluated byimmunostaining for MBP was performed in the CNS of 14-day-old GFAP/tTA;TRE/IFN-γ, PERK+/− mice released from doxycycline at E 14, and comparedto that of double transgenic mice on a wild-type background (FIG. 16).Immunostaining for myelin basic protein (MBP) was notably reduced in theCNS of 14-day-old GFAP/tTA; TRE/IFN-γ, PERK+/− mice released fromdoxycycline at E 14, compared with double transgenic mice on a wild-typebackground (FIG. 16). Moreover, ultrastructural examination revealedthat the majority (81%±14.9%) of axons in the spinal cord of PERK+/−mice that express IFN-γ in the CNS were unmyelinated (FIG. 17). Incontrast, double transgenic animals on a wild-type background releasedfrom doxycycline at E14 displayed considerably fewer unmyelinated axons(30%±12.9%), whereas animals maintained continuously on doxycycline torepress IFN-γ expression had even fewer unmyelinated axons (9.8%±6.1%).

These data establish a correlation between the severe tremoringphenotype induced by IFN-γ on the PERK+/− background andhypomyelination.

EXAMPLE 12 Loss of Oligodendrocytes Following IFN-γ Mis-Expression inPERK+/− Mice

To gain insight into the cellular mechanisms that account for thehypomyelination displayed by the PERK+/− mice that express IFN-γ in theCNS, the status of oligodendrocyte function in these animals wasexamined We determined the steady state levels of mRNAs encoding themyelin markers MBP, PLP and ceramide galactosyltransferase (CGT).Real-time PCR analysis showed that the MBP, PLP and CGT mRNA levels inthe brains of 14-day-old double transgenic mice on a wild-typebackground released from doxycycline at E 14 were slightly lower thannormal. These mRNA levels were even lower in the CNS of GFAP/tTA;TRE/IFN-γ, PERK+/− mice released from doxycycline at E 14 (FIG. 18). Todetermine if the decreased steady-state levels of myelin proteinencoding mRNAs was due to reduced numbers of myelinating cells wedetermined oligodendroglial numbers in these mice. Compared with controlmice, there were slightly fewer oligodendrocytes identified by CC1immunostaining in the CNS of 14-day-old GFAP/tTA; TRE/IFN-γ transgenicmice on a wild-type background released from doxycycline at E 14 (FIG.19A). In contrast, very few oligodendrocytes could be detected in thecorpus callosum and cerebellum of IFN-γ expressing transgenic mice on aPERK+/− background, and oligodendrocyte numbers in the spinal cord ofthese mice were decreased by more than 50% (FIG. 19A).

In addition, the number of oligodendrocytes that were TUNEL positive inthe cervical spinal cord of these mice was 2.5 times higher than thenumber of such cells in double transgenic mice on a wild-typebackground, following release from doxycycline at E 14 (FIGS. 19B, 19C,19D, 19E and 19F). Moreover, ultrastructural examination showed thatapoptotic oligodendrocytes contained highly condensed chromatin mass,intact membrane, shrunken cytoplasm and apoptotic body (FIG. 19G). Thesedata reinforce the hypothesis that IFN-γ damages oligodendrocytes bymeans of the ER stress pathway and indicate that PERK plays a criticalrole in protecting oligodendrocytes from the detrimental consequences ofIFN-γ-induced ER stress.

EXAMPLE 13 Oligodendrocytes in Adult Animals are Less Sensitive to IFN-γthan Actively Myelinating Oligodendrocytes from Younger Animals

Compared with the actively myelinating oligodendrocytes of young growinganimals, oligodendrocytes in adult mice produce lower levels of membraneproteins and lipids, just enough to maintain homeostasis in the myelinstructure (Morell, et al. (1999) Basic Neurochemistry: Molecular,Cellular, and Medical Aspects (Philadelphia, Pa.: Lippincott-RavenPublishers): 69-93). The ER of oligodendrocytes in adult animals maythus have more spare capacity to process increased protein load and assuch may be less sensitive to disruptions of the protein secretorypathway. To examine this possibility, double transgenic mice wereallowed to develop to maturity, at which time IFN-γ expression in theCNS was initiated. Real-time PCR analysis showed that double transgenicanimals released from doxycycline at 4 weeks of age started expressingIFN-γ at approximately 6 weeks of age, and the levels of IFN-γ mRNA andprotein in the CNS were comparable with those in developing micereleased from doxycycline at E 14 (data not shown). IFN-γ did not affectoligodendrocyte survival in adult mice, even in mice on a PERK+/−background (FIGS. 20B, 20C, 20D and 20E). Moreover, ultrastructuralexamination revealed normal myelin in the CNS of 10-week-old doubletransgenic mice with a wild-type or a PERK+/− background that werereleased from doxycycline at 4 weeks of age (FIGS. 20F, 20G, 20H and201). A modest induction of BIP and CHOP by IFN-γ was observed in thecerebellum of 10-week-old double transgenic mice released fromdoxycycline at 4 weeks of age (FIG. 20A). Nevertheless, colocalizationanalysis showed that mature oligodendrocytes did not significantlyincrease BIP expression (FIGS. 20B, 20C, 20D and 20E).

Thus, the data indicate that oligodendrocytes from adult animals areless sensitive to the presence of IFN-γ than are actively myelinatingoligodendrocytes of growing juvenile mice.

EXAMPLE 14 Administration of INF-γ at the Onset of EAE Attenuates theSeverity of the Disease

Double transgenic mice that allow for temporally regulated delivery ofINF-γ to the CNS (Lin et al., J Neurosci 24:10074-10083 (2004)) wereused to assess the role of INF-γ in the pathogenesis of EAE. GFAP/tTA;TRE/IFN-γdouble transgenic mice, as described in the Examples above,were used to determine the effect of INF-γ on the demyelination causedby EAE. All mice were fed doxycycline from the day of conception torepress the expression of INF-γ, and the experimental group were laterimmunized with MOG 35-55 peptide to induce the development to EAE. Forinduction of EAE, mice received subcutaneous injections at flanks andtail base of 200 μg MOG 35-55 peptide emulsified in complete Freund'sadjuvant (Difco) supplemented with 600 μg of Mycobacterium tuberculosis(strain H37Ra; Difco). 2 intraperitoneal injections of 400 ng pertussistoxin (List Biological Laboratories) were given 24 and 72 h later.Clinical score (0=healthy, 1=flaccid tail, 2=ataxia and/or paresis ofhindlimbs, 3=paralysis of hindlimbs and/or paresis of forelimbs,4=tetraparalysis, 5=moribund or death) were recorded daily. The controlanimals were continuously fed doxycycline (DOX+ double mice), while theexperimental animals (DOX− double mice) were deprived of the antibioticto allow for the expression of INF-γ. The effect of INF-γ was monitoredas follows.

The onset of disease was evident at day 14 in both DOX− and DOX+ doubleanimals, and no significant differences in clinical score were seen atthat time (PID14; post-immunization day 14). However, DOX− double micedeveloped significantly milder disease than the DOX+ double mice, andonly 2 of 25 animals in the DOX− group, showed hind limb paralysis,while a significantly greater portion (20/25) of the DOX+ double micehad limb paralysis (FIG. 21(a) and Table 1) TABLE 1 Delivery of INF-γ tothe CNS at the onset of EAE attenuates the severity of the disease Dayof onset of disease (PID: Mean of maximum postimmunization clinicalscore Incidence of hind day) (mean ± S.D.) limb paralysis Incidence ofdeath DOX+ double mice 13.6 ± 1.2 2.66 ± 0.80 20/25 0/25 DOX+ triplemice 14.0 ± 0.9 2.67 ± 0.94 19/25 2/25 DOX− double mice 14.7 ± 1.4 1.63± 0.51*  2/25 0/25 DOX− triple mice 13.6 ± 0.8 2.71 ± 1.11 18/25 3/25*p, 0.001, n = 25. Clinical severity scores were recorded dailyaccording to a 0-5 point scale, where 0 = healthy, 1 = flaccid tail, 2 =ataxia and/or paresis of hind limbs, 3 = paralysis of hind limbs and/orparesis of forelimbs, 4 = tetraparalysis, and 5 = moribund or dead.

Real-time PCR analysis was performed to assess the level of expressionof INF-γ in the spinal cord of DOX− and DOX+ animals. Anesthetized micewere perfused with PBS. RNA was isolated from the spinal cord usingTrizol reagent (Invitrogen) and treated with DNAseI (Invitrogen,) toeliminate genomic DNA. Reverse transcription was performed usingSuperscript First Strand Synthesis System for RT-PCR kit (Invitrogen).Taqman real-time PCR was performed with iQ supermix (Bio-Rad) on aBio-Rad iQ real-time PCR detection system as previously described 12FIG. 21(b) shows that the levels of IFN-γ in the spinal cord of theDOX-animals became detectable at EAE onset (PID14), reached peak at thepeak of disease (PID17), then decreased at the recovery stage of disease(PID 22).

The level of IFN-γ mRNA in the spinal cord of DOX− animals wassignificantly higher than than that of the DOX+ mice at all times PID14,PID17 and PID 22 (FIG. 21 b). In addition, for transgenic IFN-γ could bedetected in the spinal cord of DOX− double mice as early as PID14 (FIG.21 c). Thus, these data show that delivery of IFN-γ to the CNS at thetime of onset of EAE significantly attenuates the development of theseverity of the disease.

Real time PCR analysis of the expression of various cytokines in thespinal cord of DOX− and DOX+ animals at PID14 showed that INF-γincreased the expression of iNOs, TNF-a, IL-2, IL-12 and IL-10, but didnot affect the expression of IL-2 and IL-5 (FIG. 22).

Histopathological evaluation of the effect of INF-γ on demylinationcaused by EAE was performed on the spinal cord of the DOX+ and DOX−animals at the peak of the disease (PID17). The spinal cord of the DOX−animals showed destruction of myelin sheaths, axon damage,oligodendrocyte loss (FIGS. 23A, 23B and 23C) and perivascularinflammation (FIGS. 24A and 24B), which are characteristic of thehistopathology that is typical of EAE. In contrast, myelin, axons andoligodendrocytes from the lumbar spinal cord of DOX− animals remainedalmost intact (FIGS. 23A, 23B and 23C), and CD3 positive T cellinfiltration was lower than that seen i the DOX+ animals (FIG. 24A).Moreover, the mRNA level of myelin basic protein (MBP) in the spinalcord of DOX− double mice, as assessed by real-time PCR, revealed thatMBP mRNA was not significantly decreased by EAE when compared to MBPmRNA levels in age-matched naïve mice. However, the level of MBP mRNAwas decreased by 30% in the DOX+ double mice, (FIG. 23D).

Thus, these data show that delivery of IFN-γ to the CNS protects againstEAE-induced demyelination.

EXAMPLE 15 Administration of INF-γ at the Onset of EAE ProtectsOligodendrocytes from Demyelination Through a Cytoprotective Mechanismand Independently of its Anti-Inflammatory Properties

During EAE pathogenesis, T cells are primed in peripheral immune systemand enter the CNS well before the onset of clinical disease Hickey etal., (1991) J Neurosci Res 28:254-260. To determine whether the effectof INF-γ in protecting the CNS from the demyelinating effect of EAEresults from the anti-inflammatory activity of INF-γ, the level ofT-cell and monocyte infiltration was assessed and the expression ofknown inflammatory cytokines evaluated.

The results shown in FIGS. 24C and 24D show that IFN-γ did notsignificantly affect CD3 positive T cell infiltration, but increasedCD11b positive monocyte infiltration in the spinal cord at EAE onset(FIGS. 24E and 24F). Importantly, real-time PCR analyses showed thatdelivery of IFN-γ to the CNS strongly enhanced the expression ofinducible nitric oxide synthase (iNOs), tumor necrosis factor-γ (TNF-γ),interleukin-2 (IL-2), IL-12 and IL-10 in the spinal cord at EAE onset(FIG. 22), but did not significantly affect the expression if iNOs orTNF-γ at the peak of disease (FIG. 25). In addition, CNS delivery ofIFN-γ did not change CD11b positive monocyte infiltration at the peak ofdisease (FIG. 24B).

These data suggest that it is unlikely that IFN-γ protects EAE-induceddemyelination due to its anti-inflammatory properties; a hypothesis thathas been proposed by some investigators (Muhl et al., Int.Immunopharmacol 3:1247-1255 (2005)).

Oligodendrocyte death has been shown to modulate inflammatoryinfiltration in EAE lesions (Hisahara et al., EMBO J. 19:341-348 (2000);Hisahara et al., (2001) J Exp Med 193:111-122). It is possible thatwhile INF-γ promotes an inflammatory response at the onset of EAE, theinhibitory effect of INF-γ on the death of oligodendrocytes at a laterstage of disease may explain the decrease in T cell infiltration. Ourprevious findings have shown that transgenic mice that express INF-γunder the control of the MBP gene are resistant to oligodendrocyteapoptosis and demyelination induced by cuprizone (Gao et al., (2000) MolCell Neurosci 16:338-349). It is thought that the oligodendrocytes thatare injured by cuprizone go though apoptosis (Matsushima and Morell(2001) Brain Pathol 11: 107-116), which is closely followed by therecruitment of microglia and phagocytosis of myelin. In the cuprizoneanimal model, it is known that the demyelination oligodendrocyteapoptosis do not involve T cells or a breakdown of the blood brainbarrier.

Therefore, these data suggest that IFN-γ protects oligodendrocytes fromdemyelination through a cytoprotective effect.

EXAMPLE 16 Administration of INF-γ at the Onset of EAE ProtectsOligodendrocytes from Demyelination by Activating the PERK Pathway

Demyelination and oligodendrocyte loss are the hallmarks of multiplesclerosis (MS) and its animal model, experimental autoimmuneencephalomyelitis (EAE). It has long been known that low levels ofstress that activate downstream signaling pathways without causingsevere cell injury can protect against subsequent exposure tomore-severe stressful events. Pancreatic endoplasmic reticulum kinase(PERK) encodes an ER stress-inducible kinase that phosphorylateseukaryotic translation initiation factor 2α (eIF2α) and enhances thestress-induced expression of numerous cytoprotective genes (Harding etal., (1999) Nature 397:271-274; Lu et al., (2004) EMBO J. 23:169-179;Harding et al., (2003) Mol Cell 11:619-633).

To determine whether the PERK pathway mediates the protective effects ofIFN-γ from demyelination induced by EAE, the level ofphosphorylated-PERK (p-PERK) and phosphorylated-eIF2α (p-eIF2αx) wasmonitored in oligodendrocytes during the course of EAE.

Colocalization analysis with the CC1 antibody revealed that a fewoligodendrocytes were p-PERK positive and p-eIF2α positive in the spinalcord of control mice at EAE onset, consistent with a previous report(Chakrabarty et al., 2004). In contrast, CNS delivery of IFN-γ markedlyactivated the PERK-eIF2α pathway in oligodendrocytes (FIG. 24).

These data support a link between the activation of the PERK pathway inoligodendrocytes and a protective role of IFN-γ in EAE-induceddemyelination.

A genetics-based approach was used to examine the involvement of thePERK pathway in the protective effects of IFN-γ on EAE. Mice that areheterozygous for a loss of function mutation in PERK are phenotypicallyhealthy but display evidence of haploid insufficiency (Harding et al.,2000; Lin et al., 2005). TRE/IFN-γ mice were crossed with PERK+/− mice,and their progeny was crossed with GFAP/tTA mice to obtain tripletransgenic mice that were heterozygous for the PERK mutation.Six-week-old GFAP/tTA; TRE/IFN-γ triple-transgenic mice with a PERK+/−background that had received doxycycline since conception were immunizedwith the MOG35-55 peptide and were either simultaneously withdrawn fromdoxycycline (DOX− triple mice) or continued to receive doxycycline (DOX+triple mice). The control DOX+ triple mice showed an EAE disease coursesimilar to that of control DOX+ double mice Strikingly, CNS delivery ofIFN-γ did not ameliorate EAE in mice heterozygous for the PERK mutation.Morbidity rates, EAE severity, and mortality rates for DOX− triple micewere comparable with those for control DOX+ triple mice (Table 1).Neuropathologic analyses revealed that CNS delivery of IFN-γ at EAEonset did not prevent demyelination, axon damage, or oligodendrocyteloss in the lumbar spinal cord of mice with a PERK+/− background at thepeak of disease. In fact, MBP immunostaining, toluidine blue staining,and real-time PCR analysis for MBP consistently showed comparabledemyelination in the spinal cord of DOX− triple mice and control DOX+triple mice at the peak of disease severity (FIG. 23). In addition, wefound that the loss of function mutation in PERK did not significantlyaffect inflammatory infiltration and the expression profile of cytokinesin the course of EAE. Therefore, these data show that the activation ofthe PERK pathway by IFN-γ in oligodendrocytes is essential forprotecting neurons against demyelination caused by EAE. This suggeststhat IFN-γ activates an “integrated stress response” which is dependenton PERK pathway that provides protection against subsequent exposure toharmful agents to the neuronal system.

EXAMPLE 17 The Role of GADD34 in Demyelination: Effects of the Loss ofFunction of GADD34 In Vivo

The role of GADD-34 in demyelination was studied in mice lacking GADD-34and in which EAE was induced.

Activation of eIF2α has been observed in oligodendrocytes during EAE(Chakrabarty et al, 2004; Chakrabarty et al., 2005). As described in theexamples above, CNS delivery of IFN-γ at EAE onset has been shown toprotect against EAE-induced demyelination and to attenuate the severityof the disease by activating the PERK-dependent integrated stressresponse pathway. GADD34 is a stress-inducible gene that encodes aregulatory subunit that engages protein phosphatase-1 (PP1) and targetsdephosphorylation of the eukaryotic translation elongation factor eIF2α(Connor et al., 2001; Novoa, 2001; Novoa et al., 2003). GADD34-null miceare healthy, but a loss of GADD34 increases the level of phosphorylatedeIF2α (p-eIF2α) in stressed cells. Furthermore, it has been shown thatGADD34-null animals are markedly protected from cell death caused by ERstress (Jousse et al., 2003; Marciniak et al., 2005). Therefore, role ofeIF2α in the pathogenesis of EAE was tested using GADD34-null mice.

GADD34-null mice were generated. The mice have been backcrossed 6 timeswith C57BL/6 mice. EAE is induced as follows. Mice were given asubcutaneous injection in the flank and tail base of 200 μg MOG 35-55peptide which was emulsified in complete Freund's adjuvant andsupplemented with 600 μg of Mycobacterium tuberculosis. Two injectionseach of 400-ng of pertussis toxin were given intraperitoneally at 24 and72 h following the immunization with the MOG 35-55 peptide. Clinicalseverity scores were recorded daily according to a 0-5 point scale,where 0=healthy, 1=flaccid tail, 2=ataxia and/or paresis of hind limbs,3=paralysis of hind limbs and/or paresis of forelimbs, 4=tetraparalysis,and 5=moribund or dead.

The results in FIG. 26 show that the onset of the disease issignificantly delayed in the GADD34-null mice when compared to thecontrol animals. Therefore, inhibition of GADD34 delays the onset ofEAE.

Tissue damage in the CNS is determined by immunohistochemistry analysisand toluidine blue staining as described by Lin et al. (submitted).Spinal cord tissue is analyzed for tissue damage at the peak of diseaseseverity. An antibody against CC1 (APC7) is used as a marker to identifymature oligodendrocytes; an antibody against MBP is used to determinethe degree of demyelination; and an antibody against nonphosphorylatedneurofilament-H (SMI32) is used to detect axonal damage. In addition,the severity of demyelination and axonal injury is examined by stainingthe tissue with toluidine blue. As myelin gene expression is highlycorrelated with oligodendrocyte function, real-time PCR is perfomed todetermine the steady-state levels of mRNAs that encode for MBP, PLP, andceramide galactosyltransferase (CGT) in the spinal cord. The Taqmanreal-time PCR allows for quantifying the degree of demyelination in thelesions.

The results show that progression of EAE is accompanied by a decrease inmRNAs encoding MBP, PLP and CGT in both GADD34-null mice and the wildtype controls. However, the decrease in the GADD34-null mice precedesthat seen in the wild type animals.

It is expected that the histological results will be consistent with thetime course of the disease as assessed by the phenotypic changes thatwere quantified using clinical scores, and it is likely that loss offunction of GADD34 protects from demyelination and from the loss ofoligodendrocytes that is characteristic of EAE.

EXAMPLE 18 Loss of GADD34 Protects Oligodendrocytes from AginstDemyelination During EAE

Diverse stressful conditions are associated with phosphorylation ofeIF2α. Four mammalian eIF2α kinases have been identified: PERK, GCN2,RNA-activated protein kinase (PKR), and HRI (Proud, 2005). As describedin the Examples above the PERK-eIF2α pathway is activated inoligodendricytes during EAE by the immune cytokine IFN-γ. Chakrabarty etal. (2004) have shown that activation of the PKR-eIF2α pathway occurs ininflammatory cells in the CNS of animals with active EAE.

To confirm that the effect seen in the mice having EAE but lackingGADD34 reflects the protection of oligodendrocytes, doubleimmunostaining of CC1 and p-eIF2α is performed in the GADD34-null miceand compared to that performed in the wild type control animals.

In addition, double immunostaining of CD3 and p-eIF2α is performed todetermine whether the level of p-eIF2α is increased in T cells in theCNS of the GADD34-null mice when compared to the wild type animals. Theimmune responses in the CNS and peripheral immune system in GADD34-nulland littermate control mice are analyzed as described in Lin et al.(submitted).

It is expected that the results will indicate that the level of p-eIF2αis greater in the oligodendrocytes of the GADD34-null mice than in thewild type mice. Without being bound by any particular theory, enhancingthe phosphorylation of eIF2α is expected to prolong the integratedstress response and thus oligodendrocytes from the damage caused by EAE.

EXAMPLE 19 The Role of GADD34 in Demyelination: Effects of the Loss ofFunction of GADD34 In Vitro

To evaluate the protective effects seen in oligodendrocytes and gainedby the loss of GADD34 deletion, experiments that use siRNA to block theexpression of GADD34 are performed on purified rat oligodendrocytes inculture. The experimental protocol is described by Lin et al.(submitted). Oligodendrocyte progenitors (OPCs) are cultured fromneonatal rat brain as follows. A mixed glial culture is grown in flasksin medium containing 10% FBS, and when the astrocyte layer becomesconfluent (after 10-14 days), OPCs are separated from astrocytes andmicroglia using an orbital shaker. More than 95% of the cells are A2B5positive, GFAP negative, and CD11b negative, and are first cultured inmedium containing 0.5% FBS, PDGF (10 ng/mL), and FGF (5 ng/mL), thenthen transferred to 0.5% FBS medium without PDGF and FGF to inducedifferentiation.

Small interfering RNA (siRNA) is designed using siRNA Target Findersoftware (Ambion) and used to inhibit the expression of the rat GADD34.The target sequence of the siRNA is used in conjuction with thepSilencer Expression Vectors Insert Design Tool (Ambion) to generatehairpin siRNA that encodes DNA oligonucleotide inserts that are derivedfrom the siRNA target sequence. The program adds the loop sequence andoverhangs that are used for cloning. The hairpin siRNA-encoding DNAoligonucleotide inserts are cloned into the pSilencer 4.1-CMV vector(Ambion) according to the manufacturer's instructions, and the pSilencer4.1-CMV vectors encoding hairpin siRNAs that are specific for GADD34will be transfected into OPCs using the Nucleofector kit (Amaxa)according to the protocol of the manufacturer. Control oligodendrocytesare transfected with control vectors that are pSilencer 4.1-CMV vectorsthat lack GADD34 siRNA. After transfection, the cells are selected with2.5 μg/mL puromycin over a period of 10-14 days. The transfected OPCsare analyzed for the presence GADD34 mRNA using Taqman real-time PCR andfor the presence of GADD34 protein using Western blot analysis.

It is expected that the results suggest that siRNA specific for theGADD34 gene successfully inhibits the transcription of GADD34 and theexpression of the GADD34 protein.

In addition, the protective effect of salubrinol (Sal) is tested todetermine whether Sal protects oligodendrocytes from cytokines,oxidants, peroxynitrite donors, and glutamate. Salubrinol has been shownto specifically inhibit the PP1-GADD34 phosphatase activity, whichresults in sustained eIF2α phosphorylation in stressed cells (Boyce etal., 2005). Sal is combined with TNF-γ, H₂O₂, the peroxynitrite donorSIN-1, and glutamate is added to the cells that have been allowed todifferentiate for 7 days. Western blot analysis is used to examinewhether Sal elevates the level of p-eIF2α in cultured oligodendrocytes.Also, the viability of oligodendrocytes is determined by the MTT assay(Roche), the TUNEL assay (ApopTag kit; Serologicals), and the caspase-3activity assay (Sigma, St. Luis, Mo.) as described by Lin et al., 2001and 2005.

The results indicate that inhibiting the function of GADD34 by blockingits expression using siRNA technology or by directly inhibiting itsenzymic activity protects oligodendrocytes from reactiveoxidative/nitrative stress and glutamate cytotoxicity. Histologicanalyses at the peak of disease will reveal that GADD34 deletionelevates the level of p-eIF2α in oligodendrocytes and protects againstEAE-induced demyelination and oligodendrocyte loss. It is expected thatGADD34 siRNA transfection and Sal will protect oligodendrocytes fromcytokine exposure, reactive oxidative/nitrative stress, and glutamateexcitoxicity. Various aspects of the cytoprotective effects of Sal withthose of GADD34 siRNA transfection are compared. The protective effectsof Sal in mice with EAE and persons with MS are tested.

EXAMPLE 20 Activation of the PERK-Dependent Integrated Stress ResponsePathway in Oligodendrocytes Protects Against Demyelination

The activation of the PERK pathway is initiated by dimerization of PERK,which leads to trans-autophosphorylation and increased ability tophosphorylate its substrate, eIF2α. Normally, this dimerization event isdriven by the stress-sensing ER lumenal domain of PERK (Harding 1999).Other researchers have fused the eIF2α kinase effector domain of PERK toa polypeptide containing 2 modified FK506 binding domains (Fv2E) togenerate a fusion protein, Fv2E-PERK, and have demonstrated that theactivity of this artificial eIF2α kinase, Fv2E-PERK, is subordinate tothe dimerizer AP20187 and is uncoupled from upstream signaling of ERstress (Lu et al., 2004).

To examine the protective effects of PERK activation on oligodendrocytesin vitro oligodendrocyte precursor cells (OPCs) are transfected with aconstruct encoding Fv2E-PERK, The Fv2E-PERK construct is subcloned intothe mammalian vector pcDNA3.1 to generate a mammalian expression plasmidthat expresses a fusion protein Fv2E-PERK protein (pcDNA3.1-Fv2E-PERK).Purified rat OPCs as described above are transfected withpcDNA3.1-Fv2E-PERK using the Nucleofactor kit (Amaxa), and selected withG418 (400 ug/ml) for 10-14 days.

The OPCs are induced to differentiate for 7 days, and the activation ofthe PERK-eIF2α pathway is evaluated in the presence of the dimerizerAP20187 alone, or in combination with one of TNF-γ, H₂O₂, peroxynitritedonor SIN-1, or glutamate.

The expression of mRNA encoding Fv2-PERK is verified using real timePCR, and the expression of Fv2-PERK protein is verified by Western blotanalysis. The effect of the activation of the PERK-eIF2α pathway isassessed by Western blot analysis for p-eIF2α following addition ofAP20187 to the transfected OPCs. Further, the viability of transfectedoligodendrocytes is determined using the MTT assay, TUNEL assay, andcaspase-3 activity assay, as described above following differentiationof OPCs for 7 days. The same analyses are made following administrationof AP20187 to the OPCs in the presence of TNF-a, H₂O₂, peroxynitritedonor SIN-1, or glutamate. Oligodendrocyte viability is determined byMTT and TUNEL assays, and caspase activity.

It is expected that AP20187 will protect the Fv2-PERK-expressingoligodendrocytes from effector(s) of the ER stress pathway.

EXAMPLE 21 Identification of Genes that are Upregulated by Activation ofthe Perk Pathway

To determine the mechanisms accounting for the protective effects ofactivation of the PERK pathway on oligodendrocytes, mRNA microarrayanalysis is used to identify the cytoprotective genes that areupregulated.

OPCs that have been transfected with pcDNA3.1-Fv2E-PERK aredifferentiated for 7 days and treated with AP20187. RNA is isolated fromAP20187-treated transfected cells and control transfected cells by usingTrizol reagent (Invitrogen), and DNAseI (Invitrogen) is added toeliminate genomic DNA. Fluorescent-labeled RNA probes are prepared andhybridized to Affimetrix rat high-density oligonucleotide arrays.Primary image analysis of the arrays is performed using the Genechipsoftware package (Affymetrix). The raw data is also be analyzed by meansof GeneSpring software. Only genes whose raw hybridization signal issignificantly stronger than that of the chip background is evaluated.The raw signal strength for each gene is normalized to the mean signalstrength of all genes from the same chip to obtain the normalized signalstrength. To allow visualization of all data on the same scale forsubsequent analysis, the normalized signal strength of each gene isdivided by the median signal strength for that gene among all samples toobtain the expression level.

The results show that cytoprotective genes that are involved in theprotective effects of the PERK pathway in EAE are identified. The roleof the newly-identified genes in the in the pathogenesis of EAE isevaluated.

EXAMPLE 22 Activation of the PERK-eIF2α Pathway ProvidesCytopoprotection to Oligodendrocytes During EAE

To provide direct evidence that activation of the PERK-eIF2α pathwayprotects against EAE-induced tissue damage through its cytoprotectiveeffects on oligodendrocytes, the activity of PERK is modulated in micethat allow for controllable activation of the PERK pathway inoligodendrocytes.

Based on methods previously used to generate transgenic mice thatexpress proteins specifically in oligodendrocytes under thetranscriptional control of the regulatory sequences of the myelinproteolipid protein (PLP) gene (Fuss et al., 2000, 2001; Doerflinger etal., 2003), an expression construct that expresses the fusion Fv2E-PERK(PLP/Fv2E-PERK) is engineered, and transgene fragments are injected intofertilized C57BL/6 mouse oocytes.

Several lines of PLP/Fv2E-PERK transgenic mice that express varyiouslevels of the transgene are obtained, and transgene expression is foundnot to be deleterious to the animals. Quantitative real-time PCR is usedto determine copy numbers of the transgene that integrates into thegenome of heterozygous animals, and the level of Fv2E-PERK mRNA andprotein in the CNS is determined using real-time PCR and Western blotanalysis; The transgenic mice are given intraperitoneal injections ofAP20187, and the activity of Fv2E-PERK in the CNS is determined byWestern blot analysis for p-Fv2E-PERK and p-eIF2α. Finally, CC1 andp-eIF2α double immunostaining is perfomed to confum that the eIF2αpathway is specifically activated in oligodendrocytes in the transgenicmice that received AP20187.

The transgenic mice that allow for modest activation of the PERK pathwayin oligodendrocytes after administration of AP20187 are selected for EAEexperiments. The mice are immunized with MOG33-35 peptide as describedin Example and Fv2E-PERK in oligodendrocytes is activated byadministering AP20187 before the onset of EAE onset. The activation ofeIF2α in oligodendrocytes is verified by CC1 and p-eIF2α doubleimmunostaining, and the clinical phenotype, the histopathologic findingsin the CNS, and the immune response in the CNS are characterized asdescribed in the Examples above.

EXAMPLE 23 Activation of PERK Pathway in Remyelinating OligodendrocytesPromotes Remyelination in EAE-Induced Demyelinated Lesions

To determine that the activation of the PERK pathway promotesremyelination of oligodendrocyte in EAE-induced demyelinated lesions,EAE is induced in PLP/Fv2E-PER mice, and the role of PERK is evaluatedin the presence and absence of AP201187.

The PLP/Fv2E-PERK mice are immunized with MOG33-35 peptide as describedin Example, and Fv2E-PERK is activated in oligodendrocytes byadministering AP20187 to the mice during the recovery stage of EAE.Clinical severity scores were recorded daily according to a 0-5 pointscale, where 0=healthy, 1=flaccid tail, 2=ataxia and/or paresis of hindlimbs, 3=paralysis of hind limbs and/or paresis of forelimbs,4=tetraparalysis, and 5=moribund or dead.

The activation of eIF2α in oligodendrocytes is verified by CC1 andp-eIF2α double immunostaining. Once the severity of disease betweenAP20187-treated mice and control mice appears to be significantlydifferent, spinal cord tissue is prepared and analyzed forremyelination. As described elsewhere (Lin et al., submitted), CC1immunostaining is used to determine the mature oligodendrocyte numbersin the demyelinated lesion, and immunostaining for MBP and toluidineblue staining is used to verify the degree of demyelination. The immuneresponse in the CNS is assessed by immunostaining for CD11b and CD3immunostaining, and by real-time PCR analyses for IFN-γ, TNF-γ, iNOs,IL-2, IL4, IL-5, IL-10, IL-12, IL-17, and IL-23.

EXAMPLE 24 The PERK-eIF-2α Pathway is Activated in Oligodendrocytes fromLesions in Patients with MS

CNS tissue of patients with MS is obtained from the Human Brain andSpinal Fluid Resource Center (Los Angeles, Calif.) and The RockyMountain MS Center (Englewood, Colo.). The tissue may include brain andspinal cord tissues, spinal fluid, and other tissue specimens that arederived from persons who have had MS in their lifetime. The samples arefrozen or otherwise preserved very soon after the death of the donors,and the banked tissues are carefully catalogued along with informationabout the donor's medical history and are available to qualifiedinvestigators.

Total RNA is isolated from the frozen samples using Trizol reagent(Invitrogen) and treated with DNAseI (Invitrogen) to eliminate genomicDNA. Reverse transcription is performed using the Superscript FirstStrand Synthesis System for RT-PCR kit (Invitrogen). Using Taqmanreal-time PCR, the expression of IFN-γ and the ER stress markers BIP andCHOP is quantified. The protein levels of PERK, eIF2α, p-PERK, andp-eIF2α are determined using Western blot analysis.

The remaining frozen tissue will be embedded in optimal cuttingtemperature compound. Frozen sections (10 μm thick) of the tissuesamples are prepared, and CC1 immunostaining is used to determine thenumber of oligodendrocytes in the demyelinated lesions. MBPimmunostaining is used to verify the degree of demyelination. The immuneresponse in the CNS is assessed by CD11b immunostaining and CD3immunostaining. Furthermore, CC1 and p-PERK double immunostaining, orCC1 and p-eIF2α double immunostaining is performed to demonstrate theactivation of the PERK-eIF2α pathway in MS lesions.

In the basis of the distribution and density of inflammatory cells andactivated microglia, demyelinated MS-induced lesions can be divided intothe following 3 categories: active (acute), chronic active, and chronicinactive (Lassmann, 1998; Trapp et al., 1999). The relationship betweenthe levels of IFN-γ and the activity of the PERK pathway in the samples,and the relationship between the degree of demyelination and theactivity of the PERK pathway in the lesions, is determined.

It is expected that the PERK-eIF2α pathway is activated in theoligodendrocytes of MS lesions. Because of the heterogenous patterns ofdemyelination in MS, the activation of the PERK-eIF2α pathway isexpected to be detected in only some of the tissue samples.

EXAMPLE 25 Deletion of GADD34 Increases the Level of P-eIF2α inOligodendrocytes and Protects Against EAE-Induced Demyelination

1. Studies In Vivo

Phosphorylation of eIF2α is a highly conserved point of convergenceamong signaling pathways that adapt eukaryotic cells to diversestressful conditions (Jousse et al (2003) J. Cell. Biol. 163:767-775;Proud C G (2005) Semin. Cell. Dev. Biol. 16:3-12). Four protein kinasesare known to couple the otherwise unrelated stresses of proteinmalfolding in the ER (PERK), amino acid deprivation (GCN2), viralinfection (PKR) and heme deficiency (HRI) to the phosphorylation ofeIF2α (Proud C G (2005) Semin. Cell. Dev. Biol. 16:3-12). This eIF2αphosphorylation-dependent, stress-inducible pathway has been referred toas an integrated stress response (ISR) (Harding, et al (2003) Mol. Cell11:619-633; Proud C G (2005) Semin. Cell. Dev. Biol. 16:3-12). Torecover from stress, eIF2α is quickly dephosphorylated by a complexcontaining the enzyme phosphatase (PP1) and its essential nonenzymaticcofactor, growth arrest and DNA damage 34 (GADD34) (Connor, et al.(2001) Mol. Cell. Biol. 21: 6841-6850; Novoa et al (2001) J. Cell Biol.153:1011-1022; Novoa et al (2003) EMBO J. 22:1180-1187). The expressionof GADD34 is regulated by induction of the cytosolic transcriptionfactor ATF4, the translation of which is upregulated in the presence ofeIF2α phosphorylation, thus creating a tight auto-feedback loop (Novoaet al (2003) EMBO J. 22:1180-1187; Jiang et al (2004) Mol. Cell. Biol.24:1365-1377). GADD34 deletion increases the level of p-eIF2α instressed cells and protects cells from stress (Jousse et al (2003) J.Cell. Biol. 163:767-775; Marciniak et al (2004) Genes Dev.18:3066-3077).

As shown in the examples above, early induction of IFN-γ in the CNS hasa protective effect in animals induced to develop EAE, and that thisprotection is dependent on PERK. To test whether the early presenceIFN-γ activates the integrated stress response (ISR) through theactivation of PERK in oligodendrocytes, and protects them frominflammatory demyelination, the effect of EAE was examined in GADD34mutant mice. It was expected that in the absence of GADD34, theprolonged stress response would be beneficial.

a. The Onset of EAE is Significantly Delayed in GADD34-Null Mice

EAE was induced in GADD34-null mice and control animals as described inExample 17. Briefly, GADD34-null mice were backcrossed with C57BL/6 miceat least 6 times. EAE was induced in mice by administering to the mice asubcutaneous injection of 200 μg MOG 35-55 peptide emulsified incomplete Freund's adjuvant supplemented with 600 μg of Mycobacteriumtuberculosis in the flank and tail base. Two 400-ng intrapentonealinjections of pertussis toxin were given 24 and 72 h later. Clinicalseverity scores were recorded daily using a 0-5 point scale (0=healthy,1=flaccid tail, 2=ataxia and/or paresis of hind limbs, 3=paralysis ofhind limbs and/or paresis of forelimbs, 4=tetraparalysis, and 5=moribundor dead).

The clinical disease onset in GADD34-null mice is significantly delayedwhen compared with the onset in littermate control mice (FIG. 26). Inaddition, the severity of disease in the GADD34-null mice was milderthan control mice. Therefore, loss of GADD34 function delays the onsetof EAE and diminishes the severity of the disease.

b. Loss of GADD34 Increases the Level of P-eIF2α in Oligodendrocytes andProtects Against EAE-Induced Demyelination.

Spinal cord tissue was prepared and analyzed at the time point whencontrol mice were at the peak of disease severity. As expected, theexpression of GADD34 was upregulated in oligodendrocytes in the lumbarspinal cord of mice with EAE, which was undetectable in oligodendrocytesin the age-matched naïve mice (FIGS. 27 a and 27 b). Moreover, CC1 andp-eIF2α double labeling revealed that GADD34 deletion markedly increasedthe level of p-eIF2α in oligodendrocytes in the lumbar spinal cord ofGADD34 null mice with EAE, compared with control mice (FIGS. 27 c and 27b). Histological analysis revealed typical EAE demyelinating lesions inthe lumbar spinal cord of control mice: destruction of myelin sheaths(FIGS. 28 a and 28 c), oligodendrocyte loss (FIG. 28 e) axonal damage(FIG. 28 g). In contrast, no obvious demyelinating lesion was observedin the lumbar spinal cord of GADD34 null mice by MBP immunostaining andtoluidine blue staining at this time point (FIGS. 28 b and 28 d).Importantly, oligodendrocytes in the lumbar spinal cord of GADD34 nullmice remained almost intact (FIG. 28 f). Moreover, GADD34 deletiondramatically reduced the axonal damage in the lumbar spinal cord ofGADD34 null mice, compared with control mice (FIGS. 28 g and 28 h).Taken together, these data indicate GADD34 deletion increases the levelof p-eIF2α in oligodendrocytes, thus prolongs in the integrated-stressresponse and protects against EAE-induced demyelination.

2. Studies In Vitro

The importance of the phosphorylation of eIF2α in protecting the cellfrom stress has lead to the search for small-molecule modulators of thephosphorylation of eIF2α that could potentially be useful for thetreatment of several human diseases. Boyce et al. (Boyce, et al. (2005)Science 307:935-939) used a drug screen that would identify smallmolecules that confer cytoprotection against ER-stress-inducedapoptosis. They identified a small-molecule inhibitor of eIF2αdephosphorylation, salubrinal (SAL), which specifically inhibits thePP1-GADD34 phosphatase activity, resulting in sustained eIF2αphosphorylation. Treatment with Sal protects cells from ER stress andviral infection (Boyce, et al. (2005) Science 307:935-939).

Our hypothesis is that the integrated stress response has the potentialto protect oligodendrocytes from the harmful effects of the inflammatoryresponse in patients with multiple sclerosis (MS). As shown above micewith a null mutation in GADD34 demonstrate increased eIFaphosphorylation and a delayed response to EAE induction, including lesssevere demyelinaiton at the peak of disease. To test whether agents thatprolong eIF2α phosphorylation might provide protection tooligodendrocytes against detrimental inflammatory factors, the effect ofSalubrinol (Sal) in the presence of the immune cytokine IFN-γ was testedin an in vitro model of myelination.

Hippocampal organotypic cultures (HOC), which have been shown tomyelinate well in vitro. HOCs, were prepared and maintained as describedpreviously (Kunkler and Kraig (1997) J Cereb Blood Flow Metab. 17:2643),and were maintained in vitro for 7 days before use. SAL at variousconcentrations was combined with 100 U/ml IFN-γ and added to the HOCcultures for 7 days. Robust myelination was observed in untreated HOCs,as demonstrated by abundant levels of the myelin-specific protein myelinbasic protein (MBP) in the cultures (FIG. 29). After 7 days of 100 U/mlIFN-γ exposure, the levels of MBP decreased approximately 80% in theHOCs (FIG. 29). SAL treatment alone did not affect MBP expression.However, SAL treatment markedly attenuated the reduction of MBPexpression elicited by IFN-γ exposure (FIG. 29). The presence of IFN-γhas been shown to inhibit remyelination in demyelinated lesions (SeeExamples 2-7). Taken together, these data indicate that treatment withagents that promote or prolong eIF2α phosphorlyation could promotemyelin repair in immune-mediated demyelination diseases.

EXAMPLE 26 Inhibition of the Cytokine Signaling ProtectsOligodendrocytes from the Deleterious Effects of INF-γ

1. Generation and Evaluation of Transgenic Mice

a) Generation of Transgenic Mice that Express SOCS1 in Oligodendrocytes

The transgenic mouse line PLP/SOCS1 was generated using a constructcontaining a PLP expression cassette and SOCS1 cDNA (FIG. 30A). The PLPexpression cassette has been described elsewhere and has been used foroligodendrocyte-specific expression of a number of transgenes (Wight etal., 1993; Fuss et al., 2000; Doerflinger et al., 2003; Gonzales et al.,2005). A SOCS1 cDNA clone (Starr et al., 1998) was used as it containeda Flag-epitope sequence that served as a marker for SOCS1 expression inpolymerase chain reaction (PCR)-based or anti-Flag antibody-baseddetection methods (Einhauer and Jungbauer, 2001). Briefly, theFlag-SOCS1 cDNA was excised from the original expression vectorpEF-FLAG-I/m4A2 with XbaI. The fragment was Klenow filled and subclonedinto an intermediate vector (modified pNEB/193 vector) at the SmaIrestriction site. The resulting pNEB 193/SOCS1 vector was furtherdigested with AscI (partial digestion) and PacI to release theFlag-SOCS1 fragment, which was subcloned into the polylinker region ofthe PLP expression cassette at the same restriction sites. The PLP/SOCS1vector was digested with ApaI and SacII (partial digestion) and a linear15-kb transgene was isolated for microinjection into fertilized(C57BL/6J×DBA/2J) oocytes. Offspring positive for the transgene wereidentified by amplifying tail DNA by PCR using transgene-specificprimers. The identified founders were subsequently bred with C57BL/6mice (Jackson Laboratories, Bar Harbor, Me.) establishing a transgenicline.

b) Generation of Lines of Transgenic Mice that Express INF-γ in the CNS

The transgenic mice MBP/IFN-γ (line 172) and GFAP/tTA×TRE/IFN-γ (lines184/110 and 184/67) that overexpress IFN-γ in the CNS have beendescribed elsewhere (Corbin et al., 1996; Gao et al., 2000; Lin et al.,2004, 2005). Briefly, MBP/IFN-γ (line 172) mice are transgenic animalsin which IFN-γ expression is driven by the myelin basic protein (MBP)transcriptional control region (Gao et al., 2000). GFAP/tTA×TRE/IFN-γare double-transgenic mice obtained by mating single-transgenic GFAP/tTA(line 184) to single-transgenic TRE/IFN-γ (lines 110 and 67) mice. Thetwo TRE/IFN-γ mouse lines, line 110 and line 67, used in the experimentsproduce different amounts of IFN-γ when crossed to GFAP/tTA mice(184/110 and 184/67) (Lin et al., 2004, 2005). GFAP/tTA×TRE/IFN-γ is atetracycline-off-inducible system in which the glial fibrilary acidicprotein (GFAP) transcriptional control region drives the expression oftTA, which in turn, binds to the TRE (tet responsive element) andinitiates the expression of IFN-γ. Administration of doxycyclinesuppresses tTA DNA binding and IFN-γ expression, and doxycycline removalallows for temporally-controlled induction of IFN-γ expression (Gao etal., 1999).

c) Breeding and Evaluation of Transgenic Animals

IFN-γ-overexpressing mice were crossed to the PLP/SOCS1 mice indouble-transgenic, (MBP/IFN-γ×PLP/SOCS1) and triple-transgenic(GFAP/tTA×TRE/IFN-γ×PLP/SOCS1) mating systems. MBP/IFN-γ×PLP/SOCS1(172×PLP/SOCS1) mating was performed according to a standard matingprotocol. The GFAP/tTA×TRE/IFN-γ×PLP/SOCS1 matings were performed in a2-step mating process: GFAP/tTA mice (line 184) were initially crossedto PLP/SOCS1 mice, and double-positive (184×PLP/SOCS1) offspring werethen crossed to the TRE/IFN-γ lines 110 and 67, separately. This secondmating step was performed according to the previously described“tet-off” protocol. Doxycycline 0.05 mg/ml (Sigma-Aldich) was added tothe water of impregnated female mice until embryonic day 14, after whichthe animals were switched back to normal water, thereby allowinginitiation of IFN-γ transcription, which peaks during the postnatalperiod (Lin et al., 2005).

The litters of the mating systems (F1 generation) were examined dailyand sacrificed at postnatal day 21. Clinical evaluation includedbehavioral observation and challenged ladder walking to elicit tremor.Histological examination included quantitation of the number and densityof oligodendrocytes and examination of the myelination patterns. Braintissue was simultaneously obtained from each animal at the time ofsacrifice to verify and measure the expression of IFN-γ and Flag-SOCS1(see below). The clinical and histological findings were subsequentlystratified according to genotype. All animal procedures were conductedin compliance with the National Institutes of Health Guide for Care andUse of Laboratory Animals and were approved by the Institutional AnimalCare and Use Committee at The University of Chicago.

d) Polymerase Chain Reaction and Genotyping of Transgenic Animals

All experimental animals were genotyped using isolated tail DNA (Biotek2000 automatic system, Beckman-Coutler, Fullerton, Calif.). PCR (QiagenPCR kit, Valencia, Calif.) for transgene detection was performed usingthe following transgene-specific screening primers: Flag-SOCS1 senseprimer, 5′-CCAGGACGACGATGACAAGA-3′ and Flag-SOCS1 anti-sense primer,5′-TCAGGGGTCCCCA ATAGAAG-3′; MBP/IFN-γ sense primer,5′-ATGAGGAAGAGCTGCAAAGC-3′, and MBP/IFN-γ anti-sense primer,5-GGTGACAGACTC CAAGCACA-3′; GFAP/tTA sense primer,5′-TCGCTTTCCTCTGAACGCTTCTCG-3′ and GFAP/tTA anti-sense primer,5′-TCTGAACGCTGTGACTTGGAGTGTCC-3′; TRE/IFN-γ sense primer5′-CGAATTCGAGCTCGG TACCC-3′ and TRE/IFN-γ anti-sense primer5′-CCATCCTTGCCATTCCTCCAG-3′ (Integrated DNA Technologies Inc.).

e) Northern Blot Analyses and Quantitative PCR Methods

Total RNA was isolated from the examined animals with TRizol reagent(Invitrogen Corp., Carlsbad, Calif.). Northern blots were performed byseparating 20 μg of total RNA in a 1.2% denaturing agarose gel. Thesamples were transferred to a nylon membrane and hybridized overnightwith a SOCS1 probe that had been randomly labeled by PCR (GenAmp2400;Perkin-Elmer, Welleslay, Mass.) with [γ-³² P] dCTP and [γ-³² P] dATP(New England Nuclear/Perkin-Elmer, Welleslay, Mass.). Kodak film wasexposed to the hybridized membrane at −80° C. for 48 hrs and wasdeveloped using the M7B Kodak processor (Kodak, Rochester, N.Y.). Toevaluate the relative levels of total RNA present in each lane themembrane was stripped and hybridized with a radiolabeled probe specificfor the 28S ribosomal RNA (Baerwald et al., 1998).

Quantitative (Q-PCR, or real-time PCR) was performed by first reversetranscribing 1 μg of DNAaseI-treated (Invitrogen) total RNA usingoligo(dT)₁₂₋₁₈ and SuperScript II reverse transcriptase (InvitrogenRT-PCR kit). Q-PCR was performed using 20 ng of the cDNA in a reactioncontaining iQSupermix and the following primers and probes forFlag-SOCS1 and IFN-γ. Flag-SOCS1 sense primer, 5′-GATGACAAGACGCGCCAGATG-3′, Flag-SOCS1 anti-sense primer, 5′-GAGGACGAGGAGGGCTCTGA-3′, andFlag-SOCS1 probe, 5′-56FAM-CGCACCCAGCTGGC AGCCGACATT-3BHQ-1/-3′; IFN-γsense primer, 5′-GATATCTCGAGGAACTGGCAAAA-3′, IFN-γ anti-sense primer5′-CTACAAAGAGTCTGAGGTAGAAAGAGATAAT-3′, and IFN-γ probe5′-FAM-TGGTGACATGAAAATCCTGCAGAGCCA-BHQ 1-3′; GAPDH sense primer5′-CTCAACTACATGGTCTACATGTTCCA-3′; GAPDH anti-sense primer5′-CCATTCTCGGCCTTGACTGT-3′, and GAPDH probe,5′-5TxRd-XN/TGACTCCACTCACGGCAAATTCAACG-3BHQ-2-3′ (Integrated DNATechnologies, Inc.). The reactions were performed using a BioRad1-cycler Real-Time PCR unit, under the following conditions: 1 cycle at95° C. for 3 min, 40 cycles at 95° C. for 30 s and 60° C. for 30 s(Bio-Rad Laboratories). The mRNA levels of Flag-SOCS1 and IFN-γ werenormalized to the expression levels of GAPDH based on threshold cycles(Flag-SOCS1/GAPDH and IFN-γ/GAPDH ratios) (Lin et al., 2005).

f) Western Blot Analyses and Immunoprecipitation Methods

Total lysates from brain and spleen of several PLP/SOCS1 mice andwild-type mice were obtained by tissue homogenization in RIPA buffer(Santa Cruz Biotechnology, Santa Cruz, Calif.). After incubation on icefor 15 min, lysates were centrifuged at 14,000 rpm for 30 min and thesupernatants collected. Protein samples (50 μg) were electrophoresed on15% SDS-polyacrylamide gels, transferred to PVDF membranes (Trans-blotSD apparatus, Bio-Rad Laboratories), incubated overnight with mouseanti-Flag antibody (M2, diluted to 1:1000) (Sigma-Aldrich, St. Louis,Mo.), and detected with ECL Western blot detection reagents (AmershamBiosciences, Piscataway, N.J.). Flag protein (Sigma-Aldrich), a polymerof the Flag oligopeptide, was used as a positive control for thereaction.

Immunoprecipitation was performed with an immunoprecipitation kit (RocheMolecular Biochemicals, Indianapolis, Ind.) by incubating the proteinextracts from the brain and spleen of PLP/SOCS1 and wild-type mice withanti-Flag antibody (M2) for 4 hrs at 4° C., followed by overnightincubation with protein A/C agarose at 4° C. The immune complexes werecollected by centrifugation at 14,000 rpm for 20S and the protein wasseparated from protein A/C agarose with kit-supplied reagents. Westernblot of the immunoprecipitated protein was performed as described above.

g) Immunohistochemistry

Animals were anesthetized with 0.01 ml/g of 2.5% Avertin (Sigma-Aldrich)administered intraperitoneally and perfused with saline followed by 2%paraformaldehyde for 10 min. Brains were removed, postfixed for 1 hrwith 2% paraformaldehyde, cryopreserved with 30% sucrose for 48 h,prepared as frozen blocks (OCT compound, Sacura, Torrance, Calif.), andsectioned at a thickness of 7 μm at −20° C. (Leica C M 1800 cryostat,Leica Microsystems). Prior to immunostaining, the sections were treatedwith 0.1% Triton X-100 (Sigma-Aldrich) for 10 min and incubated with 10%bovine serum albumin (Sigma-Aldrich) or goat serum (Invitrogen) for 30min. Indirect immunostaining was performed by sequential incubation withprimary antibodies (for 2 h at room temperature or overnight at 4° C.)and FITC-conjugated or Cy3-congugated secondary antibodies (for 30 min).All of the following primary and secondary antibodies used in the studywere commercially available: mouse and rabbit anti-Flag antibody(dilution, 1:100; Sigma-Aldrich), mouse anti-CC1 antibody (dilution,1:20; Oncogene), mouse MHC class I antibody (dilution, 1:100; ChemiconInternational, Temecula, Calif.), mouse anti-PLP, proteolipid protein,antibody (dilution, 1:100; Chemicon International), mouse and rabbitanti-SOCS1 antibody (dilution, 1:100; Santa Cruz Biotechnology, SantaCruz, Calif.), rabbit anti-Stat1 antibody (dilution, 1:100; Santa CruzBiotecnology), anti-mouse or anti-rabbit FITC-conjugated secondaryantibody (dilution, 1:100; Jackson Immunoresearch, Bar Harbor, Me.), andanti-mouse or anti-rabbit Cy3-congugated antibody (dilution, 1:500;Jackson Immunoresearch). The immunostained sections were mounted usingVectorshield mounting medium containing DAPI nuclear stain (VectorLaboratories, Burlingame, Calif.) and examined using a fluorescentmicroscope (Axoplan; Carl Zeiss Microimaging).

Oligodendrocyte cell density was assessed digitally using Axiovisionsoftware, at postnatal day 21, as previously described (Lin et al.,2005). The brains were sectioned sagittally through the corpus callosumdividing the brain in two symmetrical halves. Ten frozen sections fromeach half were prepared at 7 μm thickness, and numbered in the sequenceof their preparation. The brains of three animals per study group wereprepared in this fashion. Following the CC1 immunostaining thecorresponding area of corpus callosum of each section was digitallyselected and the corresponding total area obtained. CC1 cell countingwas performed manually within the selected areas of each section, andthe number of CC1 positive cells per square area (mm²) calculated. Theresults were presented as mean±SD of CC1 (+) cells/mm² with n=3 animalsper study group.

h) Electron Microscopy

Mice selected for electron microscopy studies were perfused with 4%paraformaladehyde and 2.5% glutaraldehyde. Brains were harvested, andwhite matter structures were sectioned using a stereotype microscope(Wild M3C; Wild A G, Heebrugg, Switzerland). The tissue was furtherpostfixed in osmium tetroxide and embedded in freshly prepared Epoxyresin (Epon-812; Electron Microscope Sciences, Fort Washington, Pa.) for48 hrs at 60° C. The resin blocks were sectioned at 90 nm using LeicaUltracut ultramicrotome (Leica Microsystems) and stained with 5% uracylacetate and 2.5% lead citrate. Utrastructure of the tissue samples wasexamined using the Tecnai-F30 transmission electron microscope (FEICompany, Hillsboro, Oreg.).

Myelination patterns of the examined animals were assessed at postnatalday 21 by calculating the percent unmyelinated axons and ratio of theaxon/fiber diameters (G ratio) with Image J software (NationalInstitutes of Health, Bethesda, Md.) as previously described (Lin atal., 2005). The brains were sectioned sagittally through the corpuscallosum dividing the brain in two symmetrical halves. Approximately 2mm³ samples from the genu and the splenum of both halves of corpuscallosum were obtained using a Wild M3C stereotype microscope. Theorientation of the specimen in the resin blocks yielding axonalcross-sections (well seen myelin rings) was chosen, and established bytoluedine blue staining of a few sample sections. The resin blocks withthe chosen orientation were processed for electron microscopeexamination. Randomly selected areas were examined and tenrepresentative pictures from both genu and splenum corpus callosum wereobtained at 12000× magnification. The number of unmyelinated axons wasassessed by manual counting of axons that lacked myelin and wereencircled solely by their own plasma membrane. All unmyelinated axonspresent in the representative images were counted, and their percentagecalculated by examining a total of five hundred axons per tissue sample.The G ratio (axonal diameter/fiber diameter ratio) of myelinated axonswas assessed by digitally selecting the area encircled by the inner andouter surfaces of the myelin sheath, obtaining the axonal (inner) andthe fiber (outer) diameters, and dividing their corresponding values(axonal diameter/fiber diameter ratio). The brains of three animals pergroup were examined, and the G ratios of a total of 150 nerve fibersfrom both genu and splenum were examined. The results were presented asmean±SD of G ratio and percent unmyelinataed axons with n=3 animals perstudy group.

i) Mixed Primary Oligodendrocytes Cultures and STAT1 Translocation Assay

Mixed primary oligodendrocyte cultures were prepared as previouslydescribed (Baerwald et al., 2000). Briefly, brain tissue was harvestedfrom 2-3-day-old newborn pups of PLP/SOCS1 and C57B1/6J matings. Becausethe litters contained transgenic and wild-type pups, the brain of eachanimal was processed individually, cultured separately, and latergenotype matched. Each brain was digested separately using 0.25% trypsinand 10 μg/ml of DNAaseI (Invitrogen) in Dulbecco's modified Eagle'smedium (DMEM) for 20 min at 37° C., and cells were cultured on separatepoly-D-lysine-coated 75-mm² flasks (Sigma-Aldrich). The cultures weremaintained with 10% fetal bovine serum DMEM at 37° C. with 5% CO₂ for 12days, and then switched to a defined medium containing 5 μl/ml ofinsulin, 50 μg/ml of transferrin, 30 nM of selenium, 10 nM of biotin, 10nM of progesterone, 15 nM of T3, 0.1% bovine serum albumin, and 1%ampicillin-streptomycin (Sigma-Aldrich). On the fifth day ofdifferentiation, the cultures were treated with 100 U/mL of IFN-γ(Calbiochem, San Diego, Calif.) for 30 min. Dual immunostaining foranti-PLP and anti-Stat1 antibodies, and DAPI nuclear staining wereperformed as described above. The Stat1 nuclear translocation assay wasperformed in six separate culture preparations. One hundred PLP positivecells were manually counted in both wild-type and PLP/SOCS1 cultures.The results were presented as mean±SD percent cells positive for Stat1nuclear translocation.

j) Statistical Analysis

All data were generated from three independent experiments. Means,standard deviations, and p-values were calculated using Average, Stdev,and Anova in Microsoft Excel (Microsoft, Redmond, Wash.). Astatistically significant difference was defined as a p-value of <0.05.

2. Characterization of the PLP/SOCS1 Transgenic Mouse Line

The PLP/SOCS1 transgenic mice, which were generated as described inExample 25, were designed to express Flag epitope-tagged SOCS1 inmyelinating cells (FIG. 30A). These mice exhibit no phenotypicabnormalities, breed and produce transgenic progeny in a Mendelianfashion, and live a normal life span. Histological evaluation, includingelectron microscopy, performed at different time points up to 1 year ofage revealed no significant differences in the myelination patterns orthe number, density, or morphology of oligodendrocytes (see below)between transgenic and wild-type littermates.

Expression of the PLP/SOCS1 transgene was characterizedc at postnatalday 21 using several methods Northern blot analysis with a SOCS1 cDNAhybridization probe revealed a band of increased intensity in RNAsamples from the brains of transgenic mice relative to control brainsamples but not from other tissues (FIG. 30B). Real-time PCR analysiswith transgene-specific primers revealed the highest concentrations oftransgene-derived SOCS1 mRNA in brain, spinal cord, and sciatic nerve,with significantly lower levels in other organs including heart, thymus,spleen, and liver (FIG. 30C). Transgene expression appeared to be stableup to 12 months of age (data not shown).

Western blot analysis, using an antibody to the Flag tag, revealed a19-kD band corresponding to the expected size of SOCS1 in the PLP/SOCS1brain lysates, but not in wild-type brain lysates or PLP/SOCS1 spleenlysates (FIG. 30D). To further confirm Flag-SOCS1 protein expression, weperformed immunoprecipitation with the anti-Flag antibody, which againdetected a 19-kD positive band in the PLP/SOCS1 brainimmunoprecipitates, but not in the wild-type brain or PLP/SOCS1 spleenimmunoprecipitates (FIG. 30E).

Indirect immunostaining of wild-type and PLP/SOCS1 brains with bothanti-SOCS1 and anti-Flag antibodies also demonstrated expression of thetransgene (FIG. 30F-I). We detected both anti-Flag and anti-SOCS1immunopositivity only in PLP/SOCS1 brains.

To localize the expression of Flag-SOCS1 in the CNS, we performed dualimmunostaining of wild-type and PLP/SOCS1 brain tissue with theanti-Flag antibody and either anti-PLP antibody, a marker for myelin, oranti-CC1 antibody, a marker for the oligodendrocyte cell body. A strongcolocalization between anti-PLP and anti-Flag antibodies, as well asbetween anti-CC1 and anti-Flag antibodies (data not shown) was found,suggesting that Flag-SOCS1 was localized to the white matter andoligodendrocytes (FIG. 31). Non-colocalizing immunopositivity foranti-Flag, anti-PLP or anti-CC1 antibodies was not detected.

The expression of Flag-SOCS1 in primary mixed oligodendrocyte culturesestablished from transgenic animals by dual immunostaining with anti-PLPand anti-Flag antibodies was also detected (FIG. 32). Expression ofFlag-SOCS1 was detected only in cultures from PLP/SOCS1 animals and onlyin cells expressing PLP. Virtually all PLP-positive cells were alsopositive for Flag-SOCS1. The colocalization between anti-Flag andanti-PLP immunoreactivity appeared to involve both the cell body andcell processes (FIG. 32F).

3. Oligodendrocytes from PLP/SOCS1 Mice Exhibit DiminishedResponsiveness to INF-γ

The responsiveness of PLP/SOCS1 oligodendrocytes to IFN-γ was studied inprimary mixed glial cultures. To determine whether expression oftransgenic SOCS1 would interfere with the nuclear translocation of theIFN-γ-signaling molecule Stat1, the cell cultures were treated with 100U/mL of IFN-γ for 30 min and immunostained using anti-PLP and anti-Stat1antibodies along with the DAPI nuclear stain (FIG. 33). Examination ofStat1 subcellular localization in wild-type cultures revealed strongcolocalization with DAPI-positive nuclei in all cells, includingPLP-positive oligodendrocytes. In contrast, subcellular localization ofStat1in PLP/SOCS1 cultures revealed a differential response to IFN-γ. Intransgenic PLP-positive oligodendrocytes, Stat1 remained in thecytoplasm and did not colocalize with cell nuclei in the presence ofIFN-γ, (FIG. 33E-H). This was in contrast to the response of thesurrounding PLP-negative cells, which, similarly to wild-type cells,responded to IFN-γ with Stat1 nuclear translocation. Virtually all PLPpositive oligodendrocytes (96±3 cells) in the wild-type culturesresponded to IFN-γ stimulation with Stat1 nuclear translocation. Incontrast, Stat1 nuclear translocation was detected only in occasionalPLP positive oligodendrocytes (6±2 cells) following IFN-γ stimulation(p<0.05).

We next characterized the responsiveness of PLP/SOCS1 oligodendrocytesto IFN-γ in vivo using the induction of major histocompatibilty complexclass I (MHC class I) molecule expression as an indication of IFN-γsensitivity. The capacity of SOCS1 to inhibit IFN-γ mediated inductionof MHC class I molecule was examined in a double-transgenic system.MBP/IFN-γ (line 172) single-transgenic mice, which express a low levelof IFN-γ in the CNS (Gao et al., 2000), were mated to PLP/SOCS1 mice,and the single and double transgenic progeny were examined fordifferences in MHC class I molecule expression (FIG. 34). MHC class Imolecule expression was neither detectable in control wild-type mice norPLP/SOSC1 mice (FIG. 34A-D). Consistent with previous reports, MBP/IFN-γmice exhibited upregulated expression of the MHC class I molecule, withdiffuse protein localization along the myelin sheath (FIG. 34E, F)(Corbin et al., 1996). The double-transgenic mice (MBP/IFN-γ×PLP/SOCS1),however, displayed a differential pattern of MHC class I moleculeexpression (FIG. 34G-J). As shown in FIG. 34, oligodendrocytes andmyelin positive for Flag-tagged SOCS1 did not express detectable levelsof MHC class I molecule, whereas, cells negative for transgeneexpression, and in close proximity to the SOCS1-positive cells,demonstrated strong immunoreactivity (FIG. 34G-J). Similar differentialupregulation of MHC class I molecule expression was observed followingthe direct administration of IFN-γ in the brain of PLP/SOCS1 mice (datanot shown). Together, these data indicate that oligodendrocytes fromPLP/SOCS1 mice display diminished responsiveness to IFN-γ.

4. PLP/SOCS1 Mice are Protected Against Injurious Effects of INF-γDuring Development

Transgenic expression of IFN-γ in the CNS of developing mice results inoligodendrocyte loss and hypomyelination (Corbin et al., 1996; Lin et al2005). To determine whether SOCS1 expression could protect developingoligodendrocytes from the injurious effects of IFN-γ, we crossedPLP/SOCS1 mice to three transgenic mouse lines overexpressing IFN-γ inthe CNS at different levels: MBP/IFN-γ (line 172), GFAP/tTA×TRE/IFN-γ(lines 184/110) and GFAP/tTA×TRE/IFN-γ (lines 184/67) and the followingthree mating systems were established (detailed in the Material andMethods): MBP/IFN-γ×PLP/SOCS1 (172×PLP/SOCS1, a double transgenicsystem) and GFAP/tTA×TRE/IN-γ×PLP/SOCS1 (184/110×PLP/SOCS1 and184/67×PLP/SOCS1, two triple-transgenic systems). The litter (F1generation) of each mating system was divided into four study groupsdepending on their genotype: wild-type/single transgenic controls, miceexpressing SOCS1 only, mice expressing IFN-γ only, and mice expressingboth IFN-γ and SOCS1. A total of 40 animals per mating system (10animals per each study group) were collected and examined clinically andhistologically at postnatal day 21.

Phenotypic comparisons of littermates were performed from birth topostnatal day 21 and evaluation consisted of behavioral observation andchallenged ladder walking to elicit tremor. MBP/IFN-γ (line 172) miceexpress low levels of IFN-γ in the CNS and displayed no behavioralabnormalities, in accordance with findings reported elsewhere (Corbin etal., 1996). Mice from the F1 generation of the MBP/IFN-γ×PLP/SOCS1(172×PLP/SOCS1) mating system similarly displayed no behavioralabnormalities regardless of genotype. Double-transgenicGFAP/tTA×TRE/IFN-γ (lines 184/110) and GFAP/tTA×TRE/IFN-γ(lines 184/67)mice display mild to moderate tremor that appears during the secondpostnatal week and peaks by 21 days of age (Lin et al., 2004; 2005).Mice from the F1 generation of the GFAP/tTA×TRE/IFN-γ×PLP/SOCS1 matingsystems exhibited tremor, the incidence of which was dependent ongenotype (Table 2). TABLE 2 Incidence of tremor among the transgeniclittermates Wild-type/controls SOCS1 IFN-γ IFN-γ × SOCS1 172 × PLP/SOCS10% 0%  0% 0% 184/110 × PLP/SOCS1 0% 0%  80% (8/10) 10% (1/10) 184/67 ×PLP/SOCS1 0% 0% 100% (10/10) 30% (3/10)

Littermates from three transgenic mating systems, 172×PLP/SOCS1,184/110×PLP/SOCS/and 184/67×PLP/SOCS1 were stratified according to theirgenotype into four groups: Wild-type/control mice, mice expressing SOCS1only, mice expressing IFN-γ only, and mice expressing both IFN-γ andSOCS1. Ten mice per group were clinically followed during the firstthree postnatal weeks and the incidence of tremor recorded.

The phenotypes of wild-type mice and single-transgenic control mice(GFAP/tTA [184], TRE/IFN-γ [67 and 110]), and PLP/SOCS1 mice wereclinically normal. The tremoring phenotype, which varied in severity,was identified in almost all double-transgenic GFAP/tTA×TRE/IFN-γ miceoverexpressing IFN-γ. 80% (8/10) of 184/110 mice and 100% (10/10) of184/67 mice. Triple-transgenic GFAP/tTA×TRE/IFN-γ×PLP/SOCS1 miceoverexpressing both IFN-γ and SOCS1 appeared to be protected, becauseonly 10% (1/10) of 184/110×PLP/SOCS1 mice, and 30% (3/10) of184/67×PLP/SOCS1 mice developed tremor (Table 2).

The clinically examined littermates of all three transgenic matingsystems were further evaluated for histological abnormalities atpostnatal day 21. Three animals per study group from each mating systemwere examined histologically for oligodendrocyte and myelinabnormalities. Brain tissue was obtained from each animal at the time ofsacrifice (prior to the fixating perfusion) and total RNA isolated. Thepossibility that SOCS1 expression affected the expression of the IFN-γtransgene was examined in all three transgenic mating systems usingquantitative PCR (Q-PCR) (FIG. 35A). IFN-γ expression was detected inMBP/IFN-γ single-transgenic and MBP/IFN-γ×PLP/SOCS1 double-transgeniclittermates of the 172×PLP/SOCS1 transgenic system, inGFAP/tTA×TRE/IFN-γ double-transgenic and GFAP/tTA×TRE/IFN-γ×PLP/SOCS1triple-transgenic littermates of the 184/110×PLP/SOCS transgenic system,and in GFAP/tTA×TRE/IFN-γ double-transgenic andGFAP/tTA×TRE/IFN-γ×PLP/SOCS1 triple-transgenic littermates of the184/67×PLP/SOC1 transgenic system. Two characteristics of IFN-γexpression were observed. First, the three mating systems differed intheir expression levels; MBP/IFN-γ×PLP/SOCS1 (172×PLP/SOCS1) expressedthe lowest, and GFAP/tTA×TRE/IFN-γ×PLP/SOCS1 (184/67×PLP/SOC1) expressedthe highest IFN-γ levels. Secondly, the littermates of the same matingsystem, expressing IFN-γ only or both IFN-γ and SOCS1, did not differ intheir expression levels. No detectible levels of IFN-γ were found in thewild-type, the GFAP/tTA and TRE/IFN-γ single-transgenic, and thePLP/SOCS1 littermates (FIG. 35A).

The cerebra of three animals per study group from all transgenic matingsystems were processed for immunohistochemical analysis with the CC1antibody to determine oligodendrocyte density (FIG. 35B and FIG. 33).The MBP/IFN-γ mice expressed the lowest levels of IFN-γ in the CNScompared to GFAP/tTA×TRE/IFN-γ mice, and displayed no significantabnormalities in CC1-positive cell density, in accordance with resultsreported previously (Gao et al., 2000). We found no statisticallysignificant difference in the oligodendrocyte density among mice fromthe F1 generation of the MBP/IFN-γ×PLP/SOCS1 (172×PLP/SOCS1) matingsystem. In the triple-transgenic systems (GFAP/tTA×TRE/IFN-γ×PLP/SOCS1),we found that the oligodendrocyte density in mice from the F1 generationdiffered depending on genotype (FIG. 35B and FIG. 36). Wild-type miceand the single-transgenic mice (PLP/SOCS1, GFAP/tTA, and TRE/IFN-γ hadcomparable oligodendrocyte densities. We found severe dose-dependentoligodendocyte loss in the GFAP/tTA×TRE/IFN-γ mice overexpressing IFN-γ,compared with the wild-type and single-transgenic littermates:approximately 20% of oligodendrocytes were lost in 184/110 mice (from146±6 CC1 (+) cells/mm² in the wild-type mice to 115±8 CC1 (+) cells/mm²in the IFN-γ mice), and approximately 40% were lost in 184/67 mice (from144±5 CC1 (+) cells/mm² in the wild-type mice to 79±9 CC1 (+) cells/mm²in the IFN-γ overexpressing mice). In contrast,GFAP/tTA×TRE/IFN-γ×PLP/SOCS1 triple-transgenic littermates thatoverexpressed both IFN-γ and SOCS1 lost statistically significantlyfewer oligodendrocytes compared with mice overexpressing IFN-γ only:approximately 8% of oligodendrocytes were lost in 184/110×PLP/SOCS1 mice(from 141±6 CC1 (+) cells/mm² in the PLP/SOCS1 mice to 129±6 CC1 (+)cells/mm² in the IFN-γ and SOCS1 overexpressing mice), and approximately15% were lost in 184/67×PLP/SOCS1 mice (from 142±5 CC1 (+) cells/mm² inthe PLP/SOCS1 mice to 112±7 CC1 (+) cells/mm² in the IFN-γ and SOCS1overexpressing mice) (FIG. 35B and FIG. 36).

Myelination patterns in the harvested cerebra were further evaluatedwith electron microscopy, and the level of myelination was assessed bycalculating the G ratio (axon diameter/fiber diameter ratio) and thepercentage of unmyelinating axons (FIGS. 35C and D, and FIG. 37). Wefound no statistically significant difference in G ratios amongwild-type, the single-transgenic, and double transgenic littermates fromthe MBP/IFN-γ×PLP/SOCS1 (172×PLP/SOCS1) mating system. In thetriple-transgenic systems (GFAP/tTA×TRE/IFN-γ×PLP/SOCS1), significantdifferences in G ratios were found among the F1 generation mice,depending on genotype (FIG. 35C and FIG. 36). G ratios among thewild-type and the GFAP/tTA, TRE/IFN-γ and PLP/SOCS1 single-transgeniclittermates were similar. IFN-γ-overexpressing GFAP/tTA×TRE/IFN-γlittermates displayed significantly increased G ratios indicatinghypomyelination (defined as a G ratio >0.8): 0.89±0.02 for 184/110 miceand 0.95±0.04 for the 184/67 mice (FIG. 35C). In contrast, theirtriple-transgenic (GFAP/tTA×TRE/IFN-γ×PLP/SOCS1) littermatesoverexpressing both IFN-γ and SOCS1 had significantly lower G ratios:0.75±0.03 (within the normal range) for 184/110×PLP/SOCS1 mice, and0.82±0.08 for 184/67×PLP/SOCS1 mice (FIG. 35C and FIG. 37).

The myelin abnormalities were further quantified by determining thepercentage of unmyelinated axons in the various transgenic genotypes(FIG. 35D). We found no significant difference in the percentage ofunmyelinated axons (less than 9%) among the F1 generation littermates ofthe MBP/IFN-γ×PLP/SOCS1 (172×PLP/SOCS1) double-transgenic system,regardless of genotype (FIG. 35D). In the triple-transgenicGFAP/tTA×TRE/IFN-γ×PLP/SOCS1 systems, however, the distribution ofunmyelinated axons differed depending on genotype (FIG. 35D). There wasa significantly increased percentage of unmyelinated axons in IFN-γoverexpressing GFAP/tTA×TRE/IFN-γ littermates compared to wild-type andsingle-transgenic control mice: 41%±6 in 184/110 mice and 57±7 in 184/67mice. In contrast, triple-transgenic GFAP/tTA×TRE/IFN-γ×PLP/SOCS1overexpressing both IFN-γ and SOCS1 had a significantly lower percentageof unmyelinated axons compared with mice overexpressing IFN-γ alone:only 13%/±3 for 184/110×PLP/SOCS1 mice and 170%±4.5 for 184/67×PLP/SOCS1mice (FIG. 35D). Together, these data demonstrate that oligodendroglialexpression of SOCS1 protects mice from the clinical and morphologicalconsequences of IFN-γ expression in the CNS during development.

The presence of the T-cell-derived cytokine IFN-γ within the CNS isbelieved to play a critical role in the pathogenesis of immune-mediateddemyelinating disorders (Panitch et al, 1987; Galbinski et al., 1999;Tran et al., 2000; Vartanian et al., 1996; Horwitz et al. 1997;Steinman, 2001). Nevertheless, the cellular target of the cytokine'seffect remains unresolved. In this report we describe the generation oftransgenic mice in which the oligodendrocytes display a significantlyreduced capacity to respond to IFN-γ. These mice are protected from theinjurious effect of ectopic expression of IFN-γ within the CNS,suggesting that a direct deleterious effect of IFN-γ on oligodendrocytescontributes to immune-mediated disease pathogenesis. As discussed below,the work described has significant clinical implications.

Transgenic animals that ectopically express IFN-γ in the CNS duringpostnatal development are hypomyelinated and contain reduced numbers ofoligodendrocytes (Corbin et al., 1996; LeFerla et al., 2000; Lin et al.,2005). Moreover, the induction of IFN-γ expression in the CNS followingdemyelinating insults results in reduced oligodendroglial repopulationof the demyelinating lesions and impaired remyelination (Lin et al., inpress). Previously reported data from our laboratory suggests that thepresence of IFN-γ in the CNS activates an ER stress response inoligodendrocytes, which contributes to the observed pathological effects(Lin et al, 2005; in press). It is unclear, however, if the injuriouseffect of IFN-γ on oligdodendrocytes is a result of a direct action orwhether it represents a secondary effect, possibly through microglialactivation.

IFN-γ has also been shown to have harmful effects on oligodendrocytesand their progenitors in vitro. There is considerable evidence tosuggest that at least part of the injurious effect of this cytokine ismediated through the activation of microglial cells. IFN-γ-treatedmicroglia release cytotoxic agents, including nitric oxide and tumornecrosis factor alpha, which are known to be damaging tooligodendrocytes (Merrill et al., 1991, 1993, Loughlin et al., 1997).Studies using purified oligodendrocytes in vitro, however, suggest thatthe cytokine may have a direct, harmful effect on oligodendrocytes(Torres et al., 1995; Agresti et al., 1996; Baerwald et al., 1998;Andrews et al., 1998; Lin et al., 2005). IFN-γ has been shown to inhibitcell cycle exit of oligodendroglial progenitor cells, which maypredispose these cells to apoptotic death (Chew et al., 2005).Additionally, IFN-γ has been shown to be a very powerfulapoptosis-inducing agent for developing oligodendrocytes (Baerwald etal., 1998, 2000; Lin et al., 2005). Oligodendrocytes that have beenallowed to differentiate in vitro to the point of expressing matureoligodendroglial markers are less sensitive to the presence of thecytokine, although they do eventually succumb to necrosis (Baerwald etal., 1998).

In an effort to differentiate direct versus indirect effects of IFN-γ onoligodendrocytes in vivo, we generated transgenic mice that exhibiteddiminished oligodendrocyte-specific responsiveness to IFN-γ. Transgenicmice expressing either the dominant-negative form of IFN-γ receptorsubunit 1 (IFNGR1) or the suppressor of cytokine signaling 1 (SOCS1)have been previously described (Flodstrom et al., 2001; Gonzales at al.,2005, Hindinger et al., 2005). Overexpression of the dominant-negativeform of IFNGR1 resulted in accelerated degradation of wild-type IFNGR1and elimination of the IFN-γ cellular binding sites (Dighe et al.,1994). SOCS1 is an intracellular protein that blocks IFN-γ, mediatedStat1 activation (i.e., phosphorylation) by Jak kinases (Starr et al.,1997; Song and Shuai 1998; Sakamoto et al., 2000; Yasukawa et al., 2000;Kubo et al., 2003; Stark et al., 1998; Levy and Damell, 2002). Mousemutants with a targeted null mutation in the SOCS1 gene exhibit abnormalhypersensitivity to IFN-γ and die of multi-organ failure in the presenceof normal levels of the cytokine (Starr et al., 1998; Alexander et al.,1999; Bullen et al., 2001). Moreover, forced expression of SOCS1 hasbeen shown to result in a state of IFN-γ unresponsiveness in a varietyof cell types (Tunley et al., 2001, 2002; Chong et al., 2001, Federiciet al., 2002; Flodstom et al., 2001).

The PLP/SOCS1 mice exhibited no phenotypic or histologicalabnormalities, indicating that Stat1 activation is not required fornormal oligodendrocyte development, even though its involvement ingrowth factor signaling has been suggested in vitro (Dell'Albani et al.,1998). Our finding is supported by the phenotypic characteristics ofStat1 (−/−) knockout mice, which displayed no oligodendrocyte or myelinabnormalities but do have significantly impaired IFN-γ cellularresponses (Meraz et al., 1996). Thus, it appears that Stat1 activationplays a differential role in oligodendorocyte injury and development.

Functional examination of the PLP/SOCS1 mice further demonstrated adiminished oligodendrocyte-specific responsiveness to IFN-γ, includinginhibition of Stat1 activation (i.e. phosphorylation) and nucleartranslocation, and MHC class I molecule upregulation. When crossed withtransgenic mice overexpressing IFN-γ in the CNS, PLP/SOCS1 mice wereprotected from the deleterious clinical and histological effects ofIFN-γ. IFN-γ-overexpressing transgenic mice that also carried thePLP/SOCS1 transgene displayed significant oligodendrocyte and myelinpreservation and lower prevalence of tremor compared to IFN-γ expressingmice without the PLP/SOCS1 transgene. Results of our study therebyindicate that IFN-γ exerts a direct injurious effect on developingoligodendrocytes.

Overexpression of SOCS1 provided cellular protection tooligodendrocytes, suggesting that inhibition of IFN-γ signaling resultsin reduced cellular effects. Wild-type oligodendrocytes, as reported byothers and also observed by us, express nearly undetectable amounts ofSOCS1 under normal, and even inflammatory conditions, and have muchlower SOCS1 expression compared to the surrounding glial andinflammatory cells (Polizzotto et al., 2000; Wang and Campbell 2002;Maier et al., 2002). Such low constitutive expression may limit theoligodendrocyte capacity for effective downregulation of IFN-γ/Jak/Stat1signaling, resulting in enhanced IFN-γ cellular effects. The rescuingeffect of SOCS1 overexpression in oligodendrocytes that was observed inour experimental system supports this possibility.

Circumstantial and experimental evidence suggests that IFN-γ plays adeleterious role in the immune-mediated demyelinating disorder multiplesclerosis (Popko et al., 1997, Steinman 2001). IFN-γ is found indemyelinated lesions and its levels in cerebrospinal fluid correlatewith disease severity (Vartanian et al., 1996; Calabresi et al., 1998;Becher et al., 1999; Moldovan et al., 2003). Administration of IFN-γ toMS patients exacerbated the disease, and neutralizing antibodies toIFN-γ have been shown to delay disease progression (Panitch et al, 1987;Skurkovich et al., 2001). Diminishing the local effect of IFN-γ, perhapsthrough the targeted expression of SOCS1 by oligodendrocytes, can betherapeutically beneficial. Remyelinating oligodendrocytes after ademyelinating insult are more sensitive to the presence of IFN-γ (Lin etal., in press); therefore, such protection might be particularly usefulfor the promotion of remyelination.

Stem cell therapy is rapidly gaining interest as a potential therapeuticapproach to demyelinating disorders such as multiple sclerosis andadrenoleukodystrophy (review in Keirstead 2005). Stem cells engineeredto be resistant to the harmful cytokines present in the extracellularmilieu of the breached CNS is expected to stand a better chance ofsurviving and accomplishing remyelination. It is, therefore, oftherapeutic interest to identify signaling pathways that playdifferential roles in oligodendrocyte injury and development. Ourresults describing inhibition of IFN-γmediated oligodendrocyte injurywithout induction of any observable oligodendrocyte or myelinabnormalities provide support for such an approach.

In summary, we have demonstrated that the forced expression of SOCS1 inoligodendrocytes of transgenic mice protects against the deleteriouseffects of IFN-γ on oligodendrocytes and the process of myelination. Ourresults strongly indicate that the deleterious effect of IFN-γ onmyelinating oligodendrocytes is due, at least in part, to a directadverse effect on these cells. Moreover, our work suggests that forcedexpression of SOCS1 in oligodendrocytes can provide protection againstthe harsh environment in immune-mediated demyelinating disorders.

REFERENCES

-   Agresti C, Bernardo A, Del Russo N, Marziali G, Battistini A, Aloisi    F; Levi G, Coccia E (1998) Synergistic stimulation of MHC class I    and IRF-1 gene expression by IFN-gamma and TNF-alpha in    oligodendrocytes. Eur J Neurosci 10:2975-2983.-   Agresti C, D'rso D, Levi G (1996) Reversible inhibitory effects of    interferon-gamma and tumor necrosis factor-alpha on oligodendroglial    lineage cell proliferation and differentiation in vitro. Eur J    Neurosci 8:1106-11016.-   Alexander W. Starr R, Fenner J, Scott C, Handman E, Spring N, Corbin    J, Cornish, A Darwishe R, Owczarek C, Kay T, Nicola N, Hertzog P,    Metcalf D, Hilton D (1999) Socs1 is a critical inhibitor of    interferon-gamma signaling and prevents the potentially fatal action    of this cytokine. Cell 98:598-608.-   Andrews T, Zhang P, Bhat N (1998) TNFalpha potentiates IFN    gamma-induced cell death in oligodendrocyte progenitors. J Neurosci    Res 54:574-583.-   Becher B, Giacomini P S, Pelletier D, McCrea E, Prat A, Antel    J (1999) Interferon-gamma secretion by peripheral blood T-cell    subsets in multiple sclerosis: correlation with disease phase and    interferon-beta therapy. Ann Neurol 45:247-250.-   Baerwald K, Popko B (1998) Developing and mature oligodendrocytes    respond differently to the immune cytokine interferon-gamma. J    Neurosci Res 52:230-239.-   Baerwald K, Corbin J, Popko B (2000) Major histocompatibility    complex heavy chain accumulation in the endoplasmic reticulum of    oligodendrocytes results in myelin abnormalities. J Neurosci Res    15:160-169.-   Billiau A (1996) Interferon-γ: biology and role in pathogenesis. Adv    Immunol 62:61-130.-   Bullen D, Darwich R, Metcalf D, Handman E, Alexander W (2001)    Neutralization of interferon-gamma in neonatal SOCS1−/− mice    prevents fatty degeneration of the liver but not subsequent    inflammatory disease. Immunol 2001, 104:92-98.-   Calabresi P, Tranquill L, McFarland H, Cowan E (1998) Cytokine gene    expression in cells derived from CSF of multiple sclerosis patients.    J Neuroimmunol 14:198-205.-   Chew L., King W., Kenedy A, Gallo V (2005) Interferon-gamma inhibits    cell cycle exit in differentiating oligodendrocyte progenitor cells.    Glia 52:127-143.-   Chong M, Thomas H, Kay T (2001) gamma-Interferon signaling in    pancreatic beta-cells is persistent but can be terminated by    overexpression of suppressor of cytokine signaling-1. Diabetes    50:2744-2751.-   Corbin J, Kelly D, Rath E, Baerwald K, Suzuki K, Popko B (1996)    Targeted CNS expression of interferon-gamma in transgenic mice leads    to hypomyelination, reactive gliosis, and abnormal cerebellar    development. Mol Cell Neurosci 7:354-370.-   Dell'Albani, Kahn M, Cole R, Condorelli D, Giuffrida-Stela A, Vellis    J (1998) Oligodendrocyte survival factors, PFGF-AA and CNTF,    activate Jak/STAT signaling pathways. J Neurosci Res 54:191-205.-   Dighe A, Richards E, Old L, Schreiber R (1994) Enhanced in vivo    growth and resistance to rejection of tumor cells expressing    dominant negative IFN gamma receptors. Immunity 1:447-456.-   Doerflinger N, Macklin W, Popko B (2003) Inducible site-specific    recombination in myelinating cells. Genesis 35:63-72.-   Einhauer A, Jungbauer A (2001) The flag peptide, a versatile fusion    tag for the purification of recombinant proteins. J Biochem Biophys    49:455-465.-   Federici M, Giustiziri M, Scarponi C, Girolomini G, Albanesi    C (2002) Impaired IFN-gamma-dependent inflammatory response in human    keratinocytes overexpressing the suppressor of cytokine signaling 1.    J Immunol 169:434-443.-   Flodstrom M, Maday A, Balakrisha D, Cleary M, Yoshimura A,    Starvetnick N (2001) Target cell defense prevents development of    diabetes after viral infection. Nat Immunol 3: 373-382.-   Fuss B, Mallon B, Phan T, Ohlemeyer C, Kirchoff F, Nishiyama A,    Macklin W (2000) Purification and analysis of in vivo-differentiated    oligodendrocytes expressing the green fluorescent protein. Dev Biol    218:259-274.-   Gao X, Gilling T, Ye P, D'Ercole J, Matsushima G, Popko B (2000)    Interferon-γ protects against cuprizone-induced demyelination. Mol    Cell Neurosci 16:338-349.-   Gao X, Kemper A, Popko B (1999) Advanced transgenic and    gene-targeting approachs. Neurochem Res 24:1183-1190.-   Glabinski A, Kranowski M, Han Y, Owens T, RansohoffR (1999)    Chemokine expression in GRO mice (lacking interferon-gamma) with    experimental autoimmune encephalomyelitis. J Neurovirol 51:95-101.-   Gonzales J, Bergmann C, Fuss B, Hinton D, Kangas C, Macklin W,    Stohlman S (2005) Expression of dominant negative IFN-γ receptor on    mouse oligodendrocytes. Glia 51:22-34.-   Hindinger C, Gonzalez J, Bergmann C, Fuss B, Hinton D, Atkinson R,    Macklin W, Stohlman S (2005) Astrocyte expression of a    dominant-negative interferon-gamma receptor. J Neurosci Res    82:20-31.-   Horwitz M, Evans C, McGavern D, Rodriguez M, Oldstone M (1997)    Primary demyelination in transgenic mice expressing    interferon-gamma. Nature Med 3:1037-1041.-   Keirstead H (2005) Stem cells for the treatment of myelin loss.    Trends Neurosci 28:677-683.-   Kubo M, Hanada T, Yoshimura A (2003) Suppressors of cytokine    signaling and immunity. Nature Immunol 4:1169-1176.-   LaFerla F, Sugarman M, Lane T, Leissring M (2000) Regional dysplasia    in transgenic mice with astrocyte-derived expression of    interferon-gamma. J Mol Neurosci 15:45-59.-   Levy D, Darnell J (2002) Stats: transcriptional control and    biological impact. Nature Rev Mol Cell Biol 651-662.-   Lin W, Kemper A, McCarthy K, Pytel P Wang J, Campbell I, Utset M,    Popko B (2004) Interferon-gamma induces medullobalstoma in the    developing cerebellum. J Neurosci 24:10074-10083.-   Lin W, Harding H, Ron D, Popko B (2005) Endoplasmic reticulum stress    modulates the response of myelinating oligodendrocytes to the immune    cytokine interferon-gamma. J Cell Biol 169:603-612.-   Lin W, Kemper A, Dupree J, Harding H, Ron D, Popko B.    Interferon-gamma inhibits central nervous system remyelination    through a process modulated by endoplasmic reticulum stress. Brain    (in press).-   Loughlin A, Copelman C, Hall A, Armer T, Young B, Landon D, Cuzner    M (1997) Myelination and remyelination of aggregate rat brain cell    cultures enriched with macrophages. J Neurosci Res 47:384-392.-   Maier J, Kincaid C, Pagenstecher A, Campbell 1 (2002) Regulation of    signal transducer and activator of transcription and suppressor of    cytokine-signaling gene expression in the brain of mice with    astrocyte-targeted production of interleukin-12 or experimental    autoimmune encephalomyelitis. Am J Pathol 160:271-288.-   Merrill J, Zimmerman R (1991) Natural and induced cytotoxicity of    oligodendrocytes by microglia is inhibitable by TGF beta. Glia    4:327-31.-   Merrill J, Ignarro L, Sherman M, Melinek J, Lane T (1993) Microglial    cytotoxicity of oligodendrocytes is mediated through nitric oxide. J    Immunol 151:2132-2141.-   Meraz M, White J, Sheehan K, Bach E, Roding S, Dighe A, Kaplan D,    Riley J, Greenlund A, Campbell D, Caver-Moore K, Dubois R, Clark R,    Aguet M, Schreiber R (1996) Targeted disruption of Stat1 gene in    mice reveals unexpected physiological specificity in the Jak/STAT    signaling pathway. Cell 84:431-442.-   Moldovan I R, Rudick R A, Cotleur A C, Born S E, Lee J C, Karafa M    T, Pelfrey C M (2003) Interferon gamma responses to myelin peptides    in multiple sclerosis correlate with a new clinical measure of    disease progression. J Neuroimmunol 141:132-140.-   Panitch N, Hirsch R, Haley A, Johnson K (1987) Exacerbations of    multiple sclerosis in patients treated with gamma interferon. Lancet    1:893-895.-   Polizzotto M, Bartlett P, Turnley A (2000) Expression of “suppressor    of cytokine signaling” (SOCS) genes in the developing and adult    mouse nervous system. J Compar Neurol 423:348-358.-   Popko B, Corbin J, Baerwald K, Dupree J, Garcia A (1997) The effects    of interferon-gamma on the central nervous system. Mol Neurobiol    14:19-35.-   Pouly S, Becher B, Blain M, Antel J (2000) Interferon-gamma    modulates human oligodendrocyte susceptibility to Fas-mediated    injury. J Neuropathol Exp Neurol 59:280-286.-   Sakamoto H, Kinjyo I, Yoshimura A (2000) The janus kinase inhibitor,    Jab/SOCS1, is an interferon-gamma inducible gene and determines    sensitivity to interferons. Leuk Lymphoma 38:49-58.-   Skurkovich S, Boiko A, Beliaeva I, Buglak I, Alekseeva T, Smirnova    T, Kulakova O, Tchechonin V, Gurova O, Deomina T, Favarova O,    Skurkovith B, Gusev E (2001) Randomized study of antibodies to    IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis.    Mult Scler 7:277-284.-   Song M, Shuai K (1998) The suppressor of cytokine signaling (SOCS1)    and SOCS3 but not SOCS2 proteins inhibit interferon-mediated    antiviral and antiproliferative activities. J Biol Chem    25:35056-35062.-   Steiman L (2001) Blockade of gamma interferon might be beneficial in    MS. Mult Scler 7:275-276.-   Stark G, Kerr I, Williams B, Silverman R, Schreiber R (1998) How    cells respond to interferons. Ann Rev Biochem 67:257-264.-   Starr R, Wilson T, Viney E, Murray L, Rayner J, Jenkins J, Brendan    J, Gonda T, Alexander W, Metcalf D, Nicola N, Hilton J (1997) A    family of cytokine inducible inhibitors of signaling. Nature    387:917-921.-   Starr R. Donald M, Elefanty A, Brysha, M, Wilson T, Nicola A, Hilton    D, Alexander W (1998) Liver degeneration and lymphoid deficiency in    mice lacking suppressor of cytokine signaling-1. PNAS USA    95:14395:14999.-   Torres C, Aranguez 1, Rubio N (1995) Expression of interferon-gamma    receptors on murine oligodendrocytes and its regulation by cytokines    and mitogens. Immunology 86:250-255.-   Tran E, Prince E, Owens T (2000) IFN-gamma shapes invasion of the    central nervous system via regulation of chemokines. J Immunol    164:2759-2768.-   Traugott U (2001) Evidence for immunopathogenesis. In: Handbook of    Multiple sclerosis (Cook S, ed) 3d edition, pp163-192, New York:    Marcel Deker.-   Tunley A, Starr R, Bartlett P (2002) Failure of sensory neurons to    express class I MHC is due to differential SOCS1 expression. J    Neuroimmunol 123:35-40.-   Tunley A, Starr R, Bartlett P (2001) SOCS1 regulates    interferon-gamma mediated sensory neuron survival. Neuroreport    16:3443-3445.-   Vartanian T, Li Y, Zhao M, Stefansson K (1995) Interferon-γ induced    oligodendrocyte cell death: implications for the pathogenesis of    multiple sclerosis. Mol Med 1:732-743.-   Wang J, Campbell 1 (2002) Cytokine signaling in the brain: putting a    SOCS in it? J Neurosci Res 67:423-427.-   Wight P, Duchala C, Readhead C, Macklin W (1993) A myelin    proteolipid protein-lacZ fusion protein is developmentally regulated    and targeted to the myelin membrane in transgenic mice. J Cell Biol    123:443-454.-   Yasukawa H; Sasaki A, Yoshimura A (2000) Negative regulation of    signaling pathways. Annu Rev Immunol 18:143-164.

1. A method of inhibiting neuronal demyelination in a subject comprisingadministering to said subject an amount of biologically active agenteffective to modulate stress level of endoplasmic reticulum (ER) in amyelinating cell.
 2. The method of claim 1, wherein said biologicallyactive agent is effective to reduce a sustained stress level ofendoplasmic reticulum (ER) in a myelinating cell.
 3. The method of claim1, wherein said biologically active agent is an interferon-gamma (INF-γ)antagonist with the proviso that said interferon-gamma (INF-γ)antagonist is not an anti-INF-γ antibody when applied after the onset ofneuronal demyelination.
 4. The method of claim 1, wherein saidbiologically active agent is an interferon-gamma (INF-γ) orinterferon-gamma (INF-γ) agonist administered prior to the onset ofneuronal demyelination to yield a prophylactic effect.
 5. The method ofclaim 2, wherein said reduction of a sustained stress level of ER ischaracterized by a decrease in the levels of proteins correlated withendoplasmic reticulum (ER) stress.
 6. The method of claim 5, whereinsaid proteins correlated with ER-stress are selected from the groupconsisting of phosphorylated pancreatic ER kinase gene (p-PERK),eukaryotic translation initiation factor 2 alpha (eIF-2α), eukaryotictranslation initiation factor beta (eIF-2α), inositol requiring 1(IRE1), activating transcription factor 6 (ARTF6), CAATTenhancer-binding protein homologous protein (CHOP),binding-immunoglobulin protein (BIP), caspase-12, growth and DNA damageprotein 34 (GADD34), CreP (a constitutive repressor of eIF2 alphaphosphorylation), and X-box-binding protein-1 (XBP-1).
 7. The method ofclaim 1, wherein said myelinating cell is located in said subject'scentral nervous system or peripheral nervous system.
 8. A method ofpromoting remyelination of a neuron in a subject after an occurrence ofneuronal demyelination, comprising administering to said subject anamount of a biologically active agent effective to modulate stress levelof endoplasmic reticulum (ER) in neuronal tissues undergoingremyelination.
 9. The method of claim 8, wherein said biologicallyactive agent is effective to reduce a sustained stress level ofendoplasmic reticulum (ER) in a myelinating cell.
 10. The method ofclaim 9, wherein said reduction of a sustained stress level of ER ischaracterized by a decrease in the levels of proteins correlated withendoplasmic reticulum (ER) stress.
 11. The method of claim 10, whereinsaid protein correlated with ER stress is selected from the groupconsisting phosphorylated pancreatic ER kinase gene (p-PERK), eukaryotictranslation initiation factor 2 alpha (eIF-2α), eukaryotic translationinitiation factor beta (eIF-2β), inositol requiring 1 (IRE 1),activating transcription factor 6 (ARTF6), CAATT enhancer-bindingprotein homologous protein (CHOP), binding-immunoglobulin protein (BIP),caspase-12, growth and DNA damage protein 34 (GADD34), CreP (aconstitutive repressor of eIF2 alpha phosphorylation), and X-box-bindingprotein-1 (XBP-1).
 12. The method of claim 8, wherein said subjectsuffers from a demyelination disorder.
 13. The method of claim 8,wherein said subject suffers from multiple sclerosis.
 14. The method ofclaim 8, wherein said subject suffers from a neuronal demyelinationinflicted by a pathogen or virus.
 15. The method of claim 8, whereinsaid biologically active agent is an INF-γ antagonist.
 16. The method ofclaim 8, wherein said interferon-gamma (INF-γ) antagonist is an antibodyor an antigen-binding fragment thereof.
 17. The method of claim 8,wherein the biologically active agent is effective to activate eIF-2αpathway by increasing eIF-2α kinase activity or increasing the level ofphosphorylated eIF-2α present in a cell.
 18. The method of claim 8,wherein the biologically active agent is effective to activate eIF-2αpathway by increasing PERK kinase activity or increasing the level ofphosphorylated PERK or PERK dimer present in a cell.
 19. The method ofclaim 8, wherein the biologically active agent is effective to activateeIF-2α pathway by deactivating GADD34 pathway.
 20. The method of claim19, wherein the deactivating GADD34 pathway results in reduced GADD34signaling.
 21. The method of claim 19, wherein the deactivating GADD34pathway results in a reduction of PPI (protein phosphatase 1)phosphatase activity or a reduction in the level of PPI present in acell.
 22. A method of ameliorating progression of a demyelinationdisorder in a subject in need for such treatment, comprising reducing insaid subject the level of interferon-gamma (INF-γ) present in saidsubject's neuronal tissues that are undergoing remyelination or INF-γsignaling.
 23. The method of claim 22, wherein said reduction of saidlevel of INF-γ is effected by delivering to a demyelinated lesion anamount of a pharmaceutical composition comprised of interferon-gamma(INF-γ) antagonist.
 24. The method of claim 23, wherein saidinterferon-gamma (INF-γ) antagonist is an antibody or an antigen-bindingfragment thereof.
 25. The method of claim 22, wherein said subjectsuffers from a demyelination disorder.
 26. The method of claim 22,wherein said subject suffers from multiple sclerosis.
 27. The method ofclaim 22, wherein said subject suffers from a neuronal demyelinationdisorder inflicted by a pathogen or a virus.
 28. The method of claim 22,wherein a reduction in INF-γ signaling is effected by a reduction in thelevel of a downstream signaling molecule of INF-γ or biological activitythereof.
 29. The method of claim 28, wherein the downstream signalingmolecule of INF-γ comprises SOCS1 or Stat1.
 30. The method of claim of1, wherein the neuronal demyelination is inflicted by an inflammatoryagent.
 31. The method of claim of 8, wherein the neuronal demyelinationis inflicted by an inflammatory agent.
 32. The method of claim of 22,wherein said subject suffers from a neuronal demyelination disorderinflicted by an inflammatory agent.